0001558370-24-007782.txt : 20240510 0001558370-24-007782.hdr.sgml : 20240510 20240510160550 ACCESSION NUMBER: 0001558370-24-007782 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240510 DATE AS OF CHANGE: 20240510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14778 FILM NUMBER: 24934796 BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 10-Q 1 sngx-20240331x10q.htm 10-Q
0.180.361052123329149290000812796--12-312024Q1falseP1YP3MP3YP2YP4Y1037823810524437000000812796us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2022-12-310000812796sngx:AssetPurchaseAgreementMember2020-03-012020-03-310000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMemberus-gaap:CommonStockMember2024-01-032024-01-030000812796us-gaap:CommonStockMember2024-01-012024-03-310000812796us-gaap:RetainedEarningsMember2024-03-310000812796us-gaap:AdditionalPaidInCapitalMember2024-03-310000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000812796us-gaap:RetainedEarningsMember2023-12-310000812796us-gaap:AdditionalPaidInCapitalMember2023-12-310000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000812796us-gaap:RetainedEarningsMember2023-03-310000812796us-gaap:AdditionalPaidInCapitalMember2023-03-310000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000812796us-gaap:RetainedEarningsMember2022-12-310000812796us-gaap:AdditionalPaidInCapitalMember2022-12-310000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000812796us-gaap:CommonStockMember2024-03-310000812796us-gaap:CommonStockMember2023-12-310000812796us-gaap:CommonStockMember2023-03-310000812796us-gaap:CommonStockMember2022-12-310000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2024-04-150000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMemberus-gaap:CommonStockMember2024-01-030000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2024-01-030000812796us-gaap:SubsequentEventMember2024-04-220000812796us-gaap:GrantMember2024-01-012024-03-310000812796us-gaap:GrantMember2023-01-012023-03-310000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2024-04-152024-04-150000812796us-gaap:ConvertibleDebtMember2024-01-032024-01-030000812796sngx:AssetPurchaseAgreementMember2014-09-012014-09-300000812796sngx:PublicOfferingMember2024-01-012024-03-310000812796sngx:AtMarketIssuanceSalesAgreementMember2023-01-012023-03-310000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000812796us-gaap:RetainedEarningsMember2024-01-012024-03-310000812796us-gaap:RetainedEarningsMember2023-01-012023-03-310000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2023-04-190000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2023-04-182023-04-180000812796us-gaap:ConvertibleDebtMember2023-01-012023-03-310000812796us-gaap:MeasurementInputSharePriceMember2024-03-310000812796us-gaap:MeasurementInputRiskFreeInterestRateMember2024-03-310000812796us-gaap:MeasurementInputPriceVolatilityMember2024-03-310000812796us-gaap:MeasurementInputDiscountRateMember2024-03-310000812796us-gaap:MeasurementInputSharePriceMember2023-04-190000812796us-gaap:MeasurementInputRiskFreeInterestRateMember2023-04-190000812796us-gaap:MeasurementInputPriceVolatilityMember2023-04-190000812796us-gaap:MeasurementInputDiscountRateMember2023-04-190000812796srt:MaximumMemberus-gaap:ConvertibleDebtMember2020-12-310000812796us-gaap:ConvertibleDebtMember2020-12-310000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2024-01-032024-01-030000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2023-04-192023-04-190000812796srt:WeightedAverageMember2024-03-310000812796srt:WeightedAverageMember2023-03-310000812796us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember2024-01-012024-03-310000812796us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember2024-01-012024-03-310000812796us-gaap:CorporateNonSegmentMember2024-01-012024-03-310000812796us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember2023-01-012023-03-310000812796us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember2023-01-012023-03-310000812796us-gaap:CorporateNonSegmentMember2023-01-012023-03-310000812796sngx:ThirdTrancheMemberus-gaap:ConvertibleDebtMember2020-12-310000812796sngx:SecondTrancheMemberus-gaap:ConvertibleDebtMember2020-12-310000812796sngx:FirstTrancheMemberus-gaap:ConvertibleDebtMember2020-12-310000812796us-gaap:ConvertibleDebtMember2024-03-310000812796us-gaap:ConvertibleDebtMember2023-12-310000812796us-gaap:ResearchAndDevelopmentArrangementMember2024-03-310000812796us-gaap:LeaseAgreementsMember2024-03-310000812796us-gaap:CommonStockMemberus-gaap:SubsequentEventMembersngx:PublicOfferingMember2024-04-220000812796sngx:PreFundedWarrantMemberus-gaap:SubsequentEventMembersngx:PublicOfferingMember2024-04-220000812796sngx:CommonWarrantsMemberus-gaap:SubsequentEventMembersngx:PublicOfferingMember2024-04-220000812796us-gaap:SubsequentEventMembersngx:PublicOfferingMember2024-04-2200008127962023-03-3100008127962022-12-310000812796us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember2024-03-310000812796us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember2024-03-310000812796us-gaap:CorporateNonSegmentMember2024-03-310000812796us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember2023-12-310000812796us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember2023-12-310000812796us-gaap:CorporateNonSegmentMember2023-12-310000812796srt:MaximumMemberus-gaap:ScenarioPlanMembersngx:AssetPurchaseAgreementMember2024-01-012024-03-310000812796us-gaap:WarrantMember2024-01-012024-03-310000812796us-gaap:EmployeeStockOptionMember2024-01-012024-03-310000812796us-gaap:ConvertibleDebtSecuritiesMember2024-01-012024-03-310000812796us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000812796us-gaap:ConvertibleDebtSecuritiesMember2023-01-012023-03-310000812796us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100008127962023-12-310000812796us-gaap:SubsequentEventMembersngx:PublicOfferingMember2024-04-222024-04-220000812796sngx:PrincipalMember2024-03-310000812796sngx:InterestMember2024-03-310000812796us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2023-01-012023-03-310000812796us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000812796us-gaap:CommonStockMember2023-01-012023-03-310000812796us-gaap:OneTimeTerminationBenefitsMember2024-01-012024-03-310000812796srt:DirectorMember2024-01-012024-03-3100008127962024-03-310000812796sngx:AssetPurchaseAgreementMember2024-01-012024-03-310000812796srt:MinimumMember2024-01-012024-03-310000812796srt:MaximumMember2024-01-012024-03-310000812796sngx:CommonWarrantsMemberus-gaap:SubsequentEventMembersngx:PublicOfferingMember2024-04-222024-04-220000812796us-gaap:CommonStockMemberus-gaap:SubsequentEventMembersngx:PublicOfferingMember2024-04-222024-04-220000812796sngx:PreFundedWarrantMemberus-gaap:SubsequentEventMembersngx:PublicOfferingMember2024-04-222024-04-2200008127962023-01-012023-03-310000812796sngx:FromPeriodTillNovember2024Member2022-06-2100008127962022-06-210000812796sngx:HybryteMember2024-01-012024-03-310000812796sngx:NationalInstitutesOfHealthMember2024-03-310000812796us-gaap:ConvertibleDebtMember2024-01-012024-03-310000812796us-gaap:ConvertibleDebtMemberus-gaap:CommonStockMember2024-01-012024-03-310000812796sngx:PontifaxMedisonFinanceMembersngx:NumberOfFirstEquityInstrumentsCommonStockIssuableUponConversionMemberus-gaap:ConvertibleDebtMember2023-04-192023-04-190000812796us-gaap:ConvertibleDebtMember2020-12-012020-12-310000812796sngx:AssetPurchaseAgreementMember2020-03-3100008127962024-05-0300008127962024-01-012024-03-31xbrli:sharesiso4217:USDxbrli:sharesxbrli:pureiso4217:USDsngx:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2024

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File No. 001-14778

SOLIGENIX, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

  

41-1505029

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification Number)

29 EMMONS DRIVE, SUITE B-10 PRINCETON, NJ

  

08540

(Address of principal executive offices)

(Zip Code)

(609) 538-8200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading Symbol(s)

  

Name of each exchange on which registered

Common Stock, par value $.001 per share

SNGX

The Nasdaq Capital Market

Indicate by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of May 3, 2024, 15,799,837 shares of the registrant’s common stock (par value, $.001 per share) were outstanding.

SOLIGENIX, INC.

Index

    

Description

    

Page

Part I

FINANCIAL INFORMATION

Item 1

Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023

1

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2024 and 2023 (unaudited)

2

Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023 (unaudited)

3

Condensed Consolidated Statements of Changes in Shareholders’ Equity/(Deficit) for the Three Months Ended March 31, 2024 and 2023 (unaudited)

4

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 (unaudited)

5

Notes to Condensed Consolidated Financial Statements (unaudited)

6

Item 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

20

Item 3

Quantitative and Qualitative Disclosures About Market Risk

49

Item 4

Controls and Procedures

49

Part II

OTHER INFORMATION

Item 1

Legal Proceedings

50

Item 1A

Risk Factors

50

Item 5

Other Information

51

Item 6

Exhibits

52

SIGNATURES

53

i

PART I - FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

Soligenix, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

March 31, 

December 31, 

    

2024

    

2023

Assets

 

(unaudited)

 

  

Current assets:

 

  

 

  

Cash and cash equivalents

$

7,091,548

$

8,446,158

Contracts and grants receivable

 

117,029

 

Unbilled revenue

171,254

Research and development incentives receivable, current

 

25,253

 

23,894

Deferred issuance cost

132,681

Prepaid expenses and other current assets

 

451,876

 

866,014

Total current assets

 

7,818,387

 

9,507,320

Security deposit

 

22,777

 

22,777

Office furniture and equipment, net

 

10,339

 

11,927

Right-of-use lease assets

 

200,569

 

229,834

Research and development incentives receivable, net of current portion

 

6,313

 

25,468

Total assets

$

8,058,385

$

9,797,326

Liabilities and shareholders' equity

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

1,436,728

$

1,111,226

Accrued expenses

 

2,602,665

 

2,418,002

Accrued compensation

 

50,216

 

251,115

Lease liabilities, current

 

125,143

 

121,765

Convertible debt

2,996,136

2,250,000

Total current liabilities

 

7,210,888

 

6,152,108

Non-current liabilities:

 

  

 

  

Convertible debt

 

 

1,010,934

Lease liabilities, net of current portion

 

79,125

 

111,862

Total liabilities

 

7,290,013

 

7,274,904

Commitments and contingencies (Note 6)

 

  

 

  

Shareholders’ equity:

 

  

 

  

Preferred stock, 350,000 shares authorized; none issued or outstanding at March 31, 2024 and December 31, 2023, respectively

Common stock, $.001 par value; 75,000,000 shares authorized; 10,524,437 and 10,378,238 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively

 

10,524

 

10,378

Additional paid-in capital

 

228,353,208

 

228,193,977

Accumulated other comprehensive income

 

24,143

 

22,243

Accumulated deficit

 

(227,619,503)

 

(225,704,176)

Total shareholders’ equity

 

768,372

 

2,522,422

Total liabilities and shareholders’ equity

$

8,058,385

$

9,797,326

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

Soligenix, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

For the Three Months Ended March 31, 2024 and 2023

(Unaudited)

Three Months Ended

March 31, 

    

2024

    

2023

Revenues:

 

  

 

  

Grant revenue

$

117,029

$

257,178

Total revenues

 

117,029

 

257,178

Cost of revenues

 

(117,029)

 

(226,040)

Gross profit

 

 

31,138

Operating expenses:

 

  

 

  

Research and development

 

1,095,040

 

946,451

General and administrative

 

1,022,051

 

1,235,376

Total operating expenses

 

2,117,091

 

2,181,827

Loss from operations

 

(2,117,091)

 

(2,150,689)

Other income (expense):

 

  

 

  

Foreign currency transaction gain (loss)

 

1,209

 

(366)

Interest income (expense), net

 

28,842

 

(103,568)

Research and development incentives

6,331

6,448

Other income

40,869

Change in fair value of convertible debt

165,382

Total other income (expense)

201,764

(56,617)

Net loss before income taxes

 

(1,915,327)

 

(2,207,306)

Income tax benefit

 

 

1,161,197

Net loss applicable to common stockholders

$

(1,915,327)

$

(1,046,109)

Basic and diluted net loss per share

$

(0.18)

$

(0.36)

Basic and diluted weighted average common shares outstanding

 

10,521,233

 

2,914,929

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

Soligenix, Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive Loss

For the Three Months Ended March 31, 2024 and 2023

(Unaudited)

Three Months Ended

March 31, 

    

2024

    

2023

Net loss

$

(1,915,327)

$

(1,046,109)

Other comprehensive income (loss):

 

 

Foreign currency translation adjustments

1,900

(12,153)

Comprehensive loss

$

(1,913,427)

$

(1,058,262)

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Soligenix, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Shareholders’ Equity/(Deficit)

For the Three Months Ended March 31, 2024 and 2023

(Unaudited)

    

    

    

    

Accumulated

    

    

Mezzanine Equity-

Additional

Other

Series D Preferred Stock

Common Stock

Paid–In

Comprehensive

Accumulated

Shares

Par Value

  

  

Shares

Par Value

Capital

Income (Loss)

Deficit

Total

Balance, December 31, 2023

 

$

10,378,238

$

10,378

$

228,193,977

$

22,243

$

(225,704,176)

$

2,522,422

Issuance of common stock associated with conversion of debt

146,199

146

99,270

99,416

Share-based compensation expense

 

 

 

59,961

 

 

 

59,961

Foreign currency translation adjustment

 

 

 

 

1,900

 

 

1,900

Net loss

 

 

 

 

 

(1,915,327)

(1,915,327)

Balance, March 31, 2024

 

$

10,524,437

$

10,524

$

228,353,208

$

24,143

$

(227,619,503)

$

768,372

    

    

    

    

Accumulated

    

    

Mezzanine Equity-

Additional

Other

Series D Preferred Stock

Common Stock

Paid–In

Comprehensive

Accumulated

Shares

Par Value

Shares

Par Value

Capital

Income (Loss)

Deficit

Total

Balance, December 31, 2022

 

$

43

2,908,578

$

2,909

$

217,064,964

$

24,747

$

(219,563,446)

$

(2,470,826)

Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement

 

21,195

 

21

 

70,709

 

 

70,730

Issuance costs associated with B. Riley At Market Issuance Sales Agreement

 

 

 

(2,341)

 

 

(2,341)

Redemption of Series D preferred stock

(43)

Share-based compensation expense

 

 

 

73,634

 

 

 

73,634

Foreign currency translation adjustment

 

 

 

 

(12,153)

 

 

(12,153)

Net loss

 

 

 

 

 

(1,046,109)

 

(1,046,109)

Balance, March 31, 2023

 

$

2,929,773

$

2,930

$

217,206,966

$

12,594

$

(220,609,555)

$

(3,387,065)

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Soligenix, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

For the Three Months Ended March 31, 2024 and 2023

(Unaudited)

    

2024

    

2023

Operating activities:

 

  

 

  

Net loss

$

(1,915,327)

$

(1,046,109)

Adjustments to reconcile net loss to net cash used in operating activities:

 

  

 

  

Amortization and depreciation

 

1,588

 

1,785

Non-cash lease expense

 

29,265

 

26,936

Share-based compensation

 

59,961

 

73,634

Change in fair value of convertible debt

(165,382)

Amortization of deferred issuance costs associated with convertible debt

 

 

10,242

Change in operating assets and liabilities:

 

 

Contracts and grants receivable

 

54,225

 

(102,878)

Prepaid expenses and other current assets

 

414,138

 

60,894

Research and development incentives receivable

 

17,379

 

98,456

Operating lease liability

 

(29,359)

 

(26,256)

Accounts payable and accrued expenses

 

391,929

 

(970,757)

Accrued compensation

 

(200,899)

 

(292,200)

Net cash used in operating activities

 

(1,342,482)

 

(2,166,253)

Financing activities:

 

  

 

  

Proceeds from issuance of common stock pursuant to B. Riley At Market Issuance Sales Agreement

 

 

70,730

Costs associated with B. Riley At Market Issuance Sales Agreement

 

 

(2,288)

Deferred issuance costs associated with public offering

(8,992)

Convertible debt repayments

 

 

(1,000,000)

Net cash used in financing activities

 

(8,992)

 

(931,558)

Effect of exchange rate on cash and cash equivalents

 

(3,136)

 

4,046

Net decrease in cash and cash equivalents

 

(1,354,610)

 

(3,093,765)

Cash and cash equivalents at beginning of period

 

8,446,158

 

13,359,615

Cash and cash equivalents at end of period

$

7,091,548

$

10,265,850

Supplemental information:

 

  

 

  

Cash paid for state income taxes

$

17,965

$

2,110

Cash paid for interest

$

64,047

$

213,490

Cash paid for lease liabilities:

 

 

  

Operating lease

$

34,100

$

33,325

Non-cash investing and financing activities:

 

  

 

  

Pontifax conversion of portion of debt principal into common stock

$

99,416

Deferred issuance cost reclassified to additional paid-in capital

$

$

53

Redemption liability for Series D preferred stock

$

$

43

Public offering costs included in accounts payable

$

123,689

$

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Soligenix, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1. Nature of Business

Basis of Presentation

Soligenix, Inc. (the “Company”) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments: Specialized BioTherapeutics and Public Health Solutions.

The Company’s Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With agreement from the European Medicines Agency (“EMA”) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ in the treatment of CTCL patients with early-stage disease, the Company is targeting to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026. Upon successful completion of the second Phase 3 study, called “FLASH2” (Fluorescent Light Activated Synthetic Hypericin 2), regulatory approval will be sought to support potential commercialization worldwide.

Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, the Company’s first-in-class innate defense regulator technology, and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer and aphthous ulcers in Behçet’s Disease.

The Company’s Public Health Solutions business segment includes development programs for RiVax®, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of the vaccine programs incorporates the use of the Company’s proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.

The Company primarily generates revenues under government grants and contracts. The Company was awarded a subcontract that originally provided for approximately $1.1 million from a U.S. Food and Drug Administration (“FDA”) Orphan Products Development grant over four years for an expanded study of HyBryte™ in the treatment of CTCL. The Company will continue to apply for additional government funding.

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, development of new technological innovations, dependence on key personnel, protections of proprietary technology, compliance with the FDA regulations, and other regulatory authorities, litigation, and product liability.

Results for the three months ended March 31, 2024 are not necessarily indicative of results that may be expected for the full year.

Liquidity

In accordance with Accounting Standards Codification 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the condensed consolidated

6

financial statements are issued. As of March 31, 2024, the Company had an accumulated deficit of $227,619,503. During the three months ended March 31, 2024, the Company incurred a net loss of $1,915,327 and used $1,342,482 of cash in operating activities. The Company expects to continue to generate losses in the foreseeable future. The Company’s liquidity needs will be determined largely by the budgeted operational expenditures incurred in regards to the progression of its product candidates. Management believes that the Company has sufficient resources available to support its development activities and business operations and timely satisfy its obligations as they become due through the first quarter of 2025. The Company does not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support its operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern through 12 months after the date the financial statements are issued.

To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, the Company plans to secure additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations, securing additional proceeds from government contract and grant programs, securing additional proceeds available from the sale of shares of the common stock via an At Market Issuance Sales Agreement and potentially amending the loan agreement with Pontifax Medison Finance (“Pontifax”) to reduce the conversion price in order to allow for conversion of a portion of the debt which will reduce the Company’s debt repayments; however, none of these alternatives are committed at this time. There can be no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to it to fund continuing operations, if at all, identify and enter into any strategic transactions that will provide the capital that it will require or achieve the other strategies to alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern. If none of these alternatives are available, or if available, are not available on satisfactory terms, the Company will not have sufficient cash resources and liquidity to fund its business operations for at least the 12 months following the date the financial statements are issued. The failure to obtain sufficient capital on acceptable terms when needed may require the Company to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives and its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. In addition, market instability, including as a result of geopolitical instability, may reduce the Company’s ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern. In addition, the perception that the Company may not be able to continue as a going concern may cause others to choose not to deal with it due to concerns about its ability to meet its contractual obligations.

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

As of March 31, 2024, the Company had cash and cash equivalents of $7,091,548 as compared to $8,446,158 as of December 31, 2023, representing a decrease of $1,354,610 or 16%. As of March 31, 2024, the Company had working capital of $607,499 as compared to working capital of $3,355,212 as of December 31, 2023, representing a decrease in working capital of $2,747,713 or 82%. The decrease in cash and cash equivalents was primarily related to cash used in operating activities during the three months ended March 31, 2024. The decrease in working capital is primarily the result of the reclassification of approximately $1 million of the Company’s convertible debt balance from a non-current liability as of December 31, 2023 to a current liability as of March 31, 2024 (resulting from the amendment to the loan and security agreement with Pontifax – see Note 4), and cash used in operating activities during the three months ended March 31, 2024.

Management’s business strategy can be outlined as follows:

Following agreement from the EMA on the key design components for the second confirmatory Phase 3 placebo-controlled FLASH2 clinical trial of HyBryte™ in CTCL and positive primary endpoint results

7

from the first Phase 3 FLASH study, initiate the FLASH2 study, while at the same time, continuing discussions with the FDA on potential modifications to the development path to adequately address their feedback.
Expanding development of synthetic hypericin under the research name SGX302 into psoriasis with the conduct of a Phase 2a clinical trial, following the positive Phase 3 FLASH study and positive proof-of-concept demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.
Following feedback from the United Kingdom (“UK”) Medicines and Healthcare products Regulatory Agency (“MHRA”) that a second Phase 3 clinical trial of SGX942 (dusquetide) in the treatment in oral mucositis would be required to support a marketing authorization; design a second study and attempt to identify a potential partner(s) to continue this development program.
Expanding development of dusquetide under the research name SGX945 into Behçet’s Disease with the conduct of a Phase 2a clinical trial, where previous studies with dusquetide in oral mucositis have validated the biologic activity in aphthous ulcers induced by chemotherapy and radiation.
Continue development of the Company’s heat stabilization platform technology, ThermoVax®, in combination with its programs for RiVax® (ricin toxin vaccine), and filovirus vaccines (targeting Ebola, Sudan, and Marburg viruses and multivalent combinations), with United States (“U.S.”) government or non-governmental organization funding support.
Continue to apply for and secure additional government funding for the Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts and/or procurements.
Pursue business development opportunities for pipeline programs, as well as explore all strategic alternatives, including but not limited to merger/acquisition strategies.
Acquire or in-license new clinical-stage compounds for development, as well as evaluate new indications with existing pipeline compounds for development.

The Company’s plans with respect to its liquidity management include, but are not limited to, the following:

The Company has up to approximately $673,000 in active government grant funding still available as of March 31, 2024 to support its associated research programs through May 2026, provided the federal agencies do not elect to terminate the grants for convenience. The Company plans to submit additional contract and grant applications for further support of its programs with various funding agencies. However, there can be no assurance that the Company will obtain additional governmental grant funding.
The Company has continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expects to continue to do so for the foreseeable future.
The Company will continue to pursue Net Operating Loss (“NOL”) sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program if the program is available.
The Company plans to pursue potential partnerships for pipeline programs as well as continue to explore merger and acquisition strategies. However, there can be no assurances that the Company can consummate such transactions.
The Company completed a public offering on April 22, 2024 of 3,275,000 shares of its common stock, pre-funded warrants to purchase 8,600,000 shares of its common stock and common warrants to purchase up to 11,875,000 shares of its common stock at a combined public offering price of $0.40.

8

The pre-funded warrants have an exercise price of $0.001. The common warrants have an exercise price of $0.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to the Company from this offering were approximately $4.75 ($4.3 net) million before deducting commissions and other estimated offering expenses. The Company plans to use the proceeds for further support of its programs, as well as for working capital. See Note 8.
The Company is currently evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate such a transaction, or consummate a transaction at favorable pricing.

Nasdaq Capital Market Listing Requirements

On June 23, 2023, the Company received a letter from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between May 9, 2023 through June 22, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company would be provided with a compliance period of 180 calendar days, or until December 20, 2023, in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The Company was unable to regain compliance prior to the expiration of the 180-day period.

On December 21, 2023, the Company received another written notice (the “Notice”) from the Staff stating that the Company had not complied with the minimum bid price requirement and was not eligible for a second 180-day period because the Company did not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for Nasdaq. As a result, the Notice indicated that the Company’s common stock would be suspended from trading on Nasdaq unless the Company requested a hearing before the Nasdaq Hearings Panel by December 28, 2023. On March 26, 2024, the Company had an oral hearing with a Nasdaq Hearings Panel to appeal the Staff’s delisting determination, which stayed the trading suspension of the Common Stock pending a final written decision by the Nasdaq Hearings Panel and expiration of any additional extension period granted by the panel following the hearing.

In order to regain compliance with Nasdaq’s minimum bid price requirement, the Company’s common stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.

Note 2. Summary of Significant Accounting Policies

Principles of Consolidation

The condensed consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.

Operating Segments

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: Specialized BioTherapeutics and Public Health Solutions.

9

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.

Contracts and Grants Receivable

Contracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for credit losses has been established. If amounts become uncollectible, they are charged to operations.

Impairment of Long-Lived Assets

Office furniture and equipment and right of use assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.

The Company did not record any impairment of long-lived assets for the three months ended March 31, 2024 and 2023.

Fair Value of Financial Instruments

FASB ASC 820 — Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on March 31, 2024. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.

FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).

The three levels of the fair value hierarchy are as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from

10

observable data or are supported by observable levels at which transactions are executed in the marketplace.
Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

The carrying amounts reported in the condensed consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable, accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments.

The carrying amount reported in the condensed consolidated balance sheet as of March 31, 2024 for the convertible debt is its fair value - see Note 4. The principal amount of the convertible debt was $2,900,585 at March 31, 2024 and the fair value was $2,996,136. The fair value of the debt was estimated using the Monte Carlo valuation method, which utilizes certain unobservable inputs. As a result, the fair value estimate represents a Level 3 measurement.

11

A roll forward of the carrying value of the convertible debt to March 31, 2024 is as follows:

Balance

Conversion

Adjustment to

Balance

December 31, 2023

January 3, 2024

fair value

March 31, 2024

Convertible debt at fair value

$

3,260,934

$

(99,416)

$

(165,382)

$

2,996,136

Deferred Issuance Costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders’ equity as a reduction of additional paid-in capital generated as a result of the issuance.

Revenue Recognition

The Company’s revenues include revenues generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants.

The Company also records revenue from contracts with customers in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), Revenue From Contracts with Customers. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Certain amounts received from or billed to customers in accordance with contract terms are deferred and recognized as future performance obligations are satisfied. All amounts earned under contracts with customers other than sales-based royalties are classified as licensing revenue. Sales-based royalties under the Company’s license agreements would be recognized as royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue.

Research and Development Costs

Research and development costs are charged to expense when incurred in accordance with FASB ASC 730, Research and Development. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs.

12

Share-Based Compensation

Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then 25% each subsequent year for a period of three years. These options have a ten-year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board.

From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed under the Company’s 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestricted stock to the Company’s employees and non-employees (including consultants). The shares issued under the 2015 Plan are registered on Form S-8 (SEC File No. 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificates reflecting such shares reflect a Securities Act of 1933, as amended restrictive legend. Stock compensation expense for equity-classified awards to non-employees is measured on the date of grant and is recognized when the services are performed.

There were no options issued during the three months ended March 31, 2024 and 2023.

Foreign Currency Transactions and Translation

In accordance with FASB ASC 830 Foreign Currency Matters, the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency, the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statements of the UK subsidiary are translated into U.S. dollars and consolidated into the Company’s financials, with related translation adjustments reported as a cumulative translation adjustment (“CTA”), which is a component of accumulated other comprehensive income. During the three months ended March 31, 2024 and 2023, the Company recognized a foreign currency transaction gain of $1,209 and a foreign currency transaction loss of ($366), respectively, in the accompanying condensed consolidated statements of operations.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company’s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward periods. Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company did not recognize an income tax benefit during the three months ended March 31, 2024. The Company recognized $1,161,197 of income tax benefit, net of transaction costs from the sale of its 2021 NOL carryforwards during the three months ended March 31, 2023. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interest and penalties recorded for the three months ended March 31, 2024 and 2023. Additionally, the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at March 31, 2024 or December 31, 2023.

13

Loss Per Share

Basic earnings per share (“EPS”) excludes dilution and is computed by dividing loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Included within the Company’s weighted average common shares outstanding for the three months ended March 31, 2024, are common shares issuable upon the exercise of the pre-funded warrants associated with the May 2023 public offering, as these pre-funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.

The following table summarizes potentially dilutive adjustments to the number of common shares which were excluded from the diluted calculation because their effect would be anti-dilutive due to the losses in each period:

As of March 31, 

    

2024

    

2023

    

Common stock purchase warrants

6,538,073

Stock options

 

906,226

 

192,273

 

Convertible debt

 

2,008,100

 

146,342

 

Total

 

9,452,399

 

338,615

 

The weighted average exercise prices of the Company’s warrants and stock options outstanding at March 31, 2024 were $1.50 and $5.52 per share, respectively. The weighted average exercise prices of the Company’s stock options outstanding at March 31, 2023 was $27.56 per share. The weighted average conversion price of the Company’s convertible debt at March 31, 2024 and 2023 was $1.44 and $61.50 per share, respectively.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

Note 3. Accrued Expenses

The following is a summary of the Company’s accrued expenses:

March 31, 

December 31, 

    

2024

    

2023

    

Clinical trial expenses

$

2,070,955

$

1,993,784

Other

 

531,710

 

424,218

Total

$

2,602,665

$

2,418,002

Note 4. Debt

In December 2020, the Company entered into a $20 million convertible debt financing agreement with Pontifax. Under the terms of the agreement with Pontifax, the Company had access to up to $20 million in convertible debt financing in three tranches, which will mature on June 15, 2025 and had an interest-only period for the first two years with a fixed interest rate of 8.47% on borrowed amounts and an interest rate of 1% on amounts

14

available but not borrowed as an unused line of credit fee. After the interest-only period, the outstanding principal was to be repaid in quarterly payments of $1 million each commencing in the first quarter of 2023. The agreement is secured by a lien covering substantially all of the Company’s assets, other than intellectual property.

Upon the closing of this transaction, the Company borrowed the first tranche of $10 million, had the option to draw the second tranche of $5 million at any time during the initial 12 months of the loan and the third tranche of $5 million upon filing of the new drug application for HyBryte™, subject to certain conditions. The Company elected to let the options to borrow both the second and third tranches expire as of December 15, 2021 and March 15, 2022, respectively.

On April 19, 2023, the Company entered into an amendment to the convertible debt financing agreement dated December 15, 2020 with Pontifax. The amendment called for the immediate payment of $5 million of the outstanding principal balance and any accrued interest, waived any prepayment charge in connection with the repayment of this amount and resulted in an outstanding principal balance of $3 million. The amendment also provided for a new interest only period from the date of the amendment through June 30, 2024, reduced quarterly principal repayments from $1 million to $750,000 and eliminated the minimum cash covenant. Further, the amendment reduced the conversion price with respect to the remaining principal amount under the agreement to (i) 90% of the closing price of the Company’s common stock on the day before the delivery of the conversion notice with respect to the first 588,599 shares of the Company’s common stock issuable upon conversion and to (ii) $1.70 with respect to all shares of the Company’s common stock issuable upon conversion in excess of the first 588,599 shares so issued. The remaining terms of the agreement remain in effect without modification.

On January, 3, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Company’s common stock. Upon conversion, the Company issued 146,199 shares of the Company’s common stock at $0.68 per share, reducing the remaining principal balance by $99,416. Pontifax may elect to convert the remaining outstanding loan drawn under the first tranche into additional shares of the Company’s common stock at any time prior to repayment. The Company also has the ability to force the conversion of the loan into shares of its common stock, subject to certain conditions.

The amendment to the convertible debt financing agreement with Pontifax resulted in the extinguishment of the original convertible debt for accounting purposes. The Company concluded that the amended debt instrument has an embedded derivative that requires bifurcation pursuant to ASC 815-15-25-1 and qualifies for the fair value option in accordance with ASC 815-15-25-4 through ASC 815-15-25-6. The Company elected to account for the amended convertible debt using the fair value option, which requires the Company to record changes in fair value as a component of other income or expense. The fair value of the convertible debt as of March 31, 2024 was $2,996,136, which resulted in the recognition of $165,382 of other income from the change in the fair value of the convertible debt on the Company’s accompanying condensed consolidated statements of operations during the three months ended March 31, 2024. The fair value of the convertible debt was estimated using the Monte Carlo valuation method.

The key assumptions used in the Monte Carlo valuations were as follows:

Assumptions

12/31/2023

3/31/2024

Stock price

$

0.76

$

0.60

Volatility

141.90%

148.80%

Discount rate

13.62%

16.16%

Risk-free rate

4.65%

5.03%

Interest expense incurred during the three months ended March 31, 2024 and 2023 was $61,239 and $187,964, respectively. Interest expense paid during the three months ended March 31, 2024 and 2023 was $64,047 and $213,490, respectively.

15

Annual principal and interest payments due as of March 31, 2024 in accordance with the amended terms of the Pontifax loan agreement, including the January 3, 2024 conversion and assuming no further conversions are as follows:

Year

    

Principal

    

Interest

    

Total

Remainder of 2024

$

2,250,000

$

198,305

$

2,448,305

2025

 

650,585

 

13,889

 

664,474

Total

$

2,900,585

$

212,194

$

3,112,779

Note 5. Shareholders’ Equity

Common Stock

The following items represent transactions in the Company’s common stock for the three months ended March 31, 2024:

The Company issued Pontifax 146,199 shares of fully vested common stock pursuant to conversion of a portion of the convertible debt principal balance at a conversion price of $0.68 per share on January 3, 2024, the date of issuance. The conversion price was based on 90% of the closing price of the Company’s common stock on the day before the delivery of the conversion notice.

The issuance of the Company’s common stock in connection with the convertible debt financing agreement as described above was exempt under Section 3(a)(9) of the Securities Act of 1933, as amended.

Note 6. Commitments and Contingencies

Contractual Obligations

The Company has commitments of approximately $230,000 as of March 31, 2024 over the next five years for several licensing agreements with partners and universities. Additionally, the Company has collaboration and license agreements, which upon clinical or commercialization success, may require the payment of milestones of up to approximately $13.2 million, royalties on net sales of covered products ranging from 2% to 3% sub-license Investigational New Drug (“IND”) milestones on covered products of up to approximately $200,000, sub-license income royalties on covered products up to 15% and sub-license global net sales royalties on covered products ranging from 1.5% to 2.5%, if and when achieved. However, there can be no assurance that clinical or commercialization success will occur.

The Company currently leases office space which serves as the Company’s corporate headquarters, and both of the Company’s business segments (Specialized BioTherapeutics and Public Health Solutions), operate from this space. Pursuant to an amendment on June 21, 2022, the lease has been extended to October 2025. The current rent of $11,367 per month will be maintained until November 2024 when it will be increased to $11,625 per month where it will remain until expiration.

In September 2014, the Company entered into an asset purchase agreement with Hy Biopharma Inc. (“Hy Biopharma”) pursuant to which the Company acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharma’s synthetic hypericin product. As consideration for the assets acquired, the Company paid $275,000 in cash and issued 12,328 shares of common stock with a fair value based on the Company’s stock price on the date of grant of $3.75 million. These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in the Company’s research and development activities and do not have alternative future use pursuant to GAAP. In March 2020, the Company issued 130,413 shares of common stock to Hy Biopharma as payment for achieving

16

a milestone: the Company determining the Phase 3 clinical trial of HyBryte™ to be successful in the treatment of CTCL. The number of shares of common stock issued to Hy Biopharma was calculated using an effective price of $38.40 per share, based upon a formula set forth in the purchase agreement.

Provided the sole remaining future success-oriented milestone of FDA approval is attained, the Company will be required to make an additional payment of $5 million, if and when achieved. Such payment will be payable in restricted securities of the Company provided such number of shares does not exceed 19.9% ownership of the Company’s outstanding stock. As of March 31, 2024, no other milestone or royalty payments have been paid or accrued.

As a result of the above agreements, the Company has the following contractual obligations:

    

Research and

    

Property and

    

    

Year

    

Development

    

Other Leases

    

Total

April 1 through December 31, 2024

$

46,000

$

102,817

$

148,817

2025

 

46,000

 

116,250

 

162,250

2026

 

46,000

 

 

46,000

2027

46,000

46,000

2028

46,000

46,000

Total

$

230,000

$

219,067

$

449,067

Contingencies

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. A liability is only recorded if management determines that it is both probable and reasonably estimable.

17

Note 7. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

    

Three Months Ended

    

March 31, 

    

2024

    

2023

Revenues

  

 

  

Specialized BioTherapeutics

$

117,029

$

155,365

Public Health Solutions

101,813

Total

$

117,029

$

257,178

Income (loss) from Operations

 

  

 

  

Specialized BioTherapeutics

$

(860,604)

$

(910,377)

Public Health Solutions

(45,997)

427

Corporate

 

(1,210,490)

 

(1,240,739)

Total

$

(2,117,091)

$

(2,150,689)

Amortization and Depreciation Expense

 

  

 

  

Specialized BioTherapeutics

$

953

$

1,071

Public Health Solutions

159

178

Corporate

 

476

 

536

Total

$

1,588

$

1,785

Other (Expense) Income, Net

 

  

 

  

Specialized BioTherapeutics

$

7,540

$

6,082

Corporate

 

194,224

 

(62,699)

Total

$

201,764

$

(56,617)

Share-Based Compensation

 

  

 

  

Specialized BioTherapeutics

$

20,672

$

27,427

Public Health Solutions

588

994

Corporate

 

38,701

 

45,213

Total

$

59,961

$

73,634

    

As of

As of

    

March 31, 

December 31, 

    

2024

    

2023

    

Identifiable Assets

 

  

 

  

 

Specialized BioTherapeutics

$

301,709

$

272,099

Public Health Solutions

 

120,475

 

3,976

Corporate

 

7,636,201

 

9,521,251

Total

$

8,058,385

$

9,797,326

18

Note 8. Subsequent Events

Pontifax Conversion of Convertible Debt

On April 15, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Company’s common stock. Upon conversion, the Company issued 442,400 shares of the Company’s common stock at $0.35 per share, reducing the remaining principal balance by $154,840. Pontifax may elect to convert the remaining outstanding loan drawn under the first tranche into additional shares of the Company’s common stock at any time prior to repayment. The Company also has the ability to force the conversion of the loan into shares of its common stock, subject to certain conditions.

$4.75 million Public Offering

On April 22, 2024, the Company completed a public offering of (i) 3,275,000 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 8,600,000 shares of the Company’s common stock and (iii) common warrants to purchase 11,875,000 shares of the Company’s common stock. The shares of common stock, or pre-funded warrants in lieu thereof, and the common warrants, were sold in units, with each unit consisting of one share of common stock or one pre-funded warrant in lieu thereof and one common warrant. Each unit comprised of common stock and common warrants was sold at a per unit price of $0.40. Each unit comprised of pre-funded warrants and common warrants was sold at a per unit price of $0.399, which represents the same per unit price less the $0.001 per share exercise price of the pre-funded warrants. The common warrants are exercisable at a price of $0.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to the Company from this offering were approximately $4.75 ($4.3 net) million before deducting commissions and other estimated offering expenses payable by the Company.

19

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis provides information to explain our results of operations and financial condition. You should also read our unaudited condensed consolidated interim financial statements and their notes included in this Form 10-Q, and our audited consolidated financial statements and their notes, Risk Factors and other information included in our Annual Report on Form 10-K for the year ended December 31, 2023. We provide addresses to internet sites solely for the information to investors. We do not intend any addresses to be active links or to otherwise incorporate the contents of any website into this report.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current expectations about our future results, performance, prospects and opportunities. These forward-looking statements are not guarantees of future performance and are subject to significant risks, uncertainties, assumptions and other factors, which are difficult to predict and may cause actual results to differ materially from those expressed in, or implied by, any forward-looking statements. The forward-looking statements within this report may be identified by words such as “believes,” “anticipates,” “expects,” “intends,” “may,” “would,” “will” and other similar expressions. However, these words are not the exclusive means of identifying these statements. Statements that are not historical facts are based on our current expectations, beliefs, assumptions, estimates, forecasts and projections for our business and the industry and markets related to our business and are forward-looking statements.

Actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect these actual outcomes and results include, without limitation:

uncertainty as to whether our product candidates will be sufficiently safe and effective to support regulatory approvals;
uncertainty inherent in developing therapeutics and vaccines, and manufacturing and conducting preclinical and clinical trials;
our ability to obtain future financing or funds when needed, either through the raising of capital, the incurrence of convertible or other indebtedness or through strategic financing or commercialization partnerships;
our ability to secure government grants or contracts to support our vaccine development;
our ability to maintain our listing on Nasdaq and meet Nasdaq’s listing requirements;
that product development and commercialization efforts will be reduced or discontinued due to difficulties or delays in clinical trials or a lack of progress or positive results from research and development efforts;
maintenance and progression of our business strategy;
the possibility that our products under development may not gain market acceptance;
our expectations about the potential market sizes and market participation potential for our product candidates may not be realized;
our expected revenues (including sales, milestone payments and royalty revenues) from our product candidates and any related commercial agreements of ours may not be realized;

20

the ability of our manufacturing partners to supply us or our commercial partners with clinical or commercial supplies of our products in a safe, timely and regulatory compliant manner and the ability of such partners to timely address any regulatory issues that have arisen or may arise in the future;
competition existing today or that may arise in the future, including the possibility that others may develop technologies or products superior to our products; and
other factors, including those “Risk Factors” set forth under Part II, Item 1A. “Risk Factors” in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2023.

Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances occurring subsequent to the filing of this Form 10-Q with the United States (“U.S.”) Securities and Exchange Commission (the “SEC”) or for any other reason. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

Note Regarding Reverse Nasdaq Capital Market Listing Requirements

On June 23, 2023, we received a letter from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of our common stock for the 30 consecutive business day period between May 9, 2023 through June 22, 2023, we did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that we would be provided with a compliance period of 180 calendar days, or until December 20, 2023, in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). We were unable to regain compliance prior to the expiration of the 180-day period.

On December 21, 2023, we received another written notice (the “Notice”) from the Staff stating that we had not complied with the minimum bid price requirement and were not eligible for a second 180-day period because we did not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for Nasdaq. As a result, the Notice indicated that our common stock would be suspended from trading on Nasdaq unless we requested a hearing before the Nasdaq Hearings Panel by December 28, 2023. On March 26, 2024, we had an oral hearing with a Nasdaq Hearings Panel to appeal the Staff’s delisting determination, which stayed the trading suspension of our common stock pending a final written decision by the Nasdaq Hearings Panel and expiration of any additional extension period granted by the panel following the hearing.

In order to regain compliance with Nasdaq’s minimum bid price requirement, our Common Stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.

Our Business Overview

We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.

Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With agreement from the European Medicines Agency (“EMA”) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ in the treatment of CTCL patients with early-stage disease, we are targeting to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026. Upon successful

21

completion of the second Phase 3 study, called “FLASH2” (Fluorescent Light Activated Synthetic Hypericin 2), regulatory approval will be sought to support potential commercialization worldwide.  

Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator technology, and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer and aphthous ulcers in Behçet’s Disease.

Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and vaccine programs, targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of the vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.

An outline of our business strategy follows:

Following agreement from the EMA on the key design components for the second confirmatory Phase 3 placebo-controlled FLASH2 (Florescent Light Activated Synthetic Hypericin 2) clinical trial of HyBryte™ in CTCL and positive primary endpoint results from the first Phase 3 FLASH study, initiate the FLASH2 study, while at the same time, continuing discussions with the U.S. Food and Drug Administration (“FDA”) on potential modifications to the development path to adequately address their feedback.
Expanding development of synthetic hypericin under the research name SGX302 into psoriasis with the conduct of a Phase 2a clinical trial, following the positive Phase 3 FLASH study and positive proof-of-concept demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.
Following feedback from the United Kingdom (“UK”) Medicines and Healthcare products Regulatory Agency (“MHRA”) that a second Phase 3 clinical trial of SGX942 in the treatment of oral mucositis would be required to support a marketing authorization; design a second study and attempt to identify a potential partner(s) to continue this development program.
Expanding development of dusquetide under the research name SGX945 into Behçets Disease with the conduct of a Phase 2a clinical trial, where previous studies with dusquetide in oral mucositis have validated the biologic activity in aphthous ulcers induced by chemotherapy and radiation.
Continue development of our heat stabilization platform technology, ThermoVax®, in combination with programs for RiVax® (ricin toxin vaccine), and filovirus vaccines (targeting Ebola, Sudan, and Marburg viruses and multivalent combinations), with U.S. government and non-governmental organization funding support.
Continue to apply for and secure additional government funding for each of our Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts and/or procurements.
Pursue business development opportunities for pipeline programs, as well as explore all strategic alternatives, including but not limited to merger/acquisition strategies.
Acquire or in-license new clinical-stage compounds for development, as well as evaluate new indications with existing pipeline compounds for development.

22

Corporate Information

We were incorporated in Delaware in 1987 under the name Biological Therapeutics, Inc. In 1987, we merged with Biological Therapeutics, Inc., a North Dakota corporation, pursuant to which we changed our name to “Immunotherapeutics, Inc.” We changed our name to “Endorex Corp.” in 1996, to “Endorex Corporation” in 1998, to “DOR BioPharma, Inc.” in 2001, and finally to “Soligenix, Inc.” in 2009. Our principal executive offices are located at 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540 and our telephone number is (609) 538-8200.

Our Product Candidates in Development

The following tables summarize our product candidates under development:

Specialized BioTherapeutics Product Candidates

Soligenix Product Candidate

   

Therapeutic Indication

   

Stage of Development

HyBryte™

Cutaneous T-Cell Lymphoma

Phase 2 trial completed; demonstrated significantly higher response rate compared to placebo; Phase 3 trial completed; demonstrated statistical significance in primary endpoint in March 2020 (Cycle 1) and demonstrated continued improvement in treatment response with extended treatment in April 2020 (Cycle 2) and October 2020 (Cycle 3); NDA submitted to FDA December 2022; FDA RTF letter received February 2023; second Phase 3 trial based upon EMA-accepted protocol targeted to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026; discussions continue with FDA on modifying the development path to adequately address FDA’s preference for a longer duration comparative study over a placebo-controlled trial.

SGX302

Mild-to-Moderate Psoriasis

Positive proof-of-concept demonstrated in a small Phase 1/2 pilot study; Phase 2a protocol and Investigation New Drug (“IND”) clearance received from the FDA; Phase 2a study remains ongoing having demonstrated biological effect in Cohort 1 and clinically meaningful benefit in Cohort 2

SGX942†

Oral Mucositis in Head and Neck Cancer

Phase 2 trial completed; demonstrated significant response compared to placebo with positive long-term (12 month) safety also reported; Phase 3 clinical trial results announced December 2020: the primary endpoint of median duration of severe oral mucositis (“SOM”) did not achieve the pre-specified criterion for statistical significance (p≤0.05); although biological activity was observed with a 56% reduction in the median duration of

23

Soligenix Product Candidate

   

Therapeutic Indication

   

Stage of Development

SOM from 18 days in the placebo group to 8 days in the SGX942 treatment group; analyzed full dataset from Phase 3 study and designing a second Phase 3 clinical trial; continued development contingent upon identification of partnership

SGX945

Aphthous Ulcers in Behçet’s Disease

Phase 2a protocol and IND clearance received from the FDA; Phase 2a study to be initiated in the second half of 2024

Public Health Solutions†

Soligenix Product Candidate

   

Indication

   

Stage of Development

ThermoVax®

Thermostability of vaccines for Ricin toxin, Ebola, and Marburg viruses

Pre-clinical

RiVax®

Vaccine against Ricin Toxin Poisoning

Phase 1a, 1b, and 1c trials completed, safety and neutralizing antibodies for protection demonstrated

SGX943

Therapeutic against Emerging Infectious Diseases

Pre-clinical

Contingent upon continued government contract/grant funding or other funding source.

Specialized BioTherapeutics Overview

Synthetic Hypericin

Synthetic Hypericin is a potent photosensitizer that is topically applied to skin lesions, taken up by cutaneous T-cells and then activated by safe visible light. Hypericin is also found in several species of Hypericum plants, although the active moiety used in HyBryte™ and SGX302 is chemically synthesized by a proprietary manufacturing process and not extracted from plants. Importantly, hypericin is optimally activated with visible light thereby avoiding the negative consequences of ultraviolet (“UV”) light. Other light therapies using UVA or UVB light can result in serious adverse effects including secondary skin cancers.

Combined with photoactivation, in clinical trials synthetic hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. In both settings, it appears that the mode of action is an induction of cell death in a concentration as well as a light dose-dependent fashion. These effects appear to result, in part, from the generation of singlet oxygen during photoactivation of hypericin.

Synthetic hypericin is one of the most efficient known generators of singlet oxygen, the key component for phototherapy. The generation of singlet oxygen induces necrosis and apoptosis in cells. The use of topical synthetic hypericin coupled with directed visible light results in generation of singlet oxygen only at the treated

24

site. We believe that the use of visible light (as opposed to cancer-causing UV light) is a major advance in photodynamic therapy. In a small published Phase 1/2 proof of concept pilot clinical study using synthetic hypericin twice weekly for six weeks, statistically significant efficacy was demonstrated in patients with CTCL (58.3% response, p=0.04) and psoriasis (80% response, p<0.02). Subsequently, a Phase 3 study in CTCL has further confirmed the biological efficacy of synthetic hypericin (termed HyBryte™ in the context of CTCL).

HyBryte™ – for Treating Cutaneous T-Cell Lymphoma

HyBryte™ is a novel, first-in-class, PDT that utilizes safe visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a photosensitizer which is topically applied to skin lesions and then activated by visible fluorescent light 16 to 24 hours later.

Based on the positive and previously published Phase 1/2 results, we initiated our Phase 3 clinical study of HyBryte™ for the treatment of CTCL during December 2015 and completed the trial in 2020. This trial, referred to as the “FLASH” (Fluorescent Light Activated Synthetic Hypericin) study, aimed to evaluate the response to HyBryte™ as a skin directed therapy to treat early stage CTCL. We completed the study with approximately 35 CTCL centers across the U.S. participating in this trial. The Phase 3 protocol was a highly powered, double-blind, randomized, placebo-controlled, multicenter trial that enrolled 169 subjects (166 evaluable). The trial consisted of three treatment cycles, each of eight weeks duration. Treatments were administered twice weekly for the first six weeks and treatment response was determined at the end of the eighth week. In the first treatment cycle, approximately 66% of subjects received HyBryte™ and 33% received placebo treatment of their index lesions. In the second cycle, all subjects received HyBryte™ treatment of their index lesions, and in the third cycle, all subjects received HyBryte™ treatment of all of their lesions. The majority of subjects enrolled elected to continue into the third optional, open-label cycle of the study. Subjects were followed for an additional six months after their last evaluation visit. The primary efficacy endpoint was assessed on the percentage of patients in each of the two treatment groups (i.e., HyBryte™ and placebo) achieving a partial or complete response of the treated lesions, defined as a ≥ 50% reduction in the total Composite Assessment of Index Lesion Disease Severity (“CAILS”) score for three index lesions at the Cycle 1 evaluation visit (Week 8) compared to the total CAILS score at baseline. Secondary endpoints for the trial included the duration of responses, the extent of the regression of the tumors, and the safety of the treatment. We continue to work closely with the Cutaneous Lymphoma Foundation, as well as the National Organization for Rare Disorders.

Positive primary endpoint analysis for the Phase 3 study for HyBryte™ was completed in March 2020. The study enrolled 169 patients (166 evaluable) randomized 2:1 to receive either HyBryte™ (116 patients) or placebo (50 patients) and demonstrated a statistically significant treatment response (p=0.04) in the CAILS primary endpoint assessment at 8 weeks for Cycle 1. A total of 16% of the patients receiving HyBryte™ achieved at least a 50% reduction in their index lesions compared to only 4% of patients in the placebo group at 8 weeks. HyBryte™ treatment in the first cycle was safe and well tolerated.

Analysis of the second open-label treatment cycle (Cycle 2) was completed in April 2020, showing that continued treatment with HyBryte™ twice weekly for an additional 6 weeks (12 weeks total) increased the positive response rate to 40% (p<0.0001 compared to placebo and p<0.0001 compared to 6-weeks treatment). After the subsequent additional 6-week treatment, the response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold. Treatment responses were assessed at Week 8 (after 6 weeks of treatment) and at Week 16 (after 12 weeks of treatment). A positive response was defined as an improvement of at least 50% in the CAILS score for the three index lesions evaluated in both Cycles 1 and 2. The data continued to indicate that HyBryte™ was safe and well tolerated.

Analysis of the optional third open-label treatment cycle (Cycle 3) was completed in October 2020. Cycle 3 was focused on safety and all patients could elect to receive HyBryte™ treatment of all their lesions for an additional 6 weeks or up to 18 weeks in total. Of note, 66% of patients elected to continue with this optional safety cycle of the study. Of the subset of patients that received HyBryte™ throughout all three cycles of treatment (18 weeks), 49% of them demonstrated a treatment response (p=0.046 vs. patients completing 12 weeks of HyBryte™ treatment in Cycle 2; p<0.0001 vs. patients receiving placebo in Cycle 1). Moreover, in a subset of

25

patients evaluated in this cycle, it was demonstrated that HyBryte™ is not systemically available, consistent with the general safety of this topical product observed to date. At the end of Cycle 3, HyBryte™ continued to be well tolerated despite extended and increased use of the product to treat multiple lesions.

In addition, continued analysis of results from the protocol mandated efficacy cycles (Cycles 1 and 2) of the study revealed that 12 weeks of treatment (Cycle 2) with HyBryte™ is equally effective on both patch (response 37%, p=0.0009) and plaque (response 42%, p<0.0001) lesions when compared to Cycle 1 placebo lesion responses, further demonstrating the unique benefits of the more deeply penetrating visible light activation of hypericin.

Following the first Phase 3 study of HyBryte™ for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support marketing approval.  With agreement from the EMA on the key design components, the confirmatory Phase 3 trial will be a randomized, double-blind, placebo-controlled, multicenter study treating approximately 80 subjects with early-stage CTCL. It will evaluate the efficacy and safety of HyBryte™ topically applied to CTCL lesions twice weekly for 18 weeks, with each application followed 21 (±3) hours later by the administration of safe, visible light at a wavelength of 500 to 650 nm. The light will be administered starting at 6 J/cm2 twice weekly. This will be increased upwards by 2 J/cm2 until: 1) the patient experiences a Grade 1 erythema, 2) the patient reaches the maximum dose of 30 J/cm2, or 3) the patient cannot tolerate the treatment time, whichever comes first. All of the patient’s lesions that are readily available for exposure to the visible light source will be treated and three to five index lesions of each patient will be prospectively identified and indexed for the modified composite assessment of index lesions severity (“mCAILS”) evaluation prior to randomization (baseline). The primary efficacy endpoint will be assessed on the percent of patients in each of the two treatment groups (i.e., HyBryte™ and placebo) achieving a Partial or Complete Response (yes/no) of the treated lesions defined as a ≥ 50% reduction in the total mCAILS score for the three to five index lesions following 18 weeks of treatment compared to the total mCAILS score at baseline.  Other secondary measures will assess treatment response (including duration), degree of improvement, time to relapse and safety.  Following treatment, all patients will be followed every four weeks for a total of 12 weeks (through Week 30). The Data Monitoring Committee will conduct one (1) interim analysis when approximately 60% of the total subjects have completed the primary endpoint evaluation. The primary efficacy endpoint and the key safety endpoints will be analyzed. A sample size recalculation may be performed after examining the assumptions or the trial halted for either futility, safety concerns, or overwhelming efficacy. The Company, participating clinical investigators, and any personnel involved in trial conduct will remain blinded to study treatment until completion of the trial.

HyBryte™ has received Orphan Drug designation as well as Fast Track designation from the FDA. The Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition to providing a seven-year term of market exclusivity for HyBryte™ upon final FDA approval, Orphan Drug designation also positions us to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of FDA user fees for the potential submission of a NDA for HyBryte™, and certain tax credits. In addition, Fast Track is a designation that the FDA reserves for a drug intended to treat a serious or life-threatening condition and one that demonstrates the potential to address an unmet medical need for the condition. Fast Track designation is designed to facilitate the development and expedite the review of new drugs. For instance, we were eligible to submit a NDA for HyBryte™ on a rolling basis, permitting the FDA to review sections of the NDA prior to receiving the complete submission. Additionally, NDAs for Fast Track development programs ordinarily will be eligible for priority review. HyBryte™ for the treatment of CTCL also was granted Orphan Drug designation from the EMA Committee for Orphan Medical Products and Promising Innovative Medicine (“PIM”) designation from the MHRA, as well as Innovation Passport under the Innovative Licensing and Access Pathway (“ILAP”) in the UK.

During January 2021, we signed an exclusive Supply, Distribution and Services Agreement with The Daavlin Distributing Co. (“Daavlin”), securing long-term supply and distribution of a commercially ready light device, which is an integral component of the regulatory and commercial strategy for HyBryte™ for the treatment of CTCL. Pursuant to the agreement, Daavlin will exclusively manufacture the proprietary light device for use with

26

HyBryte™ for the treatment of CTCL. Upon approval of HyBryte™ by the FDA, we will promote HyBryte™ and the companion light device, and facilitate the direct purchase of the device from Daavlin. Daavlin will exclusively distribute and sell the HyBryte™ light device to us, physicians and patients.

In April 2021, the FDA conditionally accepted HyBryte™ as the proposed brand name for SGX301 or synthetic hypericin, in the treatment of early stage CTCL. The name HyBryte™ was developed in compliance with the FDA’s Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names. The FDA’s conditional approval validates HyBryte™ as a proprietary name that is consistent with the FDA’s goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use. Final approval of the HyBryte™ proprietary name is conditioned on FDA approval of the product candidate, SGX301.

In May 2021, HyBryte™ was awarded an "Innovation Passport" for the treatment of early stage CTCL in adults under the UK’s ILAP. The decision to award the Innovation Passport to the HyBryte™ program was made by the Innovative Licensing and Access Pathway Steering Group, which is comprised of representatives from MHRA, the National Institute for Health and Care Excellence (“NICE”), and the Scottish Medicines Consortium (“SMC”). ILAP was launched at the start of 2021 to accelerate the development and access to promising medicines, thereby facilitating patient access to new medicines. The pathway, part of the UK’s plan to attract life sciences development in the post-Brexit era, features enhanced input and interactions with the MHRA, NICE, and SMC. The innovation passport designation is the first step in the ILAP process and triggers the MHRA and its partner agencies to create a target development profile to chart out a roadmap for regulatory and development milestones with the goal of early patient access in the UK. Other benefits of ILAP include a 150-day accelerated assessment, rolling review and a continuous benefit risk assessment.

As a result of discussions with the FDA regarding the HyBryte™ NDA submission and due to disruptions caused by the global COVID-19 pandemic resulting in delays by the commercial active pharmaceutical ingredient (“API”) contract manufacturer affecting the timing of availability of the pre-requisite amount of accrued stability data required to file the NDA, we filed the NDA with the FDA in December of 2022. We did not pursue a rolling NDA submission, so that we could provide additional supportive data in the NDA filing.

In June 2021, we received a Paediatric Investigation Plan (“PIP”) waiver from the EMA for HyBryte™. As part of the regulatory process for the registration of new medicines with the EMA, pharmaceutical companies are required to provide a PIP outlining their strategies for investigation of the new medicinal products in the pediatric population. In some instances, a waiver negating the need for a PIP for certain conditions may be granted by the EMA when development of a medicine for use in children is not feasible or appropriate, as is the case for HyBryte™ in CTCL which is extremely rare in children.

In September 2021, we were granted orphan drug designation for the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond CTCL as previously granted by the FDA.

In July 2022, the results of our successful Phase 3 FLASH study evaluating HyBryte™ for the treatment of CTCL were published in the Journal of the American Medical Association (JAMA) Dermatology.

In July 2022, we received agreement from the FDA on an initial pediatric study plan (“iPSP”) for HyBryte™ for the treatment of CTCL. The agreed iPSP stipulates that we intend to request a full waiver of pediatric studies upon submission of the NDA. Agreement with FDA on an iPSP is one of the regulatory requirements that must be met prior to submitting a NDA.

In September 2022, the FDA awarded an Orphan Products Development grant to support the evaluation of HyBryte™ for expanded treatment in patients with early-stage CTCL. The grant, totaling $2.6 million over four years, was awarded to a prestigious academic institution that was a leading enroller in the published positive Phase 3 FLASH study in the treatment of early stage CTCL.

In December 2022, we submitted the HyBryte™ NDA for the treatment of CTCL with the FDA.

27

In February 2023, we received a RTF letter from the FDA for the HyBryte™ NDA. Upon preliminary review, the FDA determined that the NDA was not sufficiently complete to permit substantive review.

In April 2023, the United States Adopted Names (“USAN”) Council approved the use of the nonproprietary name of “hypericin sodium” for the novel active ingredient in both HyBryte™ (research name SGX301) for the treatment of CTCL and SGX302 for the treatment of mild-to-moderate psoriasis.

In April 2023, we had a Type A meeting with the FDA to clarify and respond to the issues identified in the RTF letter received from the FDA and to seek additional guidance concerning information that the FDA would require for a resubmitted NDA to be deemed acceptable to file, in order to advance HyBryte™ towards marketing approval and U.S. commercialization. In order to accept an NDA filing for HyBryte™, the FDA is requiring positive results from a second, Phase 3 pivotal study in addition to the Phase 3, randomized, double-blind, placebo-controlled FLASH study previously conducted in this orphan indication. Based on this feedback, we have decided to collaboratively engage in discussions with the FDA in order to define the protocol and evaluate the feasibility of conducting the additional clinical trial.

In May 2023, we were granted a follow-on Type A meeting with the FDA to initiate formal discussions regarding the protocol design of a second, Phase 3 pivotal study evaluating HyBryte™ in the treatment of CTCL in support of potential FDA marketing approval. While discussions have been collaborative, the FDA has expressed a preference for a longer duration comparative study over a placebo-controlled trial.  Given the shorter time to potential commercial revenue and the similar trial design to the first FLASH study afforded by the EMA accepted protocol, we determined to initiate the FLASH2 study in support of worldwide potential approval. At the same time, we will continue discussions with the FDA on modifying the development path to adequately address their feedback.

In August 2023, patient enrollment was opened for the investigator-initiated study (“IIS”). IIS is supported by an Orphan Products Development grant of $2.6 million over four years awarded by the FDA to a prestigious academic institution that was a leading enroller in the published positive Phase 3 FLASH study in the treatment of early stage CTCL. The IIS will evaluate the expanded treatment, including up to 12 months of treatment, with HyBryte™ in patients with early-stage CTCL.

In March 2024, we received agreement from the EMA on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ in the treatment of CTCL patients with early-stage disease. This confirmatory 18-week study is expected to enroll approximately 80 patients in the US and Europe and is targeted to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026.

We estimate the potential worldwide market for HyBryte™ is in excess of $250 million for the treatment of CTCL. This potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be realized.

Cutaneous T-Cell Lymphoma

CTCL is a class of non-Hodgkin’s lymphoma (“NHL”), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most NHLs, which generally involve B-cell lymphocytes (involved in producing antibodies), CTCL is caused by an expansion of malignant T-cell lymphocytes (involved in cell-mediated immunity) normally programmed to migrate to the skin. These skin-trafficking malignant T-cells migrate to the skin, causing various lesions to appear that may change shape as the disease progresses, typically beginning as a rash and eventually forming plaques and tumors. Mycosis fungoides (“MF”) is the most common form of CTCL. It generally presents with skin involvement only, manifested as scaly, erythematous patches. Advanced disease with diffuse lymph node and visceral organ involvement is usually associated with a poorer response rate to standard therapies. A relatively uncommon sub-group of CTCL patients present with

28

extensive skin involvement and circulating malignant cerebriform T-cells, referred to as Sézary syndrome. These patients have substantially graver prognoses (expected five-year survival rate of 24%), than those with MF (expected five-year survival rate of 88%).

CTCL mortality is related to stage of disease, with median survival generally ranging from about 12 years in the early stages to only 2.5 years when the disease has advanced. There is currently no FDA-approved drug for front-line treatment of early stage CTCL. Treatment of early-stage disease generally involves skin-directed therapies. One of the most common unapproved therapies used for early-stage disease is oral 5 or 8-methoxypsoralen (“Psoralen”) given with ultraviolet A (“UVA”) light, referred to as PUVA, which is approved for dermatological conditions such as disabling psoriasis not adequately responsive to other forms of therapy, idiopathic vitiligo and skin manifestations of CTCL in persons who have not been responsive to other forms of treatment. Psoralen is a mutagenic chemical that interferes with DNA causing mutations and other malignancies. Moreover, UVA is a carcinogenic light source that when combined with the Psoralen, results in serious adverse effects including secondary skin cancers; therefore, the FDA requires a Black Box warning for PUVA.

CTCL constitutes a rare group of NHLs, occurring in about 4% of the more than 1.7 million individuals living with the disease in the United States and Europe (European Union and United Kingdom).  It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of CTCL that it affects approximately 31,000 individuals in the U.S. (based on SEER data, with approximately 3,200 new cases seen annually) and approximately 38,000 individuals in Europe (based on ECIS prevalence estimates, with approximately 3,800 new cases annually).

SGX302 – for Treating Mild-to-Moderate Psoriasis

SGX302 (synthetic hypericin) is a potent photosensitizer that is topically applied to skin lesions and taken up by cutaneous T-cells. With subsequent activation by safe, visible light, T-cell apoptosis is induced, addressing the dysregulated T-cells found in psoriasis lesions. Other PDTs have shown efficacy in psoriasis with a similar apoptotic mechanism, albeit using UV light associated with more severe potential long-term toxicities. The use of visible light in the red-yellow spectrum has the advantage of deeper penetration into the skin (much more than UV light) potentially treating deeper skin disease and thicker plaques and lesions, similar to what was observed in the positive Phase 3 FLASH study in CTCL. Further, this treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with both the frequently used DNA-damaging drugs and other phototherapies that are dependent on UVA or UVB exposure. The use of SGX302 coupled with safe, visible light also avoids the risk of serious infections and cancer associated with the systemic immunosuppressive treatments used in psoriasis.

In September 2021, following the validation of synthetic hypericin’s biologic activity in the positive Phase 3 FLASH study in CTCL, as well as positive proof-of-concept demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients, we decided to expand this novel therapy into a Phase 2a clinical trial in mild-to-moderate psoriasis.

In June 2022, we received FDA IND clearance for our Phase 2a clinical trial (protocol number HPN-PSR-01) titled, "Phase 2 Study Evaluating SGX302 in the Treatment of Mild-to-Moderate Psoriasis." In December 2022, we initiated patient enrollment for the Phase 2a study (protocol number HPN-PSR-01) evaluating SGX302 in the treatment of mild-to-moderate psoriasis. The Phase 2a clinical trial (protocol number HPN-PSR-01) will target enrollment of up to 42 patients ages 18 years or older with mild to moderate, stable psoriasis covering 2 to 30% of the body. In both Parts A and B, all patients will apply the study drug twice per week and activate the drug with visible light 24 ± 6 hours later using the supplied visible light devices and according to the manufacturer's instructions. Patients will undergo treatments for a total of 18 weeks and, on completion, will be followed for a four-week follow-up period in which patients will not receive other psoriasis treatments. In Part A, five to ten patients will be assigned open-label SGX302 (0.25% hypericin) at the time of enrollment. Once the tolerability and response to SGX302 has been established, Part B of the protocol will commence. In Part B, patients will be randomized to double-blind treatment groups at a ratio 1:1 of active drug to placebo ointment.

29

Active dermatologic assessment of treated lesions for adverse events will be performed immediately before and during light treatments. Patients will be assessed for overall disease status through four weeks of follow-up. Efficacy endpoints will include the extent of lesion clearance and patient reported quality of life indices. Routine safety data also will be collected.

In October 2022, we announced the formation of a Medical Advisory Board to provide medical/clinical strategic guidance to advance the Phase 2a clinical development of SGX302 for the treatment of mild-to-moderate psoriasis.

In July 2023, we expanded the Phase 2a trial of SGX302 after demonstration of biological effect in the initial five subjects (Cohort 1).  The study is expected to enroll at least an additional ten subjects, exploring the use of SGX302 in the standard of care psoriasis setting, prior to undertaking the larger phase of the study.

In January 2024, positive preliminary results of clinical success were demonstrated in the Cohort 2 subjects enrolled in the ongoing Phase 2a study. In the four evaluable patients from Cohort 2 (one patient withdrew early in the treatment course for personal reasons unrelated to the study), two reached a disease status of “Almost Clear” represented by an Investigator Global Assessment score of 1, which is considered the standard clinical measure for treatment success in psoriasis. In addition, the Psoriasis Activity and Severity Index score, another well-characterized measure of treatment success, for patients in Cohort 2 had a mean drop of approximately 50% over the 18-week treatment. SGX302 therapy was well tolerated by all patients with no drug related adverse events identified.

We estimate the potential worldwide market for SGX302 is in excess of $1 billion for the treatment of mild-to-moderate psoriasis. This potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be realized.

Psoriasis

Psoriasis is a chronic, non-communicable, itchy and often painful inflammatory skin condition for which there is no cure. Psoriasis has a significantly detrimental impact on patients' quality of life, and is associated with cardiovascular, arthritic, and metabolic diseases, as well as psychological conditions such as anxiety, depression and suicide. Many factors contribute to development of psoriasis including both genetic and environmental factors (e.g., skin trauma, infections, and medications). The lesions develop because of rapidly proliferating skin cells, driven by autoimmune T-cell mediated inflammation. Of the various types of psoriasis, plaque psoriasis is the most common and is characterized by dry, red raised plaques that are covered by silvery-white scales occurring most commonly on the elbows, knees, scalp, and lower back. Approximately 80% of patients have mild-to-moderate disease. Mild psoriasis is generally characterized by the involvement of less than 3% of the body surface area (“BSA”), while moderate psoriasis will typically involve 3-10% BSA and severe psoriasis greater than 10% BSA. Between 20% and 30% of individuals with psoriasis will go on to develop chronic, inflammatory arthritis (psoriatic arthritis) that can lead to joint deformations and disability. Studies have also associated psoriasis, and particularly severe psoriasis, with an increased relative risk of lymphoma, particularly CTCL. Although psoriasis can occur at any age, most patients present with the condition before age 35.

Treatment of psoriasis is based on its severity at the time of presentation with the goal of controlling symptoms. It varies from topical options including PDT to reduce pain and itching, and potentially reduce the inflammation driving plaque formation, to systemic treatments for more severe disease. Most common systemic treatments and even current topical photo/photodynamic therapy such as UV A and B, carry a risk of increased skin cancer.

30

Psoriasis is the most common immune-mediated inflammatory skin disease. According to the World Health Organization (“WHO”) Global Report on Psoriasis 2016, the prevalence of psoriasis is between 1.5% and 5% in most developed countries, with some suggestions of incidence increasing with time. It is estimated, based upon review of historic published studies and reports and an interpolation of data that psoriasis affects 3% of the U.S. population or more than 7.5 million people. Current estimates have as many as 60-125 million people worldwide living with the condition. The global psoriasis treatment market was valued at approximately $15 billion in 2020 and is projected to reach as much as $40 billion by 2027.

Dusquetide

Dusquetide (research name: SGX94) is an IDR that regulates the innate immune system to simultaneously reduce inflammation, eliminate infection and enhance tissue healing. Dusquetide is based on a new class of short, synthetic peptides known as IDRs. It has a novel mechanism of action in that it modulates the body’s reaction to both injury and infection and is both simultaneously anti-inflammatory and anti-infective. IDRs have no direct antibiotic activity but modulate host responses, increasing survival after infections with a broad range of bacterial Gram-negative and Gram-positive pathogens including both antibiotic sensitive and resistant strains, as well as accelerating resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- or radiation-therapy. IDRs represent a novel approach to the control of infection and tissue damage via highly selective binding to an intracellular adaptor protein, sequestosome-1, also known as p62, which has a pivotal function in signal transduction during activation and control of the innate defense system. Preclinical data indicate that IDRs may be active in models of a wide range of therapeutic indications including life-threatening bacterial infections as well as the severe side-effects of chemo- and radiation-therapy. Additionally, due to selective binding to p62, dusquetide may have potential anti-tumor action.

Dusquetide has demonstrated efficacy in numerous animal disease models including mucositis, oncology, colitis, skin infection and other bacterial infections and has been evaluated in a double-blind, placebo-controlled Phase 1 clinical trial in 84 healthy volunteers with both single ascending dose and multiple ascending dose components. Dusquetide was shown to have a good safety profile and be well-tolerated in all dose groups when administered by IV over 7 days and was consistent with safety results seen in pre-clinical studies. We believe that market opportunities for dusquetide include, but are not limited to, oral and gastrointestinal mucositis, oncology (e.g., breast cancer), acute Gram-positive bacterial infections (e.g., methicillin resistant Staphylococcus aureus (“MRSA”)), acute Gram-negative infections (e.g., acinetobacter, melioidosis), and acute radiation syndrome.

SGX942 – for Treating Oral Mucositis in Head and Neck Cancer

SGX942 is our product candidate containing our IDR technology, dusquetide, targeting the treatment of oral mucositis in head and neck cancer patients. Oral mucositis in this patient population is an area of unmet medical need where there are currently no approved drug therapies. Accordingly, we received Fast Track designation for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients from the FDA. In addition, dusquetide has been granted PIM designation in the UK by the MHRA for the treatment of SOM in head and neck cancer patients receiving chemoradiation therapy.

We initiated a Phase 2 clinical study of SGX942 for the treatment of oral mucositis in head and neck cancer patients in December of 2013. We completed enrollment in this trial and released positive results in December 2015. In this Phase 2 proof-of-concept clinical study that enrolled 111 patients, SGX942, at a dose of 1.5 mg/kg, successfully reduced the median duration of SOM by 50%, from 18 days to 9 days (p=0.099) in all patients and by 67%, from 30 days to 10 days (p=0.040) in patients receiving the most aggressive chemoradiation therapy for treatment of their head and neck cancer. The p-values met the prospectively defined statistical threshold of p<0.1 in the study protocol. A less severe occurrence of oral mucositis, ulcerative oral mucositis (defined as oral mucositis with a WHO score ≥2 corresponding to the occurrence of overt ulceration in the mouth), was also monitored during the study. In the patients receiving the most aggressive chemoradiation therapy, the median duration of oral mucositis was found to decrease from 65 days in the placebo treated patients to 51 days in the patients treated with SGX942 1.5 mg/kg (p=0.099).

31

In addition to identifying the best dose of 1.5 mg/kg, this study achieved all objectives, including increased incidence of “complete response” of tumor at the one month follow-up visit (47% in placebo vs. 63% in SGX942 at 1.5 mg/kg). Decreases in mortality and decreases in infection rate were also observed with SGX942 treatment, consistent with the preclinical results observed in animal models. Data from this Phase 2 trial are published in the Journal of Biotechnology.

SGX942 was found to be generally safe and well tolerated, consistent with the safety profile observed in the prior Phase 1 study conducted in 84 healthy volunteers. The long-term (12 month) follow-up data was consistent with the preliminary positive safety and efficacy findings. While the placebo population experienced the expected 12-month survival rate of approximately 80%, as defined in the Surveillance, Epidemiology, and End Results statistics 1975-2012 from the National Cancer Institute, the SGX942 1.5 mg/kg treatment group reported a 12-month survival rate of 93% (7% mortality in the SGX942 1.5 mg/kg group compared to 19% in the placebo group). Similarly, tumor resolution (complete response) at 12 months was better in the SGX942 1.5 mg/kg treatment group relative to the placebo population (80% in the 1.5 mg/kg group compared to 74% in the placebo group). The long-term follow-up results from the Phase 2 study are published in Biotechnology Reports.

In September 2016, we and SciClone Pharmaceuticals, Inc. (“SciClone”) entered into an exclusive license agreement, pursuant to which we granted rights to SciClone to develop, promote, market, distribute and sell SGX942 in defined territories. Under the terms of the license agreement, SciClone will be responsible for all aspects of development, product registration and commercialization in the territories, having access to data generated by us. In exchange for exclusive rights, SciClone will pay us royalties on net sales, and we will supply commercial drug product to SciClone on a cost-plus basis, while maintaining worldwide manufacturing rights.

Based on the positive and previously published Phase 2 results (Study IDR-OM-01), in July 2017, we initiated a Phase 3 clinical trial referred to as the “DOM–INNATE” (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) study. Approximately 50 U.S. and European oncology centers participated in this trial. The Phase 3 protocol (Study IDR-OM-02) was a highly powered, double-blind, randomized, placebo-controlled, multinational trial that sought to enroll approximately 260 subjects with squamous cell carcinoma of the oral cavity and oropharynx who were scheduled to receive a minimum total cumulative radiation dose of 55 Gy fractionated as 2.0-2.2 Gy per day with concomitant cisplatin chemotherapy given as a dose of 80-100 mg/m2 every third week. Subjects were randomized to receive either 1.5 mg/kg SGX942 or placebo given twice a week during and for two weeks following completion of chemoradiation therapy (“CRT”). The primary endpoint for the study was the median duration of SOM, which was assessed by oral examination at each treatment visit and then through six weeks following completion of CRT. Oral mucositis is evaluated using the WHO Grading system. SOM is defined as a WHO Grade of ≥3. Subjects are followed for an additional 12 months after the completion of treatment.

In April 2019, the Paediatric Committee of the EMA approved our PIP for SGX942, a prerequisite for filing a Marketing Authorization Application (“MAA”) for any new medicinal product in Europe. The EMA also agreed that we may defer conducting the PIP until successful completion of our pivotal Phase 3 clinical trial of SGX942, which allowed us to file the adult indication MAA prior to completion of the PIP.

In June 2020, the pivotal Phase 3 DOM–INNATE study (Study IDR-OM-02) completed enrollment of 268 subjects. In December 2020, the results of our Phase 3 clinical trial for SGX942 showed that the primary endpoint of median duration of SOM did not achieve the pre-specified criterion for statistical significance (p≤0.05); although biological activity was observed with a 56% reduction in the median duration of SOM from 18 days in the placebo group to 8 days in the SGX942 treatment group. Despite this clinically meaningful improvement, the variability in the distribution of the data yielded a p-value that was not statistically significant. Other secondary endpoints supported the biological activity of dusquetide, including a statistically significant 50% reduction in the median duration of SOM in the per-protocol population, which decreased from 18 days in the placebo group to 9 days in the SGX942 treatment group (p=0.049), consistent with the findings in the Phase 2 trial (Study IDR-OM-01). Similarly, incidence of SOM also followed this biological trend as seen in the Phase 2 study, decreasing by 16% in the SGX942 treatment group relative to the placebo group in the per-protocol

32

population. The per-protocol population was defined as the population receiving a minimum of 55 Gy radiation and at least 10 doses of study drug (placebo or SGX942) throughout the intended treatment period, with no major protocol deviations (e.g. breaks in study drug administration longer than 8 days between successive doses).

Following analysis of the full dataset, including the 12-month long-term follow-up safety data in late 2021, we held a meeting with the MHRA to review the study results and to obtain further clarity on the future of the oral mucositis development program. The meeting was informative with the outcome being that based on the SGX942 biologic activity observed and the consistency in response between the Phase 2 and Phase 3 trials, the Phase 3 DOM-INNATE study could serve as the first of two Phase 3 studies required to support potential marketing authorization, assuming the second Phase 3 clinical trial achieves the required level of statistical significance in its primary endpoint. With the benefit of a robust preclinical and clinical data package for SGX942, we now will analyze the data to design a second Phase 3 study and will look to identify a potential partner(s) to continue this development program.

In January 2022, dusquetide proved effective at reducing tumor size in nonclinical xenograft models. Recent studies, recapitulating results from previously published studies, have confirmed the efficacy of dusquetide as a stand-alone and combination anti-tumor therapy, with radiation, chemotherapy and targeted therapy, in the context of the MCF-7 breast cancer cell line. Of note, these results are consistent with a potential direct anti-tumor effect identified with SGX942 and is another important consideration in the oral mucositis treatment space.

In June 2022, an article was published describing the binding of our IDR, dusquetide, to the p62 protein. Dusquetide binds to p62 or SQSTM-1, a scaffold protein implicated in a number of intracellular signaling networks implicated in tumor cell survival, including autophagy. This publication elaborates on the direct interaction of dusquetide with p62, as well as some of the direct downstream consequences of that interaction, consistent with its observed anti-infective, anti-tumor and anti-inflammatory activities. This information advances the understanding of dusquetide's novel mechanism of action and supports the development of analogs related to dusquetide.

We estimate the potential worldwide market for SGX942 is in excess of $500 million for the treatment of oral mucositis. This potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be realized.

Oral Mucositis

Mucositis is the clinical term for damage done to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonly associated with the mouth, followed by the small intestine. We estimate, based upon our review of historic studies and reports, and an interpolation of data on the incidence of mucositis, that mucositis affects approximately 500,000 people in the U.S. per year and occurs in 40% of patients receiving chemotherapy. Mucositis can be severely debilitating and can lead to infection, sepsis, the need for parenteral nutrition and narcotic analgesia. The gastrointestinal damage causes severe diarrhea. These symptoms can limit the doses and duration of cancer treatment, leading to sub-optimal treatment outcomes.

The mechanisms of mucositis have been extensively studied and have been linked to the interaction of chemotherapy and/or radiation therapy with the innate defense system. Bacterial infection of the ulcerative lesions is regarded as a secondary consequence of dysregulated local inflammation triggered by therapy-induced cell death, rather than as the primary cause of the lesions.

We estimate, based upon our review of historic studies and reports, and an interpolation of data on the incidence of oral mucositis, that oral mucositis is a subpopulation of approximately 90,000 patients in the U.S., with a comparable number in Europe. Oral mucositis almost always occurs in patients with head and neck

33

cancer treated with radiation therapy (greater than 80% incidence of severe mucositis) and is common in patients undergoing high dose chemotherapy and hematopoietic cell transplantation, where the incidence and severity of oral mucositis depends greatly on the nature of the conditioning regimen used for myeloablation.

SGX945 – for Treating Aphthous Ulcers in Behçet’s Disease

SGX945 is our product candidate containing our IDR technology, dusquetide, targeting the treatment of aphthous Ulcers in Behçet’s Disease. Behçet’s Disease is an orphan disease and an area of unmet medical need.

In November 2023, the FDA cleared the IND application for a Phase 2a clinical trial entitled, “Pilot Study of SGX945 (Dusquetide) in the Treatment of Aphthous Ulcers in Behçet’s Disease.” The study is designed to evaluate the safety and potential efficacy of SGX945 (dusquetide) in the resolution of aphthous flares in Behçet’s Disease and is expected to begin patient enrollment in the second half of 2024.

In January 2024, SGX945 received Fast Track designation for the treatment of oral lesions of Behçet’s Disease from the FDA.

In February 2024, we announced the formation of a Medical Advisory Board to provide medical/clinical strategic guidance to advance the clinical development of SGX945 for the treatment of Behçet's Disease.

We estimate the potential worldwide market for SGX945 is in excess of $200 million for the treatment of aphthous ulcers in Behçet’s Disease. This potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be realized.

Behçet’s Disease

Behçet’s Disease (“BD”) is commonly known as an inflammatory disorder of the blood vessels (vasculitis). Often first diagnosed in young adults, its effects and severity will wax and wane over time. Major signs and symptoms usually include mouth sores (approximately 95% of patients), skin rashes and lesions (approximately 50% of patients), genital sores (approximately 50% of patients), leg ulcers (approximately 40% of patients) and eye inflammation (approximately 15% of patients). It is a painful disease, directly impacting the patient’s quality of life and ability to productively engage in life activities, including work.

BD is thought to be an auto-immune disease with both genetic and environmental factors. It is most common along the “silk road” in the Middle East and East Asia, including Turkey, Iran, Japan and China. There are approximately 18,000 known cases of BD in the U.S. and 80,000 in Europe. There are as many as 1,000,000 people worldwide living with BD.

There is no cure for BD, rather treatments are prescribed to manage symptoms. Treatments may include both maintenance therapies and those specifically addressing mucocutaneous flares (e.g., mouth ulcers, genital ulcers and leg ulcers). Corticosteroids are generally applied topically to sores and as eyedrops and may also be given systemically to reduce inflammation. Although used frequently, they have limited efficacy over the long-term and have significant side effects that become more concerning with more chronic use. Genital ulcers are often associated with significant genital scarring while leg ulcers can result in a post-thrombotic syndrome. Other treatments for BD flares involve suppressing the immune system with drugs (e.g., cyclosporine or cyclophosphamide). These drugs come with a higher risk of infection, liver and kidney problems, low blood counts and high blood pressure. Finally, anti-inflammatory drugs are also used, including anti-TNF medications. The only approved drug in BD is apremilast, which is used as a maintenance therapy to prevent formation of oral ulcers. Unfortunately, apremilast is associated with both high cost and side effects including diarrhea, nausea, upper respiratory tract infection and headache.

34

Public Health Solutions Overview

ThermoVax® – Thermostability Platform Technology

ThermoVax® is a novel method for thermostabilizing vaccines with a variety of adjuvants, resulting in a single vial which can be reconstituted with water for injection immediately prior to use. One of the adjuvants utilized in ThermoVax® is aluminum salts (known colloquially as “Alum”). Alum is the most widely employed adjuvant technology in the vaccine industry.

The value of ThermoVax® lies in its potential ability to eliminate the need for cold chain production, transportation, and storage for Alum-adjuvanted vaccines. This would relieve the high costs of producing and maintaining vaccines under refrigerated conditions. Based on historical reports from WHO and other scientific reports, we believe that a meaningful proportion of vaccine doses globally are wasted due to excursions from required cold chain temperature ranges. This is due to the fact that many vaccines need to be maintained either between 2 and 8 degrees Celsius (“C”), frozen below -20 degrees C, or frozen below -60 degrees C, and even brief excursions from these temperature ranges usually necessitate the destruction of the product or the initiation of costly stability programs specific for the vaccine lots in question. ThermoVax® has the potential to facilitate easier storage and distribution of strategic national stockpile vaccines for ricin exposure in emergency settings.

ThermoVax® development, specifically in the context of an Alum adjuvant, was supported pursuant to our $9.4 million NIAID grant enabling development of thermo-stable ricin (RiVax®) and anthrax vaccines. Proof-of-concept preclinical studies with ThermoVax® indicate that it is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions. These studies were conducted with our Alum-adjuvanted ricin toxin vaccine, RiVax® and our Alum-adjuvanted anthrax vaccine. Each vaccine was manufactured under precise lyophilization conditions using excipients that aid in maintaining native protein structure of the key antigen. When RiVax® was kept at 40 degrees C (104 degrees Fahrenheit (“F”)) for up to one year, all of the animals vaccinated with the lyophilized RiVax® vaccine developed potent and high titer neutralizing antibodies. In contrast, animals that were vaccinated with the liquid RiVax® vaccine kept at 40 degrees C did not develop neutralizing antibodies and were not protected against ricin exposure. The ricin A chain is extremely sensitive to temperature and rapidly loses the ability to induce neutralizing antibodies when exposed to temperatures higher than 8 degrees C. When the anthrax vaccine was kept for up to 16 weeks at 70 degrees C, it was able to develop a potent antibody response, unlike the liquid formulation kept at the same temperature. Moreover, we also have demonstrated the compatibility of our thermostabilization technology with other secondary adjuvants such as TLR-4 agonists.

We also entered into a collaboration agreement with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (“JABSOM”), University of Hawai’i at Manoa (“UH Manoa”) and Hawaii Biotech, Inc. (“HBI”) to develop a heat stable subunit Ebola vaccine. Dr. Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept efficacy with subunit Ebola vaccines in non-human primates (“NHP”). The most advanced Ebola vaccines involve the use of vesicular stomatitis virus and adenovirus vectors – live, viral vectors which complicate the manufacturing, stability and storage requirements. Dr. Lehrer’s vaccine candidate is based on highly purified recombinant protein antigens, circumventing many of these manufacturing difficulties. Dr. Lehrer and HBI have developed a robust manufacturing process for the required proteins. Application of ThermoVax® may allow for a product that can avoid the need for cold chain distribution and storage, yielding a vaccine ideal for use in both the developed and developing world. This agreement has expired in accordance with its terms.

In December 2010, we executed a worldwide exclusive license agreement with the University of Colorado (“UC”) for certain patents relating to ThermoVax® in all fields of use. In April 2018, the UC delivered a notice of termination of our license agreement based upon our failure to achieve one of the development milestones: initiation of the Phase 1 clinical trial of the heat stabilization technology by March 31, 2018. After negotiating with the UC, we and the UC agreed to extend the termination date to October 31, 2018 in order to allow us time

35

to agree upon a potential agreement that would allow us to keep the rights to, and to continue to develop, the heat stabilization technology or a product candidate containing the heat stabilization technology in our field of use.

During September 2017, we were awarded funding of approximately $700,000 over five years under a NIAID Research Project (R01) grant awarded to UH Manoa for the development of a trivalent thermostabilized filovirus vaccine (including protection against Zaire ebolavirus, Sudan ebolavirus and Marburg Marburgvirus). Previous collaborations demonstrated the feasibility of developing a heat stable subunit Ebola vaccine. Under the terms of the subaward, we will continue to support vaccine formulation development with our proprietary vaccine thermostabilization technology, ThermoVax®. Ultimately, the objective is to produce a thermostable trivalent filovirus vaccine for protection against Ebola and related diseases, allowing worldwide distribution without the need for cold storage. Based on current U.S. government needs, efforts have been expanded to focus on a monovalent or bivalent vaccine to specifically address Marburg marburgvirus.

In October 2018, in a series of related transactions, (a) we and the UC agreed to terminate the original license agreement, (b) the UC and VitriVax, Inc. (“VitriVax”) executed a worldwide exclusive license agreement for the heat stabilization technology for all fields of use, and (c) we and VitriVax executed a worldwide exclusive sublicense agreement, which was amended and restated in October 2020, for the heat stabilization technology for use in the fields of ricin and Ebola vaccines. We paid a $100,000 sublicense fee on the effective date of the sublicense agreement. Under the amended sublicense agreement to maintain the sublicense we are obliged to pay a minimum annual royalty of $20,000 until first commercial sale of a sublicensed product, upon which point, we shall pay an earned royalty of 2% of net sales subject to a minimum royalty of $50,000 each year. We are also required to pay royalty on any sub-sublicense income based on a declining percentage of all sub-sublicense income calculated within the contractual period until reaching a minimum of 15% after two years. In addition, we are required to pay VitriVax milestone fees of: (a) $25,000 upon initiation of a Phase 2 clinical trial of the sublicensed product, (b) $100,000 upon initiation of a Phase 3 clinical trial of the sublicensed product, (c) $100,000 upon regulatory approval of a sublicensed product, and (d) $1 million upon achieving $10 million in aggregate net sales of a sublicensed product in the U.S. or equivalent. To date none of these milestones have been met.

In March 2020, we entered into a research collaboration with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, JABSOM, UH Manoa to further expand the filovirus collaboration to investigation of potential coronavirus vaccines, including for SARS-CoV-2 (causing COVID-19). This research collaboration will utilize the technology platform developed in the search for filovirus vaccines and will use well-defined surface glycoprotein(s) from one or more coronaviruses, which are expected to be protective for COVID-19.

During April 2020, we obtained an exclusive worldwide license for CoVaccine HT™, a novel vaccine adjuvant, from SERB Pharmaceuticals (formerly BTG Specialty Pharmaceuticals, a division of Boston Scientific Corporation) (“SERB”), for the fields of coronavirus infection (including SARS-CoV-2, the cause of COVID-19), and pandemic flu. CoVaccine HT™ is a novel adjuvant, which has been shown to enhance both cell-mediated and antibody-mediated immunity. We and our collaborators, including UH Manoa and Dr. Axel Lehrer, have successfully demonstrated the utility of CoVaccine HT™ in the development of our heat stable filovirus vaccine program, with vaccine candidates against Ebola and Marburg virus disease. Given this previous success, CoVaccine HT™ will potentially be an important component of our vaccine technology platform currently being assessed for use against coronaviruses including SARS-CoV-2, the cause of COVID-19. The license agreement was executed between us and SERB, which owns the CoVaccine HT™ intellectual property.

In September 2020, the Journal of Pharmaceutical Sciences published a scientific article detailing the thermostabilization of the filovirus GP proteins and key assays describing their stability.

During October 2020, Frontiers in Immunology published a scientific article describing CiVax™, a prototype COVID-19 vaccine, using the novel CoVaccine HT™ adjuvant and demonstrating significant immunogenicity, including strong total and neutralizing antibody responses, with a balanced Th1 response, as well as

36

enhancement of cell mediated immunity. These are all considered to be critical attributes of a potential COVID-19 vaccine.

In December 2020, NIAID awarded us a Direct to Phase II Small Business Innovation Research (“SBIR”) grant of approximately $1.5 million to support manufacture, formulation (including thermostabilization) and characterization of COVID-19 and Ebola Virus Disease (“EVD”) vaccine candidates in conjunction with the CoVaccine HT™ adjuvant. This award also is supporting immune characterization of this novel, emulsified adjuvant that has unique potency and compatibility with lyophilization strategies to enable thermostabilization of subunit vaccines.

During August 2021, positive data demonstrated the efficacy of multiple filovirus vaccine candidates in NHP, including thermostabilized multivalent vaccines in a single vial platform presentation. Collaborators at UH Manoa describe the potent efficacy of vaccine candidates protecting against three life-threatening filoviruses, Zaire ebolavirus, Sudan ebolavirus and Marburg Marburgvirus in an article titled "Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques from Ebola, Sudan, and Marburg Viruses", published in Frontiers in Immunology. These vaccine candidates contain highly purified protein antigens combined with the novel CoVaccine HT™ adjuvant, in both monovalent (single antigen) and bivalent (two antigen) formulations. Most recently, efforts to formulate all three antigens and adjuvant into a thermostable single-vial vaccine platform has also been shown to protect 75% of vaccinated NHPs against subsequent Sudan ebolavirus challenge, with further development to test efficacy against other filovirus infections ongoing.

During August 2021, Vaccine published a scientific article describing the formulation of single-vial platform presentations of monovalent (single antigen), bivalent (two antigens) and trivalent (three antigens) combinations of filovirus vaccine candidates.

During September 2021, an accelerated preprint was posted on bioRxiv of pre-clinical immunogenicity studies for CiVax™ (heat stable COVID-19 vaccine program) demonstrating durable broad-spectrum neutralizing antibody responses, including against the Beta, Gamma and Delta variants of concern. The scientific article was subsequently published on March 9, 2022 in ACS Infectious Diseases. The work is part of an ongoing collaboration with Axel Lehrer, PhD, Associate Professor at the Department of Tropical Medicine, Medical Microbiology and Pharmacology, JABSOM, UH Manoa. Development continues under a non-dilutive $1.5M grant from the NIAID awarded to us in December 2020.

In December 2021, 100% protection of NHPs against lethal Sudan ebolavirus challenge was achieved using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with water immediately prior to use. This milestone is part of an ongoing collaboration with UH Manoa and further demonstrates the broad applicability of the vaccine platform, and its potential role in the U.S. government's initiative for pandemic preparedness.

In May 2022, the U.S. Patent and Trademark Office issued a Notice of Allowance for the patent application titled “Composition and Methods of Manufacturing Trivalent Filovirus Vaccines.” The allowed claims are directed to unique, proprietary composition and methods directed to combinations of glycoprotein antigens with nano-emulsion adjuvants comprising sucrose fatty acid esters prior to lyophilization. The described vaccine platform has previously been successfully applied to filovirus vaccines (as mono-, bi- and tri-valent candidates for Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus) as well as SARS-CoV-2 vaccine. No currently licensed lyophilized vaccine that contains an adjuvant is presented in a single vial format and there are few reports of successfully using nano-emulsions in lyophilized formulations. Previous work has demonstrated the use of a single vial platform to co-lyophilize antigen(s) and a nano-emulsion adjuvant, CoVaccine HT™, maintaining key adjuvant stability characteristics including particle size and colloidal stability, as well as maintaining immunogenicity. This most recent milestone confirms that, in the context of lethal challenge with Sudan ebolavirus, complete protection is maintained with the thermostabilized formulation.

In June 2022, 100% protection of NHPs against lethal Marburg marburgvirus challenge was achieved using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with sterile water immediately

37

prior to use. This important milestone is part of an ongoing collaboration with UH Manoa, demonstrating the successful presentation of one or more antigen(s) within the same formulation while maintaining full potency and thermostability. It further demonstrates the broad applicability of the heat stable vaccine platform, and its potential role in the U.S. government's initiative for pandemic preparedness.

In September 2023, positive data demonstrated two-year stability of thermostabilized bivalent and trivalent filovirus vaccine candidates at temperatures of 40 degrees C (104 degrees F) when formulated in a single vial, needing reconstitution only with sterile water immediately prior to use. This important milestone is part of an ongoing collaboration with UH Manoa, demonstrating the successful presentation of one or more antigen(s) within the same formulation while maintaining full potency and thermostability. It further demonstrates the broad applicability of the heat stable vaccine platform, and its potential role in the U.S. government's initiative for pandemic preparedness.

In January 2024, Vaccine published the preclinical efficacy results of our novel, single-vial, thermostabilized bivalent filovirus vaccine providing 100% protection against both Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections. The manuscript was entitled “Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection”.

In April 2024, we received orphan drug designation for the active ingredient in SuVax™, the subunit protein vaccine of recombinantly expressed SUDV glycoprotein, for the prevention and post-exposure prophylaxis against SUDV infection.

In April 2024, we received orphan drug designation for the active ingredient in MarVax™, the subunit protein vaccine of recombinantly expressed MARV glycoprotein, for the prevention and post-exposure prophylaxis against MARV infection. 

In April 2024, we received notice of intent to grant additional patents based on our patent application titled “Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines” in the United Kingdom and South Africa, with other international jurisdictions pending.

RiVax® – for Protection Against Ricin Toxin Exposure

RiVax® is our proprietary vaccine candidate being developed to protect against exposure to ricin toxin and if approved, would be the first ricin vaccine. The immunogen in RiVax® induces a protective immune response in animal models of ricin exposure and functionally active antibodies in humans. The immunogen consists of a genetically inactivated ricin A chain subunit that is enzymatically inactive and lacks residual toxicity of the holotoxin. RiVax® has demonstrated statistically significant (p < 0.0001) preclinical survival results, providing 100% protection against acute lethality in an aerosol exposure non-human primate model (Roy et al, 2015, Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection, PNAS USA 112:3782-3787), and has also been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Results of the first Phase 1 human trial of RiVax® established that the immunogen was safe and induced antibodies that we believe may protect humans from ricin exposure. The antibodies generated from vaccination, concentrated and purified, were capable of conferring immunity passively to recipient animals, indicating that the vaccine was capable of inducing functionally active antibodies in humans. The outcome of this study was published in the Proceedings of the National Academy of Sciences (Vitetta et al., 2006, A Pilot Clinical Trial of a Recombinant Ricin Vaccine in Normal Humans, PNAS, 103:2268-2273). The second trial that was completed in September 2012 and was sponsored by University of Texas Southwestern Medical Center (“UTSW”) evaluated a more potent formulation of RiVax® that contained an Alum adjuvant. The results of the Phase 1b study indicated that Alum-adjuvanted RiVax® was safe and well tolerated, and induced greater ricin neutralizing antibody levels in humans than adjuvant-free RiVax®. The outcomes of this second study were published in the Clinical and Vaccine Immunology.

38

We have adapted the original manufacturing process for the immunogen contained in RiVax® for thermostability and large scale manufacturing and recent studies have confirmed that the thermostabilized RiVax® formulation enhances the stability of the RiVax® antigen, enabling storage for at least 1 year at temperatures up to 40 degrees C (104 degrees F). The program will pursue approval via the FDA “Animal Rule” since it is not possible to test the efficacy of the vaccine in a clinical study which would expose humans to ricin. Uniform, easily measured and species-neutral immune correlates of protection that can be measured in humans and animals, and are indicative of animal survival to subsequent ricin challenge, are central to the application of the “Animal Rule.” Recent work has identified such potential correlates of immune protection in animals and work to qualify and validate these approaches is continuing, with the goal of utilizing these assays in a planned Phase 1/2 clinical trial with the thermostable RiVax® formulation. During September 2018, we published an extended stability study of RiVax®, showing up to 100% protection in mice after 12 months storage at 40 degrees C (104 degrees F) as well as identification of a potential in vitro stability indicating assay, critical to adequately confirming the long-term shelf life of the vaccine. We have entered into a collaboration with IDT Biologika GmbH (“IDT”) to scale-up the formulation/filling process and continue development and validation of analytical methods established at IDT to advance the program. We also initiated a development agreement with Emergent BioSolutions, Inc. (“EBS”) to implement a commercially viable, scalable production technology for the RiVax® drug substance protein antigen.

The development of RiVax® has been sponsored through a series of overlapping challenge grants, UC1, and cooperative grants, U01, from the NIH, granted to us and to UTSW where the vaccine originated. The second clinical trial was supported by a grant from the FDA’s Office of Orphan Products to UTSW. To date, we and UTSW have collectively received approximately $25 million in grant funding from the NIH for the development of RiVax®. In September 2014, we entered into a contract with the NIH for the development of RiVax® pursuant to which we were awarded an additional $21.2 million of funding in the aggregate. The development agreements with EBS and IDT were specifically funded under this NIH contract.

In 2017, NIAID exercised options to fund additional animal efficacy studies and good manufacturing practices compliant RiVax® bulk drug substance and finished drug product manufacturing, which is required for the conduct of future preclinical and clinical safety and efficacy studies. The exercised options provide us with approximately $4.5 million in additional non-dilutive funding, bringing the total amount awarded to date under this contract to $21.2 million, which expired in February 2021. The total award of up to $21.2 million supported the preclinical, manufacturing and clinical development activities necessary to advance heat stable RiVax® with the FDA. In addition to this funding for the development of RiVax®, biomarkers for RiVax® testing have been successfully identified, facilitating potential approval under the FDA Animal Rule.

During December 2019, we initiated a third Phase 1 double-blind, placebo-controlled, randomized study in eight healthy adult volunteer subjects designed to evaluate the safety and immunogenicity of RiVax® utilizing ThermoVax®. During January 2020, we suspended the study after Emergent Manufacturing Operations Baltimore LLC (“EMOB”), the manufacturer of the drug substance, notified us that, after releasing the final drug product to us, EMOB identified that the active drug substance tested outside the established specification parameters. Two subjects had received doses as part of the study before the manufacturer provided this notice. Those two subjects were monitored with no safety issues noted and data was captured in accordance with the study protocol. They did not receive further doses of study drug.

During April 2020, we received notification from NIAID that they would not be exercising the final contract option to support the conduct of a Phase 1/2 clinical study in healthy volunteers. As a result, the total contract award will not exceed $21.2 million. This contract expired in February 2021.

In November 2021, an article was published on pre-clinical immunogenicity studies for RiVax® demonstrating enduring protection for at least 12 months post-vaccination. These results, coupled with the previous demonstration of efficacy in mice and NHPs as well as long-term thermostability (at least 1 year at 40 degrees C or 104 degrees F), reinforce the practicality of stockpiling and potentially utilizing the RiVax® vaccine in warfighters and civilian first responders without the complexities that arise for vaccines that require stringent cold chain handling.

39

RiVax® has been granted Orphan Drug designation as well as Fast Track designation by the FDA for the prevention of ricin intoxication. In addition, RiVax® has also been granted Orphan Drug designation in the European Union (“EU”) from the EMA Committee for Orphan Medical Products.

Assuming development efforts are successful for RiVax®, we believe potential government procurement contract(s) could reach as much as $200 million. This potential procurement contract information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this potential procurement contract value based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be realized.

As a new chemical entity, an FDA approved RiVax® vaccine has the potential to qualify for a biodefense Priority Review Voucher (“PRV”). Approved under the 21st Century Cures Act in late 2016, the biodefense PRV is awarded upon approval as a medical countermeasure when the active ingredient(s) have not been otherwise approved for use in any context. PRVs are transferable and can be sold, with sales in recent years of approximately $100 million. When redeemed, PRVs entitle the user to an accelerated review period of nine months, saving a median of seven months review time as calculated in 2009. However, FDA must be advised 90 days in advance of the use of the PRV and the use of a PRV is associated with an additional user fee ($1.3 million for fiscal year 2024).

In July 2022, we signed a worldwide exclusive agreement to license and supply our ricin antigen, used in our RiVax® vaccine, to SERB, for development of a novel therapeutic treatment against ricin toxin poisoning. In pursuit of a ricin antidote, SERB will leverage its unique broad-spectrum polyclonal antibody platform, gained in its acquisition of BTG Specialty Pharmaceuticals. This specialized manufacturing process generates binding fragments from antibodies that are specific to a given antigen, helping to ensure potency and purity. This platform is currently used to manufacture two of SERB’s currently marketed products, CroFab® and DigiFab®.

In December 2022, we published a paper demonstrating statistically significant correlates of protection predicting survival after lethal aerosolized ricin challenge in non-human primates. The article titled “Serum antibody profiling identifies vaccine-induced correlates of protection against aerosolized ricin toxin in rhesus macaques” was published in the journal npj Vaccines.

Ricin Toxin

Ricin toxin can be cheaply and easily produced, is stable over long periods of time, is toxic by several routes of exposure and thus has the potential to be used as a biological weapon against military and/or civilian targets. As a bioterrorism agent, ricin could be disseminated as an aerosol, by injection, or as a food supply contaminant. The potential use of ricin toxin as a biological weapon of mass destruction has been highlighted in a Federal Bureau of Investigation Bioterror report released in November 2007 titled Terrorism 2002-2005, which states that “Ricin and the bacterial agent anthrax are emerging as the most prevalent agents involved in WMD investigations.” Al Qaeda in the Arabian Peninsula had threatened the use of ricin toxin to poison food and water supplies and in connection with explosive devices. Domestically, the threat from ricin remains a concern for security agencies. In April 2013, letters addressed to the U.S. President, a Senator and a judge tested positive for ricin. As recently as September 2020, ricin-laced letters addressed to the White House and others addressed to Texas law enforcement agencies were intercepted before delivery raising fresh concerns about the deadly toxin.

The Centers for Disease Control and Prevention has classified ricin toxin as a Category B biological agent. Ricin works by first binding to glycoproteins found on the exterior of a cell, and then entering the cell and inhibiting protein synthesis leading to cell death. Once exposed to ricin toxin, there is no effective therapy available to reverse the course of the toxin. The recent ricin threat to government officials has heightened the awareness of this toxic threat. Currently, there is no FDA approved vaccine to protect against the possibility of ricin toxin being used in a terrorist attack, or its use as a weapon on the battlefield nor is there a known antidote for ricin toxin exposure.

40

SGX943 – for Treating Emerging and/or Antibiotic-Resistant Infectious Diseases

SGX943 is an IDR, containing the same active ingredient as SGX942. Dusquetide is a fully synthetic, 5-amino acid peptide with high aqueous solubility and stability. Extensive in vivo preclinical studies have demonstrated enhanced clearance of bacterial infection with SGX943 administration. SGX943 has shown efficacy against both Gram-negative and Gram-positive bacterial infections in preclinical models, independent of whether the bacteria is antibiotic-resistant or antibiotic-sensitive.

The innate immune system is responsible for rapid and non-specific responses to combat bacterial infection. Augmenting these responses represents an alternative approach to treating bacterial infections. In animal models, IDRs are efficacious against both antibiotic-sensitive and antibiotic-resistant infections, both Gram-positive and Gram-negative bacteria, and are active irrespective of whether the bacteria occupy a primarily extracellular or intracellular niche. IDRs are also effective as stand-alone agents or in conjunction with antibiotics. An IDR for the treatment of serious bacterial infections encompasses a number of clinical advantages including:

Treatment when antibiotics are contraindicated, such as:
obefore the infectious organism and/or its antibiotic susceptibility is known; or
oin at-risk populations prior to infection.
An ability to be used as an additive, complementary treatment with antibiotics, thereby:
oenhancing efficacy of sub-optimal antibiotic regimens (e.g., partially antibiotic-resistant infections);
oenhancing clearance of infection, thereby minimizing the generation of antibiotic resistance (e.g., in treating melioidosis); and
oreducing the required antibiotic dose, again potentially minimizing the generation of antibiotic resistance.
An ability to modulate the deleterious consequences of inflammation in response to the infection, including the inflammation caused by antibiotic-driven bacterial lysis.
Being unlikely to generate bacterial resistance since the IDR acts on the host, and not the pathogen.

Importantly, systemic inflammation and multi-organ failure is the ultimate common outcome of not only emerging and/or antibiotic-resistant infectious diseases, but also of most biothreat agents (e.g., Burkholderia pseudomallei), indicating that dusquetide would be applicable not only to antibiotic-resistant infection, but also to biothreat agents, especially where the pathogen is not known and/or has been engineered for enhanced antibiotic resistance.

Intellectual Property

In addition to orphan drug exclusivity, we maintain patent and other intellectual property protection in the U.S. and other countries with respect to our technology and product candidates. We seek to protect our proprietary position in reliance upon trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties.

41

Critical Accounting Policies

Our management’s discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”). The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses, and the disclosure of contingent assets and liabilities. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in the notes to our financial statements appearing at the beginning of this Quarterly Report on Form 10-Q, we believe that the following accounting policies are those most critical to the assumptions and estimates used in the preparation of our financial statements.

Revenue Recognition

Our revenues include revenues generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when we incur reimbursable internal expenses that are related to the government contracts and grants.

We also record revenue from contracts with customers in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), Revenue From Contracts with Customers. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Certain amounts received from or billed to customers in accordance with contract terms are deferred and recognized as future performance obligations are satisfied.  All amounts earned under contracts with customers other than sales-based royalties are classified as license revenues. Sales-based royalties under our license agreements would be recognized as royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any royalty revenue.

Research and Development Costs

As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contract and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating

42

the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to:

contract research organizations (“CROs”) in connection with performing research activities on our behalf and conducting preclinical studies and clinical trials on our behalf;
investigative sites or other service providers in connection with clinical trials;
vendors in connection with preclinical and clinical development activities; and
vendors related to product manufacturing and distribution of preclinical and clinical supplies.

We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing fees, we estimate the time period over which services will be performed, enrollment of patients, number of sites active and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions such as the fair value of stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

Material Changes in Results of Operations

Three Months Ended March 31, 2024 Compared to March 31, 2023

For the three months ended March 31, 2024 we had a net loss of $1,915,327 as compared to a net loss of $1,046,109 for the same prior year period, representing increased net loss of $869,218 or 83%. This increase in net loss was primarily due to the recognition of an income tax benefit during the three months ended March 31, 2023 with no corresponding income tax benefit recognized during the three months ended March 31, 2024.

Our revenues and associated costs incurred relate to government contracts, grants and subawards received to support the development of SGX943 for treatment of emerging and/or antibiotic-resistant infectious diseases; development of CiVax™, our vaccine candidate for the prevention of COVID-19, and evaluation of HyBryte™ for expanded treatment in patients with early-stage CTCL. For the three months ended March 31, 2024, we had revenues of $117,029 as compared to $257,178 for the same prior year period, representing a decrease of $140,149 or 54%. We also incurred costs related to those revenues for the three

43

months ended March 31, 2024 and 2023 of $117,029 and $226,040, respectively, representing a decrease of $109,011 or 48%. Our gross profit for the three months ended March 31, 2024 was zero or 0% of total revenues, as compared to a gross profit of $31,138 or 12% of total revenues for the same period in 2023, representing a decrease of $31,138 or 100%. The decrease in revenue and gross profit during the three months ended March 31, 2024 was primarily related to the conclusion of higher margin grants associated with the development of SGX943 and CiVax™ and a decrease in revenue associated with the zero margin grant for the HyBryte™ investigator initiated study.

Research and development expenses were $1,095,040 for the three months ended March 31, 2024 as compared to $946,451 for the same period in 2023, representing an increase of $148,589 or 16%. The increase was primarily due to an increase in preliminary costs associated with the anticipated initiation of our Phase 2 study in Behçet’s Disease and the second confirmatory Phase 3 CTCL trial.

General and administrative expenses were $1,022,051 for the three months ended March 31, 2024, as compared to $1,235,376 for the same period in 2023, representing a decrease of $213,325 or 17%. The decrease in general and administrative expenses for the three months ended March 31, 2024 was primarily attributable to a reduction in legal and professional fees associated with a reverse stock split of our issued and outstanding shares of common stock during the three months ended March 31, 2023.

The amendment to the convertible debt financing agreement with Pontifax Medison Finance (“Pontifax”) – see Note 4, resulted in the extinguishment of the original convertible debt for accounting purposes. We elected to account for the amended convertible debt using the fair value option, which requires us to record changes in fair value as a component of other income or expense. The fair value of the convertible debt as of March 31, 2024 was $2,996,136, which resulted in the recognition of $165,382 of other income from the change in the fair value of the convertible debt on our accompanying condensed consolidated statements of operations during the three months ended March 31, 2024. The fair value of the convertible debt was estimated using the Monte Carlo valuation method.

Interest expense, net for the three months ended March 31, 2024 was ($28,842) as compared to $103,568 for the same period in 2023, representing a decrease of $132,410 or 128%. The decrease is primarily associated with the reduction in interest resulting from the repayment of $6M of the convertible debt principal balance.

Financial Condition

Cash and Working Capital

As of March 31, 2024, we had cash and cash equivalents of $7,091,548 as compared to $8,446,158 as of December 31, 2023, representing a decrease of $1,354,610 or 16%. As of March 31, 2024, we had working capital of $607,499 as compared to working capital of $3,355,212 as of December 31, 2023, representing a decrease of $2,747,713 or 82%. The decrease in cash and cash equivalents was primarily related to cash used in operating activities during the three months ended March 31, 2024. The decrease in working capital is primarily the result of the reclassification of approximately $1 million of the convertible debt balance from a non-current liability as of December 31, 2023 to a current liability as of March 31, 2024 (resulting from the amendment to the loan and security agreement with Pontifax – see Note 4), and cash used in operating activities during the three months ended March 31, 2024.

Based on our operating budget, current rate of cash outflows, cash on hand, and proceeds from government contract and grant programs, we believe that we have sufficient resources available to support our development activities and business operations and timely satisfy our obligations as they become due through the first quarter of 2025. We do not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support our operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern through 12 months after the date that the financial statements are issued.

44

To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, we plan to secure additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations, securing additional proceeds from government contract and grant programs, securing additional proceeds available from the sale of shares of our common stock via an At Market Issuance Sales Agreement and potentially amending the loan agreement with Pontifax to reduce the conversion price in order to allow for conversion of a portion of the debt which will reduce our debt repayments; however, none of these alternatives are committed at this time. There can be no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all, identify and enter into any strategic transactions that will provide the capital that we will require or achieve the other strategies to alleviate the conditions that raise substantial doubt about our ability to continue as a going concern. If none of these alternatives are available, or if available, are not available on satisfactory terms, we will not have sufficient cash resources and liquidity to fund our business operations for at least the 12 months following the date the financial statements are issued. The failure to obtain sufficient capital on acceptable terms when needed may require us to delay, limit, or eliminate the development of business opportunities and our ability to achieve our business objectives and our competitiveness, and our business, financial condition, and results of operations will be materially adversely affected. In addition, market instability, including as a result of geopolitical instability, may reduce our ability to access capital, which could negatively affect our liquidity and ability to continue as a going concern. In addition, the perception that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability to meet our contractual obligations.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Our plans with respect to our liquidity management include, but are not limited to, the following:

We have up to approximately $673,000 in active government grant funding still available as of March 31, 2024 to support our associated research programs through May 2026, provided the federal agencies do not elect to terminate the grants for convenience. We plan to submit additional contract and grant applications for further support of our programs with various funding agencies. However, there can be no assurance that we will obtain additional governmental grant funding;
We have continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expect to continue to do so for the foreseeable future;
We will continue to pursue NOL sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program if the program is available;
We plan to pursue potential partnerships for pipeline programs as well as continue to explore merger and acquisition strategies. However, there can be no assurances that we can consummate such transactions;
We completed a public offering on April 22, 2024 of 3,275,000 shares of our common stock, pre-funded warrants to purchase 8,600,000 shares of our common stock and common warrants to purchase up to 11,875,000 shares of our common stock at a combined public offering price of $0.40. The pre-funded warrants have an exercise price of $0.001. The common warrants have an exercise price of $0.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to us from this offering were approximately $4.75 ($4.3 net) million before deducting commissions and other estimated offering expenses. We plan to use the proceeds for further support of our programs, as well as for working capital. See Note 8; and

45

We are currently evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that we can consummate such a transaction, or consummate a transaction at favorable pricing.

Nasdaq Capital Market Listing Requirements

On June 23, 2023, we received a letter from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the 30 consecutive business day period between May 9, 2023 through June 22, 2023, we did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that we would be provided with a compliance period of 180 calendar days, or until December 20, 2023, in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). We were unable to regain compliance prior to the expiration of the 180-day period.

On December 21, 2023, we received another written notice (the “Notice”) from the Staff stating that we had not complied with the minimum bid price requirement and was not eligible for a second 180-day period because we did not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for Nasdaq. As a result, the Notice indicated that our common stock would be suspended from trading on Nasdaq unless we requested a hearing before the Nasdaq Hearings Panel by December 28, 2023. On March 26, 2024, we had an oral hearing with a Nasdaq Hearings Panel to appeal the Staff’s delisting determination, which stayed the trading suspension of the Common Stock pending a final written decision by the Nasdaq Hearings Panel and expiration of any additional extension period granted by the panel following the hearing.

In order to regain compliance with Nasdaq’s minimum bid price requirement, our common stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.

Expenditures

Under our budget and based upon our existing product development agreements and license agreements, we expect our total research and development expenditures for the next 12 months to be approximately $6.0 million before any contract or grant reimbursements, all of which relates to the Specialized BioTherapeutics business segment. We anticipate contract and grant reimbursements revenue in the next 12 months of approximately $0.3 million to offset research and development expenses in the Specialized BioTherapeutics business segment.

46

The table below details our costs for research and development by program and amounts reimbursed for the three months ended March 31, 2024 and 2023:

    

2024

    

2023

Research & Development Expenses

 

  

 

  

RiVax® and ThermoVax® Vaccines

$

45,839

$

30,533

SGX942 (Dusquetide)

 

19,258

 

(318)

HyBryte™ (SGX301 or synthetic hypericin)

 

840,393

 

822,096

Other

 

189,550

 

94,140

Total

$

1,095,040

$

946,451

Reimbursed under Government Contracts and Grants

 

  

 

  

RiVax® and ThermoVax® Vaccines

$

$

CiVax™

35,247

SGX943

 

 

35,429

HyBryte™ (investigator-initiated study)

117,029

155,365

Total

117,029

226,040

Grand Total

$

1,212,069

$

1,172,491

Contractual Obligations

We have licensing fee commitments of approximately $230,000 as of March 31, 2024 over the next five years for several licensing agreements with partners and universities. Additionally, we have collaboration and license agreements, which upon clinical or commercialization success may require the payment of milestones of up to approximately $13.2 million, royalties on net sales of covered products ranging from 2% to 3%, sub-license IND milestones on covered products of up to approximately $200,000, sub-license income royalties on covered products up to 15% and sub-license global net sales royalties on covered products ranging from 1.5% to 2.5%, if and when achieved. However, there can be no assurance that clinical or commercialization success will occur.

We currently lease office space which serves as our corporate headquarters, and both of our business segments (Specialized BioTherapeutics and Public Health Solutions), operate from this space. Pursuant to an amendment on June 21, 2022, the lease has been extended to October 2025. The current rent of $11,367 per month will be maintained until November 2024 when it will be increased to $11,625 per month where it will remain until expiration. Our office space is sufficient for our current needs.

In September 2014, we entered into an asset purchase agreement with Hy Biopharma pursuant to which we acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharma’s synthetic hypericin product. As consideration for the assets acquired, we initially paid $275,000 in cash and issued 12,328 shares of common stock with a fair value based upon our stock price on the date of grant of $3.75 million. These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in our research and development activities and do not have alternative future use pursuant to GAAP.

In January 2020, our Board of Directors authorized an amendment to Dr. Schaber’s employment agreement to increase the number of shares of common stock from 334 to 33,334, issuable to Dr. Schaber immediately prior to the completion of a transaction, or series or a combination of related transactions, negotiated by our Board of Directors whereby, directly or indirectly, a majority of our capital stock or a majority of our assets are transferred from us and/or our stockholders to a third party.

In March 2020, we filed a prospectus supplement covering the offer and sale of up to 130,413 shares of our common stock which were issued to Hy Biopharma. We were required to issue the shares to Hy Biopharma as payment following the achievement of a milestone under the asset purchase agreement, specifically, the Phase 3 clinical trial of HyBryte™ being successful in the treatment of CTCL. The number of shares of our common

47

stock issued to Hy Biopharma was calculated using an effective price of $38.40 per share, based upon a formula set forth in the asset purchase agreement.

Provided the final success-oriented milestone of FDA approval is attained, we will be required to make a payment of up to $5 million, if and when achieved. The potential future payment will be payable in our common stock, not to exceed 19.9% of our outstanding stock. As of March 31, 2024, no other milestone or royalty payments have been paid or accrued.

In December 2020, we entered into a $20 million convertible debt financing agreement with Pontifax, the healthcare-dedicated venture and debt fund of the Pontifax life science funds. Under the terms of the agreement with Pontifax, we had access to up to $20 million in convertible debt financing in three tranches, which will mature on June 15, 2025 and had an interest-only period through December 2022 with a rate of 8.47% on borrowed amounts and a 1% rate on amounts available but not borrowed as an unused line of credit fee. After the interest-only period, the outstanding principal was to be repaid in quarterly payments of $1 million each commencing in the first quarter of 2023. The agreement is secured by a lien covering substantially all of our assets, other than intellectual property.

Upon the closing of this transaction, we borrowed the first tranche of $10 million. We did not utilize our option to draw the second or third tranche of $5 million each, which expired on December 15, 2021 and March 15, 2022, respectively.

In April 2023, we entered into an amendment to the convertible debt financing agreement with Pontifax. The amendment required the immediate payment of $5 million of the outstanding principal balance and any accrued interest, waived any prepayment charge in connection with the repayment of this amount and resulted in an outstanding principal balance of $3 million. The amendment also provided for a new interest only period from the date of the amendment through June 30, 2024, reduced quarterly principal repayments from $1 million to $750,000 and eliminated the minimum cash covenant. Further, the Amendment reduced the conversion price with respect to the remaining principal amount under the agreement to (i) 90% of the closing price of our common stock on the day before the delivery of the conversion notice with respect to the first 588,599 shares of our common stock issuable upon conversion and to (ii) $1.70 with respect to all shares of our common stock issuable upon conversion in excess of the first 588,599 shares so issued. The remaining terms of the agreement remain in effect without modification.

On January 3, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Company’s common stock. Upon conversion, the Company issued 146,199 shares of the Company’s common stock at $0.68 per share, reducing the remaining principal balance by $99,416. Pontifax may elect to convert the remaining outstanding loan drawn under the first tranche into additional shares of the Company’s common stock at any time prior to repayment. The Company also has the ability to force the conversion of the loan into shares of its common stock, subject to certain conditions.

The amendment to the convertible debt financing agreement with Pontifax resulted in the extinguishment of the original convertible debt for accounting purposes. We elected to account for the amended convertible debt using the fair value option, which requires us to record changes in fair value as a component of other income or expense. The fair value of the convertible debt as of March 31, 2024 was $2,996,136, which resulted in the recognition of $165,382 of other income from the change in the fair value of the convertible debt on our accompanying condensed consolidated statements of operations during the three months ended March 31, 2024. The fair value of the convertible debt was estimated using the Monte Carlo valuation method.

Interest expense incurred during the three months ended March 31, 2024 and 2023 was $61,239 and $187,964, respectively. Interest expense paid during the three months ended March 31, 2024 and 2023 was $64,047 and $213,490, respectively.

48

Contingencies

We follow subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to us but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. A liability is only recorded if we determine that it is both probable and reasonably estimable.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are in short-term marketable securities, in addition to the foreign exchange rate fluctuations related to our foreign currency transactions. We do not have any derivative financial instruments. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure.

ITEM 4 – CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As of March 31, 2024, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) using the criteria set forth by the Committee of Sponsoring Organization of the Treadway Commission (“COSO”) in Internal Control – Integrated Framework (2013 Framework). Our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded, based upon the evaluation described above, that as of March 31, 2024, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such material information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

Changes in Internal Controls

There were no changes in our internal controls over financial reporting identified in connection with the evaluation of such internal controls that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

49

PART II - OTHER INFORMATION.

ITEM 1 – LEGAL PROCEEDINGS

From time to time, we are a party to claims and legal proceedings arising in the ordinary course of business. Our management evaluates our exposure to these claims and proceedings individually and in the aggregate and allocates additional monies for potential losses on such litigation if it is possible to estimate the amount of loss and if the amount of the loss is probable.

ITEM 1A – RISK FACTORS

Our business faces significant risks. These risks include those disclosed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. If any of the events or circumstances described in the referenced risks actually occur, our business, financial condition or results of operations could be materially adversely affected and such events or circumstances could cause our actual results to differ materially from the results contemplated by the “forward-looking” statements contained in this report. These risks should be read in conjunction with the other information set forth in this Quarterly Report as well as in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in our periodic reports on Form 10-Q and Form 8-K. Additional risks not presently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business, financial condition and results of operations. We do not undertake to update any of the “forward-looking” statements or to announce the results of any revisions to these “forward-looking” statements, except as required by law.

Shareholders may suffer substantial dilution related to issued pre-funded warrants, common stock warrants, options and convertible notes.

As of May 3, 2024, we had a number of agreements or obligations that may result in dilution to investors. These include:

pre-funded warrants to purchase a total of 7,042,000 shares of our common stock at a current weighted average exercise price of $0.001 per share;

common stock warrants to purchase a total of 18,413,073 shares of our common stock at a current weighted average exercise price of $0.79;

options to purchase approximately 906,226 shares of our common stock at a current weighted average exercise price of $5.52; and

convertible promissory notes issued to Pontifax Medison Finance, of which there was $2,745,745 of principal and $21,529 of accrued interest outstanding, which notes are convertible at $1.70 per share; and

5,096,447 shares of common stock available for future issuance under our 2015 Equity Incentive Plan.

We have granted, and expect to grant in the future, options to purchase shares of our common stock to our directors, employees and consultants under our incentive compensation plan. To the extent that pre-funded warrants, common stock warrants, options or convertible promissory notes are exercised or converted, our stockholders will experience dilution and our stock price may decrease.

50

Additionally, the sale, or even the possibility of the sale, of the shares of common stock underlying these pre-funded warrants, common stock warrants, options and convertible promissory notes could have an adverse effect on the market price for our securities or on our ability to obtain future financing.

ITEM 5 – OTHER INFORMATION

During the quarter ended March 31, 2024, no directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

51

ITEM 6 – EXHIBITS

EXHIBIT NO.

   

DESCRIPTION

31.1

Certification of Chief Executive Officer pursuant to Exchange Act rule 13(a)-14(a) (under Section 302 of the Sarbanes-Oxley Act of 2002).

31.2

Certification of Chief Financial Officer pursuant to Exchange Act rule 13(a)-14(a) (under Section 302 of the Sarbanes-Oxley Act of 2002).

32.1

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document

101.SCH

Inline XBRL Taxonomy Schema

101.CAL

Inline XBRL Taxonomy Calculation Linkbase

101.DEF

Inline XBRL Taxonomy Definition Linkbase

101.LAB

Inline XBRL Taxonomy Label Linkbase

101.PRE

Inline XBRL Taxonomy Presentation Linkbase

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

52

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SOLIGENIX, INC.

May 10, 2024

By

/s/ Christopher J. Schaber

Christopher J. Schaber, PhD

President and Chief Executive Officer

(Principal Executive Officer)

May 10, 2024

By

/s/ Jonathan Guarino

Jonathan Guarino

Chief Financial Officer, Senior Vice President,

and Corporate Secretary

(Principal Financial and Accounting Officer)

53

EX-31.1 2 sngx-20240331xex31d1.htm EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934

I, Christopher J. Schaber, Ph.D., certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Soligenix, Inc. for the fiscal quarter ended March 31, 2024;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 10, 2024

  

/s/ Christopher J. Schaber

Christopher J. Schaber, Ph.D.

President and Chief Executive Officer


EX-31.2 3 sngx-20240331xex31d2.htm EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934

I, Jonathan Guarino, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Soligenix, Inc. for the fiscal quarter ended March 31, 2024;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 10, 2024

  

/s/ Jonathan Guarino

Jonathan Guarino

Senior Vice President and Chief Financial Officer


EX-32.1 4 sngx-20240331xex32d1.htm EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Form 10-Q of Soligenix, Inc. (the “Company”) for the fiscal quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 10, 2024

  

/s/ Christopher J. Schaber

Christopher J. Schaber, Ph.D.

President and Chief Executive Officer


EX-32.2 5 sngx-20240331xex32d2.htm EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Form 10-Q of Soligenix, Inc. (the “Company”) for the fiscal quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 10, 2024

  

/s/ Jonathan Guarino

Jonathan Guarino

Senior Vice President and Chief Financial Officer


EX-101.SCH 6 sngx-20240331.xsd EX-101.SCH 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Debt - Payments due (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Commitments and Contingencies - Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Carrying Value of Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Summary of Significant Accounting Policies - Loss per share, Warrants and Options expirations (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Debt - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Operating Segments (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Operating Segments link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Operating Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 sngx-20240331_cal.xml EX-101.CAL EX-101.DEF 8 sngx-20240331_def.xml EX-101.DEF EX-101.LAB 9 sngx-20240331_lab.xml EX-101.LAB EX-101.PRE 10 sngx-20240331_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2024
May 03, 2024
Document And Entity Information    
Document Type 10-Q  
Document Period End Date Mar. 31, 2024  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 001-14778  
Entity Registrant Name SOLIGENIX, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 41-1505029  
Entity Address, Address Line One 29 EMMONS DRIVE  
Entity Address, Address Line Two SUITE B-10  
Entity Address, City or Town PRINCETON,  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08540  
City Area Code 609  
Local Phone Number 538-8200  
Title of 12(b) Security Common Stock, par value $.001 per share  
Trading Symbol SNGX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   15,799,837
Entity Central Index Key 0000812796  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 7,091,548 $ 8,446,158
Contracts and grants receivable 117,029  
Unbilled revenue   171,254
Research and development incentives receivable, current 25,253 23,894
Deferred issuance cost 132,681  
Prepaid expenses and other current assets 451,876 866,014
Total current assets 7,818,387 9,507,320
Security deposit 22,777 22,777
Office furniture and equipment, net 10,339 11,927
Right-of-use lease assets 200,569 229,834
Research and development incentives receivable, net of current portion 6,313 25,468
Total assets 8,058,385 9,797,326
Current liabilities:    
Accounts payable 1,436,728 1,111,226
Accrued expenses 2,602,665 2,418,002
Accrued compensation 50,216 251,115
Lease liabilities, current 125,143 121,765
Convertible debt 2,996,136 2,250,000
Total current liabilities 7,210,888 6,152,108
Non-current liabilities:    
Convertible debt   1,010,934
Lease liabilities, net of current portion 79,125 111,862
Total liabilities 7,290,013 7,274,904
Commitments and contingencies (Note 6)
Shareholders' equity:    
Preferred stock, 350,000 shares authorized; none issued or outstanding at March 31, 2024 and December 31, 2023, respectively 0 0
Common stock, $.001 par value; 75,000,000 shares authorized; 10,524,437 and 10,378,238 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 10,524 10,378
Additional paid-in capital 228,353,208 228,193,977
Accumulated other comprehensive income 24,143 22,243
Accumulated deficit (227,619,503) (225,704,176)
Total shareholders' equity 768,372 2,522,422
Total liabilities and shareholders' equity $ 8,058,385 $ 9,797,326
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Condensed Consolidated Balance Sheets    
Preferred stock, shares authorized 350,000 350,000
Preferred stock, shares outstanding 0 0
Common stock, par value (per share) $ 0.001 $ 0.001
Common stock, shares authorized 75,000,000 75,000,000
Common stock, shares issued 10,524,437 10,378,238
Common stock, shares outstanding 10,524,437 10,378,238
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenues $ 117,029 $ 257,178
Cost of revenues (117,029) (226,040)
Gross profit   31,138
Operating expenses:    
Research and development 1,095,040 946,451
General and administrative 1,022,051 1,235,376
Total operating expenses 2,117,091 2,181,827
Loss from operations (2,117,091) (2,150,689)
Other income (expense):    
Foreign currency transaction gain (loss) 1,209 (366)
Interest income (expense), net 28,842 (103,568)
Research and development incentives 6,331 6,448
Other income   40,869
Change in fair value of convertible debt 165,382  
Total other income (expense) 201,764 (56,617)
Net loss before income taxes (1,915,327) (2,207,306)
Income tax benefit   1,161,197
Net loss applicable to common stockholders $ (1,915,327) $ (1,046,109)
Basic net loss per share (in Dollars per share) $ (0.18) $ (0.36)
Diluted net loss per share (in Dollars per share) $ (0.18) $ (0.36)
Basic weighted average common shares outstanding (in Shares) 10,521,233 2,914,929
Diluted weighted average common shares outstanding (in Shares) 10,521,233 2,914,929
Grant revenue    
Total revenues $ 117,029 $ 257,178
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Condensed Consolidated Statements of Comprehensive Loss    
Net loss $ (1,915,327) $ (1,046,109)
Other comprehensive income (loss):    
Foreign currency translation adjustments 1,900 (12,153)
Comprehensive loss $ (1,913,427) $ (1,058,262)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) - USD ($)
Preferred Stock
Series D Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total
Balance at Dec. 31, 2022   $ 2,909 $ 217,064,964 $ 24,747 $ (219,563,446) $ (2,470,826)
Balance (in shares) at Dec. 31, 2022   2,908,578        
Balance at Dec. 31, 2022 $ 43          
Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement   $ 21 70,709     70,730
Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement (in shares)   21,195        
Issuance of common stock pursuant to B. Riley At Market Issuance Sales Agreement     (2,341)     (2,341)
Declaration of Series D preferred stock $ (43)          
Share-based compensation expense     73,634     73,634
Foreign currency translation adjustment       (12,153)   (12,153)
Net loss         (1,046,109) (1,046,109)
Balance at Mar. 31, 2023   $ 2,930 217,206,966 12,594 (220,609,555) (3,387,065)
Balance (in Shares) at Mar. 31, 2023   2,929,773        
Balance at Dec. 31, 2023   $ 10,378 228,193,977 22,243 (225,704,176) 2,522,422
Balance (in shares) at Dec. 31, 2023   10,378,238        
Issuance of common stock associated with conversion of debt   $ 146 99,270     99,416
Issuance of common stock associated with conversion of debt (in shares)   146,199        
Share-based compensation expense     59,961     59,961
Foreign currency translation adjustment       1,900   1,900
Net loss         (1,915,327) (1,915,327)
Balance at Mar. 31, 2024   $ 10,524 $ 228,353,208 $ 24,143 $ (227,619,503) $ 768,372
Balance (in Shares) at Mar. 31, 2024   10,524,437        
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating activities:    
Net loss $ (1,915,327) $ (1,046,109)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization and depreciation 1,588 1,785
Non-cash lease expense 29,265 26,936
Share-based compensation 59,961 73,634
Change in fair value of convertible debt (165,382)  
Amortization of deferred issuance costs associated with convertible debt   10,242
Change in operating assets and liabilities:    
Contracts and grants receivable 54,225 (102,878)
Prepaid expenses and other current assets 414,138 60,894
Research and development incentives receivable 17,379 98,456
Operating lease liability (29,359) (26,256)
Accounts payable and accrued expenses 391,929 (970,757)
Accrued compensation (200,899) (292,200)
Net cash used in operating activities (1,342,482) (2,166,253)
Financing activities:    
Proceeds from issuance of common stock pursuant to B. Riley At Market Issuance Sales Agreement   70,730
Convertible debt repayments   (1,000,000)
Net cash used in financing activities (8,992) (931,558)
Effect of exchange rate on cash and cash equivalents (3,136) 4,046
Net decrease in cash and cash equivalents (1,354,610) (3,093,765)
Cash and cash equivalents at beginning of period 8,446,158 13,359,615
Cash and cash equivalents at end of period 7,091,548 10,265,850
Supplemental information:    
Cash paid for state income taxes 17,965 2,110
Cash paid for interest 64,047 213,490
Cash paid for lease liabilities:    
Operating lease 34,100 33,325
Non-cash investing and financing activities:    
Pontifax conversion of portion of debt principal into common stock 99,416  
Deferred issuance cost reclassified to additional paid-in capital   53
Redemption liability for Series D preferred stock   43
Public offering costs included in accounts payable 123,689  
B. Riley Sales Agreement    
Financing activities:    
Stock issuance costs associated   $ (2,288)
Public Offering    
Financing activities:    
Stock issuance costs associated $ (8,992)  
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Nature of Business
3 Months Ended
Mar. 31, 2024
Nature of Business  
Nature of Business

Note 1. Nature of Business

Basis of Presentation

Soligenix, Inc. (the “Company”) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments: Specialized BioTherapeutics and Public Health Solutions.

The Company’s Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With agreement from the European Medicines Agency (“EMA”) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ in the treatment of CTCL patients with early-stage disease, the Company is targeting to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026. Upon successful completion of the second Phase 3 study, called “FLASH2” (Fluorescent Light Activated Synthetic Hypericin 2), regulatory approval will be sought to support potential commercialization worldwide.

Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, the Company’s first-in-class innate defense regulator technology, and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer and aphthous ulcers in Behçet’s Disease.

The Company’s Public Health Solutions business segment includes development programs for RiVax®, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of the vaccine programs incorporates the use of the Company’s proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.

The Company primarily generates revenues under government grants and contracts. The Company was awarded a subcontract that originally provided for approximately $1.1 million from a U.S. Food and Drug Administration (“FDA”) Orphan Products Development grant over four years for an expanded study of HyBryte™ in the treatment of CTCL. The Company will continue to apply for additional government funding.

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, development of new technological innovations, dependence on key personnel, protections of proprietary technology, compliance with the FDA regulations, and other regulatory authorities, litigation, and product liability.

Results for the three months ended March 31, 2024 are not necessarily indicative of results that may be expected for the full year.

Liquidity

In accordance with Accounting Standards Codification 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the condensed consolidated

financial statements are issued. As of March 31, 2024, the Company had an accumulated deficit of $227,619,503. During the three months ended March 31, 2024, the Company incurred a net loss of $1,915,327 and used $1,342,482 of cash in operating activities. The Company expects to continue to generate losses in the foreseeable future. The Company’s liquidity needs will be determined largely by the budgeted operational expenditures incurred in regards to the progression of its product candidates. Management believes that the Company has sufficient resources available to support its development activities and business operations and timely satisfy its obligations as they become due through the first quarter of 2025. The Company does not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support its operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern through 12 months after the date the financial statements are issued.

To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, the Company plans to secure additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations, securing additional proceeds from government contract and grant programs, securing additional proceeds available from the sale of shares of the common stock via an At Market Issuance Sales Agreement and potentially amending the loan agreement with Pontifax Medison Finance (“Pontifax”) to reduce the conversion price in order to allow for conversion of a portion of the debt which will reduce the Company’s debt repayments; however, none of these alternatives are committed at this time. There can be no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to it to fund continuing operations, if at all, identify and enter into any strategic transactions that will provide the capital that it will require or achieve the other strategies to alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern. If none of these alternatives are available, or if available, are not available on satisfactory terms, the Company will not have sufficient cash resources and liquidity to fund its business operations for at least the 12 months following the date the financial statements are issued. The failure to obtain sufficient capital on acceptable terms when needed may require the Company to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives and its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. In addition, market instability, including as a result of geopolitical instability, may reduce the Company’s ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern. In addition, the perception that the Company may not be able to continue as a going concern may cause others to choose not to deal with it due to concerns about its ability to meet its contractual obligations.

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

As of March 31, 2024, the Company had cash and cash equivalents of $7,091,548 as compared to $8,446,158 as of December 31, 2023, representing a decrease of $1,354,610 or 16%. As of March 31, 2024, the Company had working capital of $607,499 as compared to working capital of $3,355,212 as of December 31, 2023, representing a decrease in working capital of $2,747,713 or 82%. The decrease in cash and cash equivalents was primarily related to cash used in operating activities during the three months ended March 31, 2024. The decrease in working capital is primarily the result of the reclassification of approximately $1 million of the Company’s convertible debt balance from a non-current liability as of December 31, 2023 to a current liability as of March 31, 2024 (resulting from the amendment to the loan and security agreement with Pontifax – see Note 4), and cash used in operating activities during the three months ended March 31, 2024.

Management’s business strategy can be outlined as follows:

Following agreement from the EMA on the key design components for the second confirmatory Phase 3 placebo-controlled FLASH2 clinical trial of HyBryte™ in CTCL and positive primary endpoint results
from the first Phase 3 FLASH study, initiate the FLASH2 study, while at the same time, continuing discussions with the FDA on potential modifications to the development path to adequately address their feedback.
Expanding development of synthetic hypericin under the research name SGX302 into psoriasis with the conduct of a Phase 2a clinical trial, following the positive Phase 3 FLASH study and positive proof-of-concept demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.
Following feedback from the United Kingdom (“UK”) Medicines and Healthcare products Regulatory Agency (“MHRA”) that a second Phase 3 clinical trial of SGX942 (dusquetide) in the treatment in oral mucositis would be required to support a marketing authorization; design a second study and attempt to identify a potential partner(s) to continue this development program.
Expanding development of dusquetide under the research name SGX945 into Behçet’s Disease with the conduct of a Phase 2a clinical trial, where previous studies with dusquetide in oral mucositis have validated the biologic activity in aphthous ulcers induced by chemotherapy and radiation.
Continue development of the Company’s heat stabilization platform technology, ThermoVax®, in combination with its programs for RiVax® (ricin toxin vaccine), and filovirus vaccines (targeting Ebola, Sudan, and Marburg viruses and multivalent combinations), with United States (“U.S.”) government or non-governmental organization funding support.
Continue to apply for and secure additional government funding for the Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts and/or procurements.
Pursue business development opportunities for pipeline programs, as well as explore all strategic alternatives, including but not limited to merger/acquisition strategies.
Acquire or in-license new clinical-stage compounds for development, as well as evaluate new indications with existing pipeline compounds for development.

The Company’s plans with respect to its liquidity management include, but are not limited to, the following:

The Company has up to approximately $673,000 in active government grant funding still available as of March 31, 2024 to support its associated research programs through May 2026, provided the federal agencies do not elect to terminate the grants for convenience. The Company plans to submit additional contract and grant applications for further support of its programs with various funding agencies. However, there can be no assurance that the Company will obtain additional governmental grant funding.
The Company has continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expects to continue to do so for the foreseeable future.
The Company will continue to pursue Net Operating Loss (“NOL”) sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program if the program is available.
The Company plans to pursue potential partnerships for pipeline programs as well as continue to explore merger and acquisition strategies. However, there can be no assurances that the Company can consummate such transactions.
The Company completed a public offering on April 22, 2024 of 3,275,000 shares of its common stock, pre-funded warrants to purchase 8,600,000 shares of its common stock and common warrants to purchase up to 11,875,000 shares of its common stock at a combined public offering price of $0.40.
The pre-funded warrants have an exercise price of $0.001. The common warrants have an exercise price of $0.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to the Company from this offering were approximately $4.75 ($4.3 net) million before deducting commissions and other estimated offering expenses. The Company plans to use the proceeds for further support of its programs, as well as for working capital. See Note 8.
The Company is currently evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate such a transaction, or consummate a transaction at favorable pricing.

Nasdaq Capital Market Listing Requirements

On June 23, 2023, the Company received a letter from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between May 9, 2023 through June 22, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company would be provided with a compliance period of 180 calendar days, or until December 20, 2023, in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The Company was unable to regain compliance prior to the expiration of the 180-day period.

On December 21, 2023, the Company received another written notice (the “Notice”) from the Staff stating that the Company had not complied with the minimum bid price requirement and was not eligible for a second 180-day period because the Company did not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for Nasdaq. As a result, the Notice indicated that the Company’s common stock would be suspended from trading on Nasdaq unless the Company requested a hearing before the Nasdaq Hearings Panel by December 28, 2023. On March 26, 2024, the Company had an oral hearing with a Nasdaq Hearings Panel to appeal the Staff’s delisting determination, which stayed the trading suspension of the Common Stock pending a final written decision by the Nasdaq Hearings Panel and expiration of any additional extension period granted by the panel following the hearing.

In order to regain compliance with Nasdaq’s minimum bid price requirement, the Company’s common stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2024
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Principles of Consolidation

The condensed consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.

Operating Segments

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: Specialized BioTherapeutics and Public Health Solutions.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.

Contracts and Grants Receivable

Contracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for credit losses has been established. If amounts become uncollectible, they are charged to operations.

Impairment of Long-Lived Assets

Office furniture and equipment and right of use assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.

The Company did not record any impairment of long-lived assets for the three months ended March 31, 2024 and 2023.

Fair Value of Financial Instruments

FASB ASC 820 — Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on March 31, 2024. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.

FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).

The three levels of the fair value hierarchy are as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from
observable data or are supported by observable levels at which transactions are executed in the marketplace.
Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

The carrying amounts reported in the condensed consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable, accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments.

The carrying amount reported in the condensed consolidated balance sheet as of March 31, 2024 for the convertible debt is its fair value - see Note 4. The principal amount of the convertible debt was $2,900,585 at March 31, 2024 and the fair value was $2,996,136. The fair value of the debt was estimated using the Monte Carlo valuation method, which utilizes certain unobservable inputs. As a result, the fair value estimate represents a Level 3 measurement.

A roll forward of the carrying value of the convertible debt to March 31, 2024 is as follows:

Balance

Conversion

Adjustment to

Balance

December 31, 2023

January 3, 2024

fair value

March 31, 2024

Convertible debt at fair value

$

3,260,934

$

(99,416)

$

(165,382)

$

2,996,136

Deferred Issuance Costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders’ equity as a reduction of additional paid-in capital generated as a result of the issuance.

Revenue Recognition

The Company’s revenues include revenues generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants.

The Company also records revenue from contracts with customers in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), Revenue From Contracts with Customers. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Certain amounts received from or billed to customers in accordance with contract terms are deferred and recognized as future performance obligations are satisfied. All amounts earned under contracts with customers other than sales-based royalties are classified as licensing revenue. Sales-based royalties under the Company’s license agreements would be recognized as royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue.

Research and Development Costs

Research and development costs are charged to expense when incurred in accordance with FASB ASC 730, Research and Development. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs.

Share-Based Compensation

Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then 25% each subsequent year for a period of three years. These options have a ten-year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board.

From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed under the Company’s 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestricted stock to the Company’s employees and non-employees (including consultants). The shares issued under the 2015 Plan are registered on Form S-8 (SEC File No. 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificates reflecting such shares reflect a Securities Act of 1933, as amended restrictive legend. Stock compensation expense for equity-classified awards to non-employees is measured on the date of grant and is recognized when the services are performed.

There were no options issued during the three months ended March 31, 2024 and 2023.

Foreign Currency Transactions and Translation

In accordance with FASB ASC 830 Foreign Currency Matters, the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency, the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statements of the UK subsidiary are translated into U.S. dollars and consolidated into the Company’s financials, with related translation adjustments reported as a cumulative translation adjustment (“CTA”), which is a component of accumulated other comprehensive income. During the three months ended March 31, 2024 and 2023, the Company recognized a foreign currency transaction gain of $1,209 and a foreign currency transaction loss of ($366), respectively, in the accompanying condensed consolidated statements of operations.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company’s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward periods. Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company did not recognize an income tax benefit during the three months ended March 31, 2024. The Company recognized $1,161,197 of income tax benefit, net of transaction costs from the sale of its 2021 NOL carryforwards during the three months ended March 31, 2023. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interest and penalties recorded for the three months ended March 31, 2024 and 2023. Additionally, the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at March 31, 2024 or December 31, 2023.

Loss Per Share

Basic earnings per share (“EPS”) excludes dilution and is computed by dividing loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Included within the Company’s weighted average common shares outstanding for the three months ended March 31, 2024, are common shares issuable upon the exercise of the pre-funded warrants associated with the May 2023 public offering, as these pre-funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.

The following table summarizes potentially dilutive adjustments to the number of common shares which were excluded from the diluted calculation because their effect would be anti-dilutive due to the losses in each period:

As of March 31, 

    

2024

    

2023

    

Common stock purchase warrants

6,538,073

Stock options

 

906,226

 

192,273

 

Convertible debt

 

2,008,100

 

146,342

 

Total

 

9,452,399

 

338,615

 

The weighted average exercise prices of the Company’s warrants and stock options outstanding at March 31, 2024 were $1.50 and $5.52 per share, respectively. The weighted average exercise prices of the Company’s stock options outstanding at March 31, 2023 was $27.56 per share. The weighted average conversion price of the Company’s convertible debt at March 31, 2024 and 2023 was $1.44 and $61.50 per share, respectively.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Accrued Expenses
3 Months Ended
Mar. 31, 2024
Accrued Expenses  
Accrued Expenses

Note 3. Accrued Expenses

The following is a summary of the Company’s accrued expenses:

March 31, 

December 31, 

    

2024

    

2023

    

Clinical trial expenses

$

2,070,955

$

1,993,784

Other

 

531,710

 

424,218

Total

$

2,602,665

$

2,418,002

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Debt
3 Months Ended
Mar. 31, 2024
Debt  
Debt

Note 4. Debt

In December 2020, the Company entered into a $20 million convertible debt financing agreement with Pontifax. Under the terms of the agreement with Pontifax, the Company had access to up to $20 million in convertible debt financing in three tranches, which will mature on June 15, 2025 and had an interest-only period for the first two years with a fixed interest rate of 8.47% on borrowed amounts and an interest rate of 1% on amounts

available but not borrowed as an unused line of credit fee. After the interest-only period, the outstanding principal was to be repaid in quarterly payments of $1 million each commencing in the first quarter of 2023. The agreement is secured by a lien covering substantially all of the Company’s assets, other than intellectual property.

Upon the closing of this transaction, the Company borrowed the first tranche of $10 million, had the option to draw the second tranche of $5 million at any time during the initial 12 months of the loan and the third tranche of $5 million upon filing of the new drug application for HyBryte™, subject to certain conditions. The Company elected to let the options to borrow both the second and third tranches expire as of December 15, 2021 and March 15, 2022, respectively.

On April 19, 2023, the Company entered into an amendment to the convertible debt financing agreement dated December 15, 2020 with Pontifax. The amendment called for the immediate payment of $5 million of the outstanding principal balance and any accrued interest, waived any prepayment charge in connection with the repayment of this amount and resulted in an outstanding principal balance of $3 million. The amendment also provided for a new interest only period from the date of the amendment through June 30, 2024, reduced quarterly principal repayments from $1 million to $750,000 and eliminated the minimum cash covenant. Further, the amendment reduced the conversion price with respect to the remaining principal amount under the agreement to (i) 90% of the closing price of the Company’s common stock on the day before the delivery of the conversion notice with respect to the first 588,599 shares of the Company’s common stock issuable upon conversion and to (ii) $1.70 with respect to all shares of the Company’s common stock issuable upon conversion in excess of the first 588,599 shares so issued. The remaining terms of the agreement remain in effect without modification.

On January, 3, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Company’s common stock. Upon conversion, the Company issued 146,199 shares of the Company’s common stock at $0.68 per share, reducing the remaining principal balance by $99,416. Pontifax may elect to convert the remaining outstanding loan drawn under the first tranche into additional shares of the Company’s common stock at any time prior to repayment. The Company also has the ability to force the conversion of the loan into shares of its common stock, subject to certain conditions.

The amendment to the convertible debt financing agreement with Pontifax resulted in the extinguishment of the original convertible debt for accounting purposes. The Company concluded that the amended debt instrument has an embedded derivative that requires bifurcation pursuant to ASC 815-15-25-1 and qualifies for the fair value option in accordance with ASC 815-15-25-4 through ASC 815-15-25-6. The Company elected to account for the amended convertible debt using the fair value option, which requires the Company to record changes in fair value as a component of other income or expense. The fair value of the convertible debt as of March 31, 2024 was $2,996,136, which resulted in the recognition of $165,382 of other income from the change in the fair value of the convertible debt on the Company’s accompanying condensed consolidated statements of operations during the three months ended March 31, 2024. The fair value of the convertible debt was estimated using the Monte Carlo valuation method.

The key assumptions used in the Monte Carlo valuations were as follows:

Assumptions

12/31/2023

3/31/2024

Stock price

$

0.76

$

0.60

Volatility

141.90%

148.80%

Discount rate

13.62%

16.16%

Risk-free rate

4.65%

5.03%

Interest expense incurred during the three months ended March 31, 2024 and 2023 was $61,239 and $187,964, respectively. Interest expense paid during the three months ended March 31, 2024 and 2023 was $64,047 and $213,490, respectively.

Annual principal and interest payments due as of March 31, 2024 in accordance with the amended terms of the Pontifax loan agreement, including the January 3, 2024 conversion and assuming no further conversions are as follows:

Year

    

Principal

    

Interest

    

Total

Remainder of 2024

$

2,250,000

$

198,305

$

2,448,305

2025

 

650,585

 

13,889

 

664,474

Total

$

2,900,585

$

212,194

$

3,112,779

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Shareholders' Equity
3 Months Ended
Mar. 31, 2024
Shareholders' Equity  
Shareholders' Equity

Note 5. Shareholders’ Equity

Common Stock

The following items represent transactions in the Company’s common stock for the three months ended March 31, 2024:

The Company issued Pontifax 146,199 shares of fully vested common stock pursuant to conversion of a portion of the convertible debt principal balance at a conversion price of $0.68 per share on January 3, 2024, the date of issuance. The conversion price was based on 90% of the closing price of the Company’s common stock on the day before the delivery of the conversion notice.

The issuance of the Company’s common stock in connection with the convertible debt financing agreement as described above was exempt under Section 3(a)(9) of the Securities Act of 1933, as amended.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and Contingencies
3 Months Ended
Mar. 31, 2024
Commitments and Contingencies.  
Commitments and Contingencies

Note 6. Commitments and Contingencies

Contractual Obligations

The Company has commitments of approximately $230,000 as of March 31, 2024 over the next five years for several licensing agreements with partners and universities. Additionally, the Company has collaboration and license agreements, which upon clinical or commercialization success, may require the payment of milestones of up to approximately $13.2 million, royalties on net sales of covered products ranging from 2% to 3% sub-license Investigational New Drug (“IND”) milestones on covered products of up to approximately $200,000, sub-license income royalties on covered products up to 15% and sub-license global net sales royalties on covered products ranging from 1.5% to 2.5%, if and when achieved. However, there can be no assurance that clinical or commercialization success will occur.

The Company currently leases office space which serves as the Company’s corporate headquarters, and both of the Company’s business segments (Specialized BioTherapeutics and Public Health Solutions), operate from this space. Pursuant to an amendment on June 21, 2022, the lease has been extended to October 2025. The current rent of $11,367 per month will be maintained until November 2024 when it will be increased to $11,625 per month where it will remain until expiration.

In September 2014, the Company entered into an asset purchase agreement with Hy Biopharma Inc. (“Hy Biopharma”) pursuant to which the Company acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharma’s synthetic hypericin product. As consideration for the assets acquired, the Company paid $275,000 in cash and issued 12,328 shares of common stock with a fair value based on the Company’s stock price on the date of grant of $3.75 million. These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in the Company’s research and development activities and do not have alternative future use pursuant to GAAP. In March 2020, the Company issued 130,413 shares of common stock to Hy Biopharma as payment for achieving

a milestone: the Company determining the Phase 3 clinical trial of HyBryte™ to be successful in the treatment of CTCL. The number of shares of common stock issued to Hy Biopharma was calculated using an effective price of $38.40 per share, based upon a formula set forth in the purchase agreement.

Provided the sole remaining future success-oriented milestone of FDA approval is attained, the Company will be required to make an additional payment of $5 million, if and when achieved. Such payment will be payable in restricted securities of the Company provided such number of shares does not exceed 19.9% ownership of the Company’s outstanding stock. As of March 31, 2024, no other milestone or royalty payments have been paid or accrued.

As a result of the above agreements, the Company has the following contractual obligations:

    

Research and

    

Property and

    

    

Year

    

Development

    

Other Leases

    

Total

April 1 through December 31, 2024

$

46,000

$

102,817

$

148,817

2025

 

46,000

 

116,250

 

162,250

2026

 

46,000

 

 

46,000

2027

46,000

46,000

2028

46,000

46,000

Total

$

230,000

$

219,067

$

449,067

Contingencies

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. A liability is only recorded if management determines that it is both probable and reasonably estimable.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Operating Segments
3 Months Ended
Mar. 31, 2024
Operating Segments  
Operating Segments

Note 7. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

    

Three Months Ended

    

March 31, 

    

2024

    

2023

Revenues

  

 

  

Specialized BioTherapeutics

$

117,029

$

155,365

Public Health Solutions

101,813

Total

$

117,029

$

257,178

Income (loss) from Operations

 

  

 

  

Specialized BioTherapeutics

$

(860,604)

$

(910,377)

Public Health Solutions

(45,997)

427

Corporate

 

(1,210,490)

 

(1,240,739)

Total

$

(2,117,091)

$

(2,150,689)

Amortization and Depreciation Expense

 

  

 

  

Specialized BioTherapeutics

$

953

$

1,071

Public Health Solutions

159

178

Corporate

 

476

 

536

Total

$

1,588

$

1,785

Other (Expense) Income, Net

 

  

 

  

Specialized BioTherapeutics

$

7,540

$

6,082

Corporate

 

194,224

 

(62,699)

Total

$

201,764

$

(56,617)

Share-Based Compensation

 

  

 

  

Specialized BioTherapeutics

$

20,672

$

27,427

Public Health Solutions

588

994

Corporate

 

38,701

 

45,213

Total

$

59,961

$

73,634

    

As of

As of

    

March 31, 

December 31, 

    

2024

    

2023

    

Identifiable Assets

 

  

 

  

 

Specialized BioTherapeutics

$

301,709

$

272,099

Public Health Solutions

 

120,475

 

3,976

Corporate

 

7,636,201

 

9,521,251

Total

$

8,058,385

$

9,797,326

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Subsequent Events
3 Months Ended
Mar. 31, 2024
Subsequent Events  
Subsequent Events

Note 8. Subsequent Events

Pontifax Conversion of Convertible Debt

On April 15, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Company’s common stock. Upon conversion, the Company issued 442,400 shares of the Company’s common stock at $0.35 per share, reducing the remaining principal balance by $154,840. Pontifax may elect to convert the remaining outstanding loan drawn under the first tranche into additional shares of the Company’s common stock at any time prior to repayment. The Company also has the ability to force the conversion of the loan into shares of its common stock, subject to certain conditions.

$4.75 million Public Offering

On April 22, 2024, the Company completed a public offering of (i) 3,275,000 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 8,600,000 shares of the Company’s common stock and (iii) common warrants to purchase 11,875,000 shares of the Company’s common stock. The shares of common stock, or pre-funded warrants in lieu thereof, and the common warrants, were sold in units, with each unit consisting of one share of common stock or one pre-funded warrant in lieu thereof and one common warrant. Each unit comprised of common stock and common warrants was sold at a per unit price of $0.40. Each unit comprised of pre-funded warrants and common warrants was sold at a per unit price of $0.399, which represents the same per unit price less the $0.001 per share exercise price of the pre-funded warrants. The common warrants are exercisable at a price of $0.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to the Company from this offering were approximately $4.75 ($4.3 net) million before deducting commissions and other estimated offering expenses payable by the Company.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2024
Summary of Significant Accounting Policies  
Principles of Consolidation

Principles of Consolidation

The condensed consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.

Operating Segments

Operating Segments

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: Specialized BioTherapeutics and Public Health Solutions.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.

Contracts and Grants Receivable

Contracts and Grants Receivable

Contracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for credit losses has been established. If amounts become uncollectible, they are charged to operations.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Office furniture and equipment and right of use assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.

The Company did not record any impairment of long-lived assets for the three months ended March 31, 2024 and 2023.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

FASB ASC 820 — Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on March 31, 2024. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.

FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).

The three levels of the fair value hierarchy are as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from
observable data or are supported by observable levels at which transactions are executed in the marketplace.
Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

The carrying amounts reported in the condensed consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable, accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments.

The carrying amount reported in the condensed consolidated balance sheet as of March 31, 2024 for the convertible debt is its fair value - see Note 4. The principal amount of the convertible debt was $2,900,585 at March 31, 2024 and the fair value was $2,996,136. The fair value of the debt was estimated using the Monte Carlo valuation method, which utilizes certain unobservable inputs. As a result, the fair value estimate represents a Level 3 measurement.

A roll forward of the carrying value of the convertible debt to March 31, 2024 is as follows:

Balance

Conversion

Adjustment to

Balance

December 31, 2023

January 3, 2024

fair value

March 31, 2024

Convertible debt at fair value

$

3,260,934

$

(99,416)

$

(165,382)

$

2,996,136

Deferred Issuance Costs

Deferred Issuance Costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders’ equity as a reduction of additional paid-in capital generated as a result of the issuance.

Revenue Recognition

Revenue Recognition

The Company’s revenues include revenues generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants.

The Company also records revenue from contracts with customers in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), Revenue From Contracts with Customers. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Certain amounts received from or billed to customers in accordance with contract terms are deferred and recognized as future performance obligations are satisfied. All amounts earned under contracts with customers other than sales-based royalties are classified as licensing revenue. Sales-based royalties under the Company’s license agreements would be recognized as royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue.

Research and Development Costs

Research and Development Costs

Research and development costs are charged to expense when incurred in accordance with FASB ASC 730, Research and Development. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs.

Share-Based Compensation

Share-Based Compensation

Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then 25% each subsequent year for a period of three years. These options have a ten-year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board.

From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed under the Company’s 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestricted stock to the Company’s employees and non-employees (including consultants). The shares issued under the 2015 Plan are registered on Form S-8 (SEC File No. 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificates reflecting such shares reflect a Securities Act of 1933, as amended restrictive legend. Stock compensation expense for equity-classified awards to non-employees is measured on the date of grant and is recognized when the services are performed.

There were no options issued during the three months ended March 31, 2024 and 2023.

Foreign Currency Transactions and Translation

Foreign Currency Transactions and Translation

In accordance with FASB ASC 830 Foreign Currency Matters, the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency, the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statements of the UK subsidiary are translated into U.S. dollars and consolidated into the Company’s financials, with related translation adjustments reported as a cumulative translation adjustment (“CTA”), which is a component of accumulated other comprehensive income. During the three months ended March 31, 2024 and 2023, the Company recognized a foreign currency transaction gain of $1,209 and a foreign currency transaction loss of ($366), respectively, in the accompanying condensed consolidated statements of operations.

Income Taxes

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company’s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward periods. Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company did not recognize an income tax benefit during the three months ended March 31, 2024. The Company recognized $1,161,197 of income tax benefit, net of transaction costs from the sale of its 2021 NOL carryforwards during the three months ended March 31, 2023. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interest and penalties recorded for the three months ended March 31, 2024 and 2023. Additionally, the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at March 31, 2024 or December 31, 2023.

Loss Per Share

Loss Per Share

Basic earnings per share (“EPS”) excludes dilution and is computed by dividing loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Included within the Company’s weighted average common shares outstanding for the three months ended March 31, 2024, are common shares issuable upon the exercise of the pre-funded warrants associated with the May 2023 public offering, as these pre-funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.

The following table summarizes potentially dilutive adjustments to the number of common shares which were excluded from the diluted calculation because their effect would be anti-dilutive due to the losses in each period:

As of March 31, 

    

2024

    

2023

    

Common stock purchase warrants

6,538,073

Stock options

 

906,226

 

192,273

 

Convertible debt

 

2,008,100

 

146,342

 

Total

 

9,452,399

 

338,615

 

The weighted average exercise prices of the Company’s warrants and stock options outstanding at March 31, 2024 were $1.50 and $5.52 per share, respectively. The weighted average exercise prices of the Company’s stock options outstanding at March 31, 2023 was $27.56 per share. The weighted average conversion price of the Company’s convertible debt at March 31, 2024 and 2023 was $1.44 and $61.50 per share, respectively.

Use of Estimates and Assumptions

Use of Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2024
Summary of Significant Accounting Policies  
Schedule of carrying value of convertible debt

A roll forward of the carrying value of the convertible debt to March 31, 2024 is as follows:

Balance

Conversion

Adjustment to

Balance

December 31, 2023

January 3, 2024

fair value

March 31, 2024

Convertible debt at fair value

$

3,260,934

$

(99,416)

$

(165,382)

$

2,996,136

Schedule of potentially dilutive adjustments to the weighted average number of common shares excluded from the calculation

As of March 31, 

    

2024

    

2023

    

Common stock purchase warrants

6,538,073

Stock options

 

906,226

 

192,273

 

Convertible debt

 

2,008,100

 

146,342

 

Total

 

9,452,399

 

338,615

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2024
Accrued Expenses  
Schedule of accrued expenses

March 31, 

December 31, 

    

2024

    

2023

    

Clinical trial expenses

$

2,070,955

$

1,993,784

Other

 

531,710

 

424,218

Total

$

2,602,665

$

2,418,002

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Debt (Tables)
3 Months Ended
Mar. 31, 2024
Debt  
Schedule of debt assumptions

Assumptions

12/31/2023

3/31/2024

Stock price

$

0.76

$

0.60

Volatility

141.90%

148.80%

Discount rate

13.62%

16.16%

Risk-free rate

4.65%

5.03%

Schedule of annual principle and interest payments due

Year

    

Principal

    

Interest

    

Total

Remainder of 2024

$

2,250,000

$

198,305

$

2,448,305

2025

 

650,585

 

13,889

 

664,474

Total

$

2,900,585

$

212,194

$

3,112,779

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2024
Commitments and Contingencies.  
Schedule of contractual obligation

    

Research and

    

Property and

    

    

Year

    

Development

    

Other Leases

    

Total

April 1 through December 31, 2024

$

46,000

$

102,817

$

148,817

2025

 

46,000

 

116,250

 

162,250

2026

 

46,000

 

 

46,000

2027

46,000

46,000

2028

46,000

46,000

Total

$

230,000

$

219,067

$

449,067

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Operating Segments (Tables)
3 Months Ended
Mar. 31, 2024
Operating Segments  
Schedule of operating segments

    

Three Months Ended

    

March 31, 

    

2024

    

2023

Revenues

  

 

  

Specialized BioTherapeutics

$

117,029

$

155,365

Public Health Solutions

101,813

Total

$

117,029

$

257,178

Income (loss) from Operations

 

  

 

  

Specialized BioTherapeutics

$

(860,604)

$

(910,377)

Public Health Solutions

(45,997)

427

Corporate

 

(1,210,490)

 

(1,240,739)

Total

$

(2,117,091)

$

(2,150,689)

Amortization and Depreciation Expense

 

  

 

  

Specialized BioTherapeutics

$

953

$

1,071

Public Health Solutions

159

178

Corporate

 

476

 

536

Total

$

1,588

$

1,785

Other (Expense) Income, Net

 

  

 

  

Specialized BioTherapeutics

$

7,540

$

6,082

Corporate

 

194,224

 

(62,699)

Total

$

201,764

$

(56,617)

Share-Based Compensation

 

  

 

  

Specialized BioTherapeutics

$

20,672

$

27,427

Public Health Solutions

588

994

Corporate

 

38,701

 

45,213

Total

$

59,961

$

73,634

    

As of

As of

    

March 31, 

December 31, 

    

2024

    

2023

    

Identifiable Assets

 

  

 

  

 

Specialized BioTherapeutics

$

301,709

$

272,099

Public Health Solutions

 

120,475

 

3,976

Corporate

 

7,636,201

 

9,521,251

Total

$

8,058,385

$

9,797,326

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Nature of Business (Details)
3 Months Ended
Apr. 22, 2024
USD ($)
$ / shares
shares
Jan. 03, 2024
USD ($)
Mar. 31, 2024
USD ($)
segment
shares
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
Nature of business:            
Number of operating segments | segment     2      
Net Income (Loss)     $ (1,915,327) $ (1,046,109)    
Net cash used in operating activities     (1,342,482) (2,166,253)    
Reclassification of Convertible Debt From Non-Current to current Liability     1,000,000      
Number of shares sold       70,730    
Cash and cash equivalents     7,091,548 10,265,850 $ 8,446,158 $ 13,359,615
Net decrease in cash     $ 1,354,610 3,093,765    
Percentage change in cash and cash equivalent     16.00%      
Accumulated deficit     $ 227,619,503   225,704,176  
Working capital     607,499   $ 3,355,212  
Working capital increase, decrease     $ (2,747,713)      
Working capital increase (decrease) as a percent     82.00%      
Common Stock, Shares, Issued | shares     10,524,437   10,378,238  
Repayment of debt principal       1,000,000    
Consideration paid recorded in general and administrative expense     $ 1,022,051 1,235,376    
Common Stock            
Nature of business:            
Number of shares sold       $ 21    
Subsequent Event            
Nature of business:            
Shares issued price per share | $ / shares $ 0.40          
Subsequent Event | Public Offering            
Nature of business:            
Total gross proceeds $ 4,750,000          
Shares issued price per share | $ / shares $ 0.40          
Exercise price of warrants | $ / shares $ 0.001          
Expiration term of warrants 5 years          
Net proceeds $ 4,300,000          
Subsequent Event | Common Stock | Public Offering            
Nature of business:            
Number of shares issued | shares 3,275,000          
Exercise price of warrants | $ / shares $ 0.40          
Pre-funded warrants | Subsequent Event | Public Offering            
Nature of business:            
Number of common warrants to purchase shares issued | shares 8,600,000          
Exercise price of warrants | $ / shares $ 0.001          
Common warrants | Subsequent Event | Public Offering            
Nature of business:            
Number of common warrants to purchase shares issued | shares 11,875,000          
Exercise price of warrants | $ / shares $ 0.40          
Expiration term of warrants 5 years          
Convertible Debt            
Nature of business:            
Repayment of debt principal   $ 99,416        
HyBryte            
Nature of business:            
Revenue from collaborative arrangement     $ 1,100,000      
Term (in years)     4 years      
NIH            
Nature of business:            
Government grant funding     $ 673,000,000,000      
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies (Details)
3 Months Ended
Mar. 31, 2024
USD ($)
segment
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2020
USD ($)
Finite-Lived Intangible Assets [Line Items]        
Number of operating segments | segment 2      
Impairment of long-lived assets $ 0 $ 0    
Requisite period (in years) 3 years      
Expiration period 10 years      
Option vesting rights 25%      
Foreign currency transaction gain (loss) $ 1,209 (366)    
Income tax benefit   (1,161,197)    
Interest and penalties 0 $ 0    
Unrecognized Tax Benefits 0   $ 0  
Convertible debt fair value 2,996,136      
Convertible Debt        
Finite-Lived Intangible Assets [Line Items]        
Debt instrument, face amount 2,900,585     $ 20,000,000
Convertible debt fair value $ 2,996,136      
Termination benefits        
Finite-Lived Intangible Assets [Line Items]        
Expiration period 3 months      
Directors        
Finite-Lived Intangible Assets [Line Items]        
Requisite period (in years) 1 year      
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies - Carrying Value of Convertible Debt (Details) - USD ($)
3 Months Ended
Jan. 03, 2024
Mar. 31, 2024
Mar. 31, 2023
Debt instruments      
Convertible debt repayments     $ (1,000,000)
Adjustment to fair value   $ (165,382)  
Convertible Debt      
Debt instruments      
Convertible debt at fair value as of December 31, 2022   3,260,934  
Convertible debt repayments $ (99,416)    
Adjustment to fair value   (165,382)  
Convertible debt at fair value as of September 30, 2023   $ 2,996,136  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies - Loss per share, Warrants and Options expirations (Details) - $ / shares
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded 9,452,399 338,615
Weighted average exercise price, outstanding warrants $ 1.50  
Weighted average exercise price, outstanding options 5.52 $ 27.56
Weighted Average    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Conversion price $ 1.44 $ 61.50
Common stock purchase warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded 6,538,073  
Employee Stock Option    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded 906,226 192,273
Convertible debt    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Securities excluded 2,008,100 146,342
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Accrued Expenses (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Accrued Expenses    
Clinical trail expenses $ 2,070,955 $ 1,993,784
Other 531,710 424,218
Total $ 2,602,665 $ 2,418,002
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Debt (Details) - USD ($)
1 Months Ended 3 Months Ended
Jan. 03, 2024
Apr. 19, 2023
Apr. 18, 2023
Dec. 31, 2020
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Debt instruments              
Outstanding principal             $ 1,010,934
Repayment of debt principal           $ 1,000,000  
Convertible debt fair value         $ 2,996,136    
Change in fair value of convertible debt         (165,382)    
Convertible Debt              
Debt instruments              
Debt instrument, face amount       $ 20,000,000 2,900,585    
Number of tranches       three      
Interest-only period       2 years      
Interest rate percentage       8.47%      
Unused line of credit fee, as a percent       1.00%      
Outstanding principal periodic payment       $ 1,000,000      
Repayment of debt principal $ 99,416            
Convertible debt fair value         2,996,136    
Change in fair value of convertible debt         (165,382)    
Interest expense         61,239 187,964  
Interest paid         $ 64,047 $ 213,490  
Convertible Debt | Maximum              
Debt instruments              
Debt instrument, face amount       20,000,000      
Convertible Debt | First Tranche [Member]              
Debt instruments              
Convertible note       10,000,000      
Convertible Debt | Second Tranche [Member]              
Debt instruments              
Convertible note       5,000,000      
Convertible Debt | Third Tranche [Member]              
Debt instruments              
Convertible note       $ 5,000,000      
Convertible Debt | Pontifax              
Debt instruments              
Outstanding principal periodic payment   $ 750,000 $ 1,000,000        
Amount repaid   5,000,000          
Outstanding principal   $ 3,000,000          
Shares of common stock issuable upon conversion 146,199 588,599          
Fair value per share $ 0.68            
Repayment of debt principal $ 99,416            
Convertible Debt | Pontifax | First 588,599 shares of common stock issuable upon conversion              
Debt instruments              
Reduction in conversion price as percentage of closing price of the common stock on the day before the delivery of the conversion notice   90.00%          
Reduction in conversion price   $ 1.70          
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Debt - Assumptions (Details)
Mar. 31, 2024
$ / shares
Apr. 19, 2023
$ / shares
Measurement Input, Share Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Debt Instrument, Measurement Input 0.60 0.76
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Debt Instrument, Measurement Input 1.4880 1.4190
Measurement Input, Discount Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Debt Instrument, Measurement Input 0.1616 0.1362
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Debt Instrument, Measurement Input 0.0503 0.0465
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Debt - Payments due (Details)
Mar. 31, 2024
USD ($)
Debt instruments  
Remainder of 2024 $ 2,448,305
2025 664,474
Total 3,112,779
Principal [Member]  
Debt instruments  
Remainder of 2024 2,250,000
2025 650,585
Total 2,900,585
Interest [Member]  
Debt instruments  
Remainder of 2024 198,305
2025 13,889
Total $ 212,194
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Shareholders' Equity (Details) - $ / shares
3 Months Ended
Jan. 03, 2024
Mar. 31, 2024
Convertible Debt | Pontifax    
Class of Stock [Line Items]    
Fair value per share $ 0.68  
Common Stock    
Class of Stock [Line Items]    
Number of shares issued on exercise of warrants   146,199
Common Stock | Convertible Debt    
Class of Stock [Line Items]    
Reduction in conversion price as percentage of closing price of the common stock on the day before the delivery of the conversion notice   90.00%
Common Stock | Convertible Debt | Pontifax    
Class of Stock [Line Items]    
Number of shares issued on exercise of warrants 146,199  
Fair value per share $ 0.68  
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 3 Months Ended
Mar. 31, 2020
Sep. 30, 2014
Mar. 31, 2024
Jun. 21, 2022
Other Commitments [Line Items]        
Contractual obligation     $ 449,067  
Maximum payment for commitment milestones     13,200,000  
Sub license milestones payments on covered products     $ 200,000  
Percentage of sub license income on royalties     15.00%  
Lease rent per month       $ 11,367
From Period Till November 2024 [Member]        
Other Commitments [Line Items]        
Lease rent per month       $ 11,625
Research and Development Arrangement [Member]        
Other Commitments [Line Items]        
Contractual obligation     $ 230,000  
Asset Purchase Agreement [Member]        
Other Commitments [Line Items]        
Cash paid to acquire intangible asset   $ 275,000    
Issuance of shares for assets (in shares)   12,328    
Fair value of shares issued in connection with asset purchase   $ 3,750,000    
Issuance of common stock 130,413      
Effective price per share (in dollars per share) $ 38.40      
Ownership of company outstanding     19.90%  
Minimum        
Other Commitments [Line Items]        
Percentage for royalties     2.00%  
Percentage of global net sales royalties on covered products     1.50%  
Maximum        
Other Commitments [Line Items]        
Percentage for royalties     3.00%  
Percentage of global net sales royalties on covered products     2.50%  
Maximum | Asset Purchase Agreement [Member] | Scenario, Plan [Member]        
Other Commitments [Line Items]        
Contingent consideration     $ 5,000,000  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitments and Contingencies - Maturity (Details)
Mar. 31, 2024
USD ($)
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]  
April 1 through December 31, 2024 $ 148,817
2025 162,250
2026 46,000
2027 46,000
2028 46,000
Total 449,067
Research and Development Arrangement [Member]  
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]  
April 1 through December 31, 2024 46,000
2025 46,000
2026 46,000
2027 46,000
2028 46,000
Total 230,000
Lease Agreements [Member]  
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]  
April 1 through December 31, 2024 102,817
2025 116,250
Total $ 219,067
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Operating Segments (Details)
3 Months Ended
Mar. 31, 2024
USD ($)
segment
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Segment reporting      
Revenues $ 117,029 $ 257,178  
Income (loss) from Operations (2,117,091) (2,150,689)  
Amortization and Depreciation Expense 1,588 1,785  
Other (Expense) Income, Net 201,764 (56,617)  
Share-Based Compensation 59,961 73,634  
Identifiable Assets $ 8,058,385   $ 9,797,326
Number of operating segments | segment 2    
Operating Segments [Member] | Specialized BioTherapeutics [Member]      
Segment reporting      
Revenues $ 117,029 155,365  
Income (loss) from Operations (860,604) (910,377)  
Amortization and Depreciation Expense 953 1,071  
Other (Expense) Income, Net 7,540 6,082  
Share-Based Compensation 20,672 27,427  
Identifiable Assets 301,709   272,099
Operating Segments [Member] | Public Health Solutions [Member]      
Segment reporting      
Revenues   101,813  
Income (loss) from Operations (45,997) 427  
Amortization and Depreciation Expense 159 178  
Share-Based Compensation 588 994  
Identifiable Assets 120,475   3,976
Corporate [Member]      
Segment reporting      
Income (loss) from Operations (1,210,490) (1,240,739)  
Amortization and Depreciation Expense 476 536  
Other (Expense) Income, Net 194,224 (62,699)  
Share-Based Compensation 38,701 $ 45,213  
Identifiable Assets $ 7,636,201   $ 9,521,251
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Subsequent Events (Details) - USD ($)
3 Months Ended
Apr. 22, 2024
Apr. 15, 2024
Jan. 03, 2024
Mar. 31, 2024
Mar. 31, 2023
Subsequent Event          
Repayment of debt principal         $ 1,000,000
Common Stock          
Subsequent Event          
Issuance of common stock associated with conversion of debt (in shares)       146,199  
Convertible Debt          
Subsequent Event          
Repayment of debt principal     $ 99,416    
Convertible Debt | Pontifax          
Subsequent Event          
Fair value per share     $ 0.68    
Repayment of debt principal     $ 99,416    
Convertible Debt | Pontifax | Common Stock          
Subsequent Event          
Issuance of common stock associated with conversion of debt (in shares)     146,199    
Fair value per share     $ 0.68    
Subsequent Event          
Subsequent Event          
Shares issued price per share $ 0.40        
Subsequent Event | Public Offering          
Subsequent Event          
Shares issued price per share 0.40        
Exercise price of warrants 0.001        
Price per unit $ 0.399        
Expiration term of warrants 5 years        
Total gross proceeds $ 4,750,000        
Net proceeds $ 4,300,000        
Subsequent Event | Public Offering | Pre-funded warrants          
Subsequent Event          
Number of common warrants to purchase shares issued 8,600,000        
Number of shares in an unit 1        
Exercise price of warrants $ 0.001        
Subsequent Event | Public Offering | Common warrants          
Subsequent Event          
Number of common warrants to purchase shares issued 11,875,000        
Number of warrants in an unit 1        
Exercise price of warrants $ 0.40        
Expiration term of warrants 5 years        
Subsequent Event | Public Offering | Common Stock          
Subsequent Event          
Number of shares issued 3,275,000        
Number of shares in an unit 1        
Exercise price of warrants $ 0.40        
Subsequent Event | Convertible Debt | Pontifax          
Subsequent Event          
Issuance of common stock associated with conversion of debt (in shares)   442,400      
Fair value per share   $ 0.35      
Repayment of debt principal   $ 154,840      
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Pay vs Performance Disclosure - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net Income (Loss) $ (1,915,327) $ (1,046,109)
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

,"2.[7MP[WT4;=Y3 M4?M_RO$?4$L#!!0 ( +& JEB7BKL

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 112 226 1 false 43 0 false 5 false false R1.htm 00090 - Document - Document And Entity Information Sheet http://soligenix.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) Sheet http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) Statements 6 false false R7.htm 00500 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Nature of Business Sheet http://soligenix.com/role/DisclosureNatureOfBusiness Nature of Business Notes 8 false false R9.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10301 - Disclosure - Accrued Expenses Sheet http://soligenix.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 10 false false R11.htm 10401 - Disclosure - Debt Sheet http://soligenix.com/role/DisclosureDebt Debt Notes 11 false false R12.htm 10501 - Disclosure - Shareholders' Equity Sheet http://soligenix.com/role/DisclosureShareholdersEquity Shareholders' Equity Notes 12 false false R13.htm 10601 - Disclosure - Commitments and Contingencies Sheet http://soligenix.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 10701 - Disclosure - Operating Segments Sheet http://soligenix.com/role/DisclosureOperatingSegments Operating Segments Notes 14 false false R15.htm 10801 - Disclosure - Subsequent Events Sheet http://soligenix.com/role/DisclosureSubsequentEvents Subsequent Events Notes 15 false false R16.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPolicies 16 false false R17.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 30303 - Disclosure - Accrued Expenses (Tables) Sheet http://soligenix.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://soligenix.com/role/DisclosureAccruedExpenses 18 false false R19.htm 30403 - Disclosure - Debt (Tables) Sheet http://soligenix.com/role/DisclosureDebtTables Debt (Tables) Tables http://soligenix.com/role/DisclosureDebt 19 false false R20.htm 30603 - Disclosure - Commitments and Contingencies (Tables) Sheet http://soligenix.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://soligenix.com/role/DisclosureCommitmentsAndContingencies 20 false false R21.htm 30703 - Disclosure - Operating Segments (Tables) Sheet http://soligenix.com/role/DisclosureOperatingSegmentsTables Operating Segments (Tables) Tables http://soligenix.com/role/DisclosureOperatingSegments 21 false false R22.htm 40101 - Disclosure - Nature of Business (Details) Sheet http://soligenix.com/role/DisclosureNatureOfBusinessDetails Nature of Business (Details) Details http://soligenix.com/role/DisclosureNatureOfBusiness 22 false false R23.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Carrying Value of Convertible Debt (Details) Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueOfConvertibleDebtDetails Summary of Significant Accounting Policies - Carrying Value of Convertible Debt (Details) Details 24 false false R25.htm 40204 - Disclosure - Summary of Significant Accounting Policies - Loss per share, Warrants and Options expirations (Details) Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails Summary of Significant Accounting Policies - Loss per share, Warrants and Options expirations (Details) Details 25 false false R26.htm 40301 - Disclosure - Accrued Expenses (Details) Sheet http://soligenix.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://soligenix.com/role/DisclosureAccruedExpensesTables 26 false false R27.htm 40401 - Disclosure - Debt (Details) Sheet http://soligenix.com/role/DisclosureDebtDetails Debt (Details) Details http://soligenix.com/role/DisclosureDebtTables 27 false false R28.htm 40402 - Disclosure - Debt - Assumptions (Details) Sheet http://soligenix.com/role/DisclosureDebtAssumptionsDetails Debt - Assumptions (Details) Details 28 false false R29.htm 40403 - Disclosure - Debt - Payments due (Details) Sheet http://soligenix.com/role/DisclosureDebtPaymentsDueDetails Debt - Payments due (Details) Details 29 false false R30.htm 40501 - Disclosure - Shareholders' Equity (Details) Sheet http://soligenix.com/role/DisclosureShareholdersEquityDetails Shareholders' Equity (Details) Details http://soligenix.com/role/DisclosureShareholdersEquity 30 false false R31.htm 40601 - Disclosure - Commitments and Contingencies (Details) Sheet http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://soligenix.com/role/DisclosureCommitmentsAndContingenciesTables 31 false false R32.htm 40602 - Disclosure - Commitments and Contingencies - Maturity (Details) Sheet http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails Commitments and Contingencies - Maturity (Details) Details 32 false false R33.htm 40701 - Disclosure - Operating Segments (Details) Sheet http://soligenix.com/role/DisclosureOperatingSegmentsDetails Operating Segments (Details) Details http://soligenix.com/role/DisclosureOperatingSegmentsTables 33 false false R34.htm 40801 - Disclosure - Subsequent Events (Details) Sheet http://soligenix.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://soligenix.com/role/DisclosureSubsequentEvents 34 false false R35.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Uncategorized 35 false false R36.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Cover 36 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 13 fact(s) appearing in ix:hidden were eligible for transformation: sngx:DebtInstrumentPeriodPrincipalPaymentDeferred, sngx:GuaranteeObligationsTermDuration, sngx:ShareBasedCompensationArrangementServicePeriod, sngx:SharebasedCompensationExpirationPeriod, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:PreferredStockSharesOutstanding, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - sngx-20240331x10q.htm 9 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies - sngx-20240331x10q.htm 9 [dq-0712-Presentation-Base-Set-Order] Role '40801 - Disclosure - Subsequent Events (Details)', a level 4, Detail role, appears before '995410 - Disclosure - Pay vs Performance Disclosure', a level 1, Note role. https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd 30, sngx-20240331.xsd 123 sngx-20240331.xsd sngx-20240331_cal.xml sngx-20240331_def.xml sngx-20240331_lab.xml sngx-20240331_pre.xml sngx-20240331x10q.htm http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sngx-20240331x10q.htm": { "nsprefix": "sngx", "nsuri": "http://soligenix.com/20240331", "dts": { "schema": { "local": [ "sngx-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] }, "calculationLink": { "local": [ "sngx-20240331_cal.xml" ] }, "definitionLink": { "local": [ "sngx-20240331_def.xml" ] }, "labelLink": { "local": [ "sngx-20240331_lab.xml" ] }, "presentationLink": { "local": [ "sngx-20240331_pre.xml" ] }, "inline": { "local": [ "sngx-20240331x10q.htm" ] } }, "keyStandard": 190, "keyCustom": 36, "axisStandard": 18, "axisCustom": 0, "memberStandard": 26, "memberCustom": 17, "hidden": { "total": 20, "http://xbrl.sec.gov/dei/2023": 5, "http://soligenix.com/20240331": 5, "http://fasb.org/us-gaap/2023": 10 }, "contextCount": 112, "entityCount": 1, "segmentCount": 43, "elementCount": 446, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 390, "http://xbrl.sec.gov/dei/2023": 30, "http://xbrl.sec.gov/ecd/2023": 4, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://soligenix.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:GrantsReceivableCurrent", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R3": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_7tk3pm1S2UaJLa4wI5aA4Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_7tk3pm1S2UaJLa4wI5aA4Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "00200 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:CostOfRevenue", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R5": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "longName": "00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R6": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "longName": "00400 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit)", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fvM_gIhwVUKlROlY1ONVnw", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fvM_gIhwVUKlROlY1ONVnw", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "00500 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://soligenix.com/role/DisclosureNatureOfBusiness", "longName": "10101 - Disclosure - Nature of Business", "shortName": "Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://soligenix.com/role/DisclosureAccruedExpenses", "longName": "10301 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://soligenix.com/role/DisclosureDebt", "longName": "10401 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://soligenix.com/role/DisclosureShareholdersEquity", "longName": "10501 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://soligenix.com/role/DisclosureCommitmentsAndContingencies", "longName": "10601 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://soligenix.com/role/DisclosureOperatingSegments", "longName": "10701 - Disclosure - Operating Segments", "shortName": "Operating Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://soligenix.com/role/DisclosureSubsequentEvents", "longName": "10801 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://soligenix.com/role/DisclosureAccruedExpensesTables", "longName": "30303 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://soligenix.com/role/DisclosureDebtTables", "longName": "30403 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "30603 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://soligenix.com/role/DisclosureOperatingSegmentsTables", "longName": "30703 - Disclosure - Operating Segments (Tables)", "shortName": "Operating Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "longName": "40101 - Disclosure - Nature of Business (Details)", "shortName": "Nature of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_lt8ZA-L-F0eiVhV70_ZAvQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "sngx:ReclassificationOfConvertibleDebtFromNonCurrentToCurrentLiability", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R23": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_lt8ZA-L-F0eiVhV70_ZAvQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R24": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueOfConvertibleDebtDetails", "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Carrying Value of Convertible Debt (Details)", "shortName": "Summary of Significant Accounting Policies - Carrying Value of Convertible Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_DkmRjkJfn0igXyvwbspZdQ", "name": "us-gaap:RepaymentsOfConvertibleDebt", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_z-tKjh5kL0qsM9fM-MealQ", "name": "us-gaap:ConvertibleDebt", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R25": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails", "longName": "40204 - Disclosure - Summary of Significant Accounting Policies - Loss per share, Warrants and Options expirations (Details)", "shortName": "Summary of Significant Accounting Policies - Loss per share, Warrants and Options expirations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_7tk3pm1S2UaJLa4wI5aA4Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_7tk3pm1S2UaJLa4wI5aA4Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://soligenix.com/role/DisclosureAccruedExpensesDetails", "longName": "40301 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://soligenix.com/role/DisclosureDebtDetails", "longName": "40401 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "As_Of_12_31_2023_jVxuR-PF8k-xXp6DUC3u5A", "name": "us-gaap:LongTermDebt", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Kte1Mxal80OPZed1-N1ZRw", "name": "sngx:NumberOfTranches", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R28": { "role": "http://soligenix.com/role/DisclosureDebtAssumptionsDetails", "longName": "40402 - Disclosure - Debt - Assumptions (Details)", "shortName": "Debt - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_3_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_NdMyRrZdnkeER1NAn2OphA", "name": "us-gaap:DebtInstrumentMeasurementInput", "unitRef": "Unit_Divide_USD_shares_i0RTfygsKEmCBEdEn8Q9Lw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_NdMyRrZdnkeER1NAn2OphA", "name": "us-gaap:DebtInstrumentMeasurementInput", "unitRef": "Unit_Divide_USD_shares_i0RTfygsKEmCBEdEn8Q9Lw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails", "longName": "40403 - Disclosure - Debt - Payments due (Details)", "shortName": "Debt - Payments due (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "longName": "40501 - Disclosure - Shareholders' Equity (Details)", "shortName": "Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_1_3_2024_srt_CounterpartyNameAxis_sngx_PontifaxMedisonFinanceMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_x4Xj02IyakqQ7Jxnyddt4A", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "Unit_Divide_USD_shares_i0RTfygsKEmCBEdEn8Q9Lw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3t627gStOkSqfjWX6KGoEA", "name": "sngx:DebtInstrumentReductionInConversionPricePercentageOfClosingPriceClosingPriceOfCommonStockOnDayBeforeDeliveryOfConversionNotice", "unitRef": "Unit_Standard_pure_TNOPx7-Df0GQcaueq1SFNw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R31": { "role": "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "40601 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:ContractualObligation", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "sngx:PaymentForCommitmentMilestones", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R32": { "role": "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails", "longName": "40602 - Disclosure - Commitments and Contingencies - Maturity (Details)", "shortName": "Commitments and Contingencies - Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_AcfUvrU9aEG0Ah9ta4xA2Q", "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "longName": "40701 - Disclosure - Operating Segments (Details)", "shortName": "Operating Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_sngx_BioTherapeuticsMember_HwWRYp2ES0Saopblb0Ni2A", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R34": { "role": "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "longName": "40801 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_DkmRjkJfn0igXyvwbspZdQ", "name": "us-gaap:RepaymentsOfConvertibleDebt", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_22_2024_To_4_22_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_sngx_PublicOfferingMember_feswEalV0U6MaORSnx3cQA", "name": "sngx:WarrantsIssuedPricePerUnit", "unitRef": "Unit_Divide_USD_shares_i0RTfygsKEmCBEdEn8Q9Lw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "unique": true } }, "R35": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Uncategorized", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_G9pToCWYKE6_3Fia6hWFfA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Cover", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_Tl8QKG0HYkSrnpc2GXxr2w", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240331x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r15" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r586" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://soligenix.com/role/DisclosureAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/DisclosureAccruedExpensesDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Clinical trail expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r25", "r26", "r77", "r137", "r433", "r465", "r466" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r9", "r26", "r386", "r389", "r415", "r461", "r462", "r689", "r690", "r691", "r702", "r703", "r704" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r637" ] }, "us-gaap_AdditionalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalCashFlowElementsAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Additional Cash Flow Elements [Abstract]", "terseLabel": "Cash paid for lease liabilities:" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r72", "r586", "r752" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r355", "r356", "r357", "r477", "r702", "r703", "r704", "r732", "r754" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r643" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r643" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r643" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r643" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r57", "r58", "r325" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r608", "r619", "r629", "r654" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r611", "r622", "r632", "r657" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r643" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r650" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r615", "r623", "r633", "r650", "r658", "r662", "r670" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r668" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred issuance costs associated with convertible debt", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r296", "r411", "r579", "r580", "r695" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Securities excluded", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r189" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r36" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r36" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "terseLabel": "Contingent consideration", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r728", "r729", "r730" ] }, "sngx_AssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "AssetPurchaseAgreementMember", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Asset Purchase Agreement.", "label": "Asset Purchase Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "verboseLabel": "Identifiable Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r102", "r133", "r161", "r198", "r219", "r225", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r379", "r383", "r397", "r428", "r511", "r586", "r599", "r720", "r721", "r739" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r130", "r139", "r161", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r379", "r383", "r397", "r586", "r720", "r721", "r739" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "sngx_AtMarketIssuanceSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "AtMarketIssuanceSalesAgreementMember", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to B. Riley Sales Agreement.", "label": "B. Riley Sales Agreement" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r665" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r666" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r661" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r661" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r661" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r661" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r661" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r661" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r326", "r327", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r350", "r351", "r352", "r353", "r354" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r664" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r663" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r662" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r662" ] }, "sngx_BioTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "BioTherapeuticsMember", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "BioTherapeutics.", "label": "Specialized BioTherapeutics [Member]" } } }, "auth_ref": [] }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostNetNoncurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Capitalized Contract Cost, Net, Noncurrent", "terseLabel": "Research and development incentives receivable, net of current portion", "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent." } } }, "auth_ref": [ "r238" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r32" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r31", "r86", "r157" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "negatedLabel": "Net decrease in cash", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r86" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r641" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r116", "r134", "r135", "r136", "r161", "r182", "r183", "r186", "r188", "r192", "r193", "r233", "r261", "r264", "r265", "r266", "r272", "r273", "r304", "r305", "r308", "r311", "r318", "r397", "r471", "r472", "r473", "r474", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r499", "r521", "r539", "r549", "r550", "r551", "r552", "r553", "r676", "r696", "r706" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r134", "r135", "r136", "r192", "r304", "r305", "r306", "r308", "r311", "r316", "r318", "r471", "r472", "r473", "r474", "r581", "r676", "r696" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r319" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of common warrants to purchase shares issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r319" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r642" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r642" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Nature of business:", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r377" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "terseLabel": "Commitments and contingencies (Note 6)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r22", "r64", "r429", "r498" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r92", "r255", "r256", "r555", "r717" ] }, "sngx_CommonStockIssuedEffectivePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://soligenix.com/20240331", "localname": "CommonStockIssuedEffectivePricePerShare", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock Issued Effective Price Per Share", "terseLabel": "Effective price per share (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r589", "r590", "r591", "r593", "r594", "r595", "r596", "r702", "r703", "r732", "r750", "r754" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r71" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r71", "r499" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r71" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r10", "r71", "r499", "r517", "r754", "r755" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $.001 par value; 75,000,000 shares authorized; 10,524,437 and 10,378,238 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r71", "r431", "r586" ] }, "sngx_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "CommonWarrantsMember", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common warrants.", "label": "Common warrants" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r647" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r646" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r648" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r645" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r27", "r141", "r143", "r149", "r424", "r440" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r164", "r200", "r217", "r218", "r219", "r220", "r221", "r223", "r227", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r271", "r272", "r681", "r682", "r720", "r721" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r164", "r200", "r217", "r218", "r219", "r220", "r221", "r223", "r227", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r271", "r272", "r681", "r682", "r720", "r721" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r60", "r564" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligation", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation", "terseLabel": "Contractual obligation", "totalLabel": "Total", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r699" ] }, "us-gaap_ContractualObligationDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInFourthYear", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInNextTwelveMonths", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInSecondYear", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInThirdYear", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleAbstract", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]" } } }, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of contractual obligation", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r700" ] }, "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Remainder of Fiscal Year", "terseLabel": "April 1 through December 31, 2024", "documentation": "Amount of contractual obligation to be paid in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt.", "periodEndLabel": "Convertible debt at fair value as of September 30, 2023", "periodStartLabel": "Convertible debt at fair value as of December 31, 2022", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r13", "r104", "r748" ] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Current", "terseLabel": "Convertible debt", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Convertible debt fair value", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueOfConvertibleDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r94", "r275", "r276", "r286", "r287", "r288", "r292", "r293", "r294", "r295", "r296", "r576", "r577", "r578", "r579", "r580" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Convertible debt securities", "terseLabel": "Convertible debt", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r726" ] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of carrying value of convertible debt", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable", "terseLabel": "Convertible note", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r13", "r104", "r748" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Corporate [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r12", "r218", "r219", "r220", "r221", "r227", "r708" ] }, "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cost, Depreciation and Amortization", "terseLabel": "Amortization and depreciation", "verboseLabel": "Amortization and Depreciation Expense", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service." } } }, "auth_ref": [ "r692" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "negatedLabel": "Cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r81", "r161", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r397", "r720" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r126", "r162", "r163", "r278", "r306", "r416", "r561", "r563" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Pontifax conversion of portion of debt principal into common stock", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r34", "r35" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r93", "r159", "r274", "r280", "r281", "r282", "r283", "r284", "r285", "r290", "r297", "r298", "r300" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r13", "r68", "r69", "r103", "r104", "r164", "r275", "r276", "r277", "r278", "r279", "r281", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r412", "r576", "r577", "r578", "r579", "r580", "r697" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r95", "r277" ] }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Shares of common stock issuable upon conversion", "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity." } } }, "auth_ref": [ "r20", "r51", "r98", "r99", "r277" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Debt instrument, face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r62", "r63", "r275", "r412", "r577", "r578" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r19", "r276" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt instruments", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r164", "r275", "r276", "r277", "r278", "r279", "r281", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r299", "r412", "r576", "r577", "r578", "r579", "r580", "r697" ] }, "us-gaap_DebtInstrumentMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMeasurementInput", "presentation": [ "http://soligenix.com/role/DisclosureDebtAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Measurement Input", "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt." } } }, "auth_ref": [ "r396" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r21", "r164", "r275", "r276", "r277", "r278", "r279", "r281", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r412", "r576", "r577", "r578", "r579", "r580", "r697" ] }, "sngx_DebtInstrumentPeriodPrincipalPaymentDeferred": { "xbrltype": "durationItemType", "nsuri": "http://soligenix.com/20240331", "localname": "DebtInstrumentPeriodPrincipalPaymentDeferred", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The period during which payment on the debt is for interest only, and payments of principal are deferred until after this period.", "label": "Debt Instrument, Period Principal Payment Deferred", "terseLabel": "Interest-only period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Interest", "terseLabel": "Interest paid", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Outstanding principal periodic payment", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r21" ] }, "sngx_DebtInstrumentReductionInConversionPriceNotice": { "xbrltype": "perShareItemType", "nsuri": "http://soligenix.com/20240331", "localname": "DebtInstrumentReductionInConversionPriceNotice", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the reduction in conversion price.", "label": "Reduction in conversion price" } } }, "auth_ref": [] }, "sngx_DebtInstrumentReductionInConversionPricePercentageOfClosingPriceClosingPriceOfCommonStockOnDayBeforeDeliveryOfConversionNotice": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240331", "localname": "DebtInstrumentReductionInConversionPricePercentageOfClosingPriceClosingPriceOfCommonStockOnDayBeforeDeliveryOfConversionNotice", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the reduction in conversion price to percentage of closing price of the common stock on the day before the delivery of the conversion notice.", "label": "Reduction in conversion price as percentage of closing price of the common stock on the day before the delivery of the conversion notice" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r21", "r51", "r54", "r61", "r62", "r63", "r65", "r97", "r99", "r164", "r275", "r276", "r277", "r278", "r279", "r281", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r299", "r412", "r576", "r577", "r578", "r579", "r580", "r697" ] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Issuance Costs", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r132" ] }, "us-gaap_DeferredCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Costs, Current", "terseLabel": "Deferred issuance cost", "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r688" ] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deposits Assets, Noncurrent", "terseLabel": "Security deposit", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r683" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Directors", "documentation": "Person serving on board of directors." } } }, "auth_ref": [ "r709", "r751" ] }, "sngx_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://soligenix.com/20240331", "localname": "DocumentAndEntityInformationAbstract", "lang": { "en-us": { "role": { "label": "Document And Entity Information" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r603" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r636" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share (in Dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r150", "r170", "r171", "r172", "r173", "r174", "r179", "r182", "r186", "r187", "r188", "r190", "r393", "r394", "r425", "r441", "r566" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share (in Dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r150", "r170", "r171", "r172", "r173", "r174", "r182", "r186", "r187", "r188", "r190", "r393", "r394", "r425", "r441", "r566" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r36", "r37" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r403" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r601" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r601" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r601" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r675" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r601" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r601" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r601" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r601" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r127", "r145", "r146", "r147", "r165", "r166", "r167", "r169", "r175", "r177", "r191", "r234", "r235", "r320", "r355", "r356", "r357", "r374", "r375", "r385", "r386", "r387", "r388", "r389", "r390", "r392", "r404", "r405", "r406", "r407", "r408", "r409", "r415", "r461", "r462", "r463", "r477", "r539" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r644" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r608", "r619", "r629", "r654" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r605", "r616", "r626", "r651" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r650" ] }, "sngx_FairValueAdjustmentOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "FairValueAdjustmentOfConvertibleDebt", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 }, "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueOfConvertibleDebtDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of convertible debt.", "label": "Fair Value Adjustment of Convertible Debt", "negatedLabel": "Change in fair value of convertible debt", "terseLabel": "Change in fair value of convertible debt", "verboseLabel": "Adjustment to fair value" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://soligenix.com/role/DisclosureDebtAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://soligenix.com/role/DisclosureDebtAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r11" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of debt assumptions", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r11" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r423" ] }, "sngx_FirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "FirstTrancheMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "First tranche.", "label": "First Tranche [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign currency transaction gain (loss)", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r399", "r400", "r401", "r402", "r536" ] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), Realized", "terseLabel": "Foreign currency transaction gain (loss)", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r519", "r597", "r736", "r737", "r753" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions and Translation", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r398" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r612", "r623", "r633", "r658" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r612", "r623", "r633", "r658" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r612", "r623", "r633", "r658" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r612", "r623", "r633", "r658" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r612", "r623", "r633", "r658" ] }, "sngx_FromPeriodTillNovember2024Member": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "FromPeriodTillNovember2024Member", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to rent till period November 2024.", "label": "From Period Till November 2024 [Member]" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "verboseLabel": "Consideration paid recorded in general and administrative expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r82", "r523" ] }, "sngx_GovernmentGrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "GovernmentGrantsReceivableCurrent", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Government Grants Receivable Current", "terseLabel": "Government grant funding" } } }, "auth_ref": [] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantMember", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Grant revenue", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r725" ] }, "us-gaap_GrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantsReceivableCurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Grants Receivable, Current", "terseLabel": "Contracts and grants receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r686" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r80", "r161", "r198", "r218", "r224", "r227", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r397", "r568", "r720" ] }, "sngx_GuaranteeObligationsTermDuration": { "xbrltype": "durationItemType", "nsuri": "http://soligenix.com/20240331", "localname": "GuaranteeObligationsTermDuration", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Guarantee Obligations Term Duration", "label": "Guarantee Obligations Term Duration", "terseLabel": "Term (in years)" } } }, "auth_ref": [] }, "sngx_HybryteMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "HybryteMember", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "HyBryte", "label": "HyBryte" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of long-lived assets", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r695", "r715" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r91" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r78", "r106", "r198", "r218", "r224", "r227", "r426", "r437", "r568" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "terseLabel": "Income tax benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r109", "r115", "r176", "r177", "r206", "r368", "r376", "r442" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r144", "r366", "r367", "r370", "r371", "r372", "r373", "r470" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid", "terseLabel": "Cash paid for state income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r30", "r33" ] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Contracts and grants receivable", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r679", "r694" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Employee-Related Liabilities", "terseLabel": "Accrued compensation", "documentation": "Amount of increase (decrease) in employer-related costs classified as other and current." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Receivables", "negatedLabel": "Research and development incentives receivable", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r6" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r615", "r623", "r633", "r650", "r658", "r662", "r670" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r668" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r604", "r674" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r604", "r674" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r604", "r674" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r84", "r294", "r302", "r579", "r580" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income (expense), net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "sngx_InterestMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "InterestMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails" ], "lang": { "en-us": { "role": { "documentation": "Interest.", "label": "Interest [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r152", "r155", "r156" ] }, "us-gaap_LeaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseAgreementsMember", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Lease Agreements [Member]", "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset." } } }, "auth_ref": [ "r59" ] }, "sngx_LeaseRentalPerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "LeaseRentalPerMonth", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lease rental per month", "label": "Lease Rental Per Month", "terseLabel": "Lease rent per month" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r16", "r161", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r380", "r383", "r384", "r397", "r497", "r567", "r599", "r720", "r739", "r740" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r76", "r105", "r435", "r586", "r698", "r714", "r735" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and shareholders' equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r18", "r131", "r161", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r380", "r383", "r384", "r397", "r586", "r720", "r739", "r740" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Unused line of credit fee, as a percent", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Outstanding principal", "verboseLabel": "Convertible debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r13", "r104", "r287", "r301", "r577", "r578", "r748" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails": { "parentTag": "sngx_TotalLongTerm", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r164", "r292" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails": { "parentTag": "sngx_TotalLongTerm", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Remainder of 2024", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r701" ] }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentTable", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment [Table]", "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueOfConvertibleDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r21" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueOfConvertibleDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r21", "r47" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r322", "r421", "r460", "r489", "r490", "r544", "r545", "r546", "r547", "r548", "r556", "r557", "r570", "r581", "r583", "r588", "r722", "r741", "r742", "r743", "r744", "r745", "r746" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r642" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r642" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r733" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r733" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r733" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r733" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://soligenix.com/role/DisclosureDebtAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r395" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://soligenix.com/role/DisclosureDebtAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r322", "r421", "r460", "r489", "r490", "r544", "r545", "r546", "r547", "r548", "r556", "r557", "r570", "r581", "r583", "r588", "r722", "r741", "r742", "r743", "r744", "r745", "r746" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r661" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r669" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r643" ] }, "sngx_NationalInstitutesOfHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "NationalInstitutesOfHealthMember", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the National Institute of Health.", "label": "NIH" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r154" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r86", "r87", "r88" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r79", "r88", "r107", "r129", "r140", "r142", "r147", "r161", "r168", "r170", "r171", "r172", "r173", "r176", "r177", "r184", "r198", "r218", "r224", "r227", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r394", "r397", "r439", "r520", "r537", "r538", "r568", "r597", "r720" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss applicable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r151", "r170", "r171", "r172", "r173", "r179", "r180", "r185", "r188", "r198", "r218", "r224", "r227", "r568" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r642" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r612", "r623", "r633", "r650", "r658" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r640" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r639" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r650" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r669" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r669" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "sngx_NoncashOrPartNoncashDeferredIssuanceCostReclassifiedToAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "NoncashOrPartNoncashDeferredIssuanceCostReclassifiedToAdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Deferred issuance cost reclassified to additional-paid-in capital.", "label": "NoncashOrPartNoncashDeferredIssuanceCostReclassifiedToAdditionalPaidInCapital", "terseLabel": "Deferred issuance cost reclassified to additional paid-in capital" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)", "verboseLabel": "Other (Expense) Income, Net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r83" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "sngx_NumberOfFirstEquityInstrumentsCommonStockIssuableUponConversionMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "NumberOfFirstEquityInstrumentsCommonStockIssuableUponConversionMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to first shares of common stock issuable upon conversion.", "label": "First 588,599 shares of common stock issuable upon conversion" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r707" ] }, "sngx_NumberOfSharesInUnit": { "xbrltype": "sharesItemType", "nsuri": "http://soligenix.com/20240331", "localname": "NumberOfSharesInUnit", "presentation": [ "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares in an unit.", "label": "Number of Shares in an Unit", "terseLabel": "Number of shares in an unit" } } }, "auth_ref": [] }, "sngx_NumberOfTranches": { "xbrltype": "stringItemType", "nsuri": "http://soligenix.com/20240331", "localname": "NumberOfTranches", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of tranches.", "label": "Number of Tranches", "terseLabel": "Number of tranches" } } }, "auth_ref": [] }, "sngx_NumberOfWarrantsInUnit": { "xbrltype": "sharesItemType", "nsuri": "http://soligenix.com/20240331", "localname": "NumberOfWarrantsInUnit", "presentation": [ "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants in an unit.", "label": "Number of Warrants in an Unit", "terseLabel": "Number of warrants in an unit" } } }, "auth_ref": [] }, "us-gaap_OneTimeTerminationBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OneTimeTerminationBenefitsMember", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Termination benefits", "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities." } } }, "auth_ref": [ "r572", "r573", "r574", "r575" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "verboseLabel": "Income (loss) from Operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r198", "r218", "r224", "r227", "r568" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r414" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r414" ] }, "sngx_OperatingLeasePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "OperatingLeasePaid", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease.", "label": "Operating Lease Paid", "terseLabel": "Operating lease" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right-of-use lease assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r413" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash lease expense", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r695" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r221", "r227" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Nature of Business" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusiness" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r67", "r101", "r467", "r468" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r17" ] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsLineItems", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsTable", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments", "verboseLabel": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r85" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r642" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r610", "r621", "r631", "r656" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r613", "r624", "r634", "r659" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r613", "r624", "r634", "r659" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r638" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "auth_ref": [] }, "sngx_PaymentForCommitmentMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PaymentForCommitmentMilestones", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment for commitment milestones.", "label": "Payment For Commitment Milestones", "terseLabel": "Maximum payment for commitment milestones" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedLabel": "Stock issuance costs associated", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r28" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "terseLabel": "Cash paid to acquire intangible asset", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r108", "r728", "r729", "r730" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r641" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r641" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r640" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r650" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r643" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r639" ] }, "sngx_PercentageChangeInCashAndCashEquivalents": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PercentageChangeInCashAndCashEquivalents", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage change in cash and cash equivalents.", "label": "Percentage Change In Cash And Cash Equivalents", "terseLabel": "Percentage change in cash and cash equivalent" } } }, "auth_ref": [] }, "sngx_PercentageForRoyalties": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PercentageForRoyalties", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage for royalties.", "label": "Percentage For Royalties", "terseLabel": "Percentage for royalties" } } }, "auth_ref": [] }, "sngx_PercentageOfGlobalNetSalesRoyaltiesOnCoveredProducts": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PercentageOfGlobalNetSalesRoyaltiesOnCoveredProducts", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of global net sales royalties on covered products.", "label": "Percentage of Global Net Sales Royalties on Covered Products", "terseLabel": "Percentage of global net sales royalties on covered products" } } }, "auth_ref": [] }, "sngx_PercentageOfOwnershipOutstandingStock": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PercentageOfOwnershipOutstandingStock", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership outstanding stock.", "label": "Percentage Of Ownership Outstanding Stock", "terseLabel": "Ownership of company outstanding" } } }, "auth_ref": [] }, "sngx_PercentageOfSubLicenseIncomeRoyalties": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PercentageOfSubLicenseIncomeRoyalties", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of sub license income royalties.", "label": "Percentage of Sub License Income Royalties", "terseLabel": "Percentage of sub license income on royalties" } } }, "auth_ref": [] }, "sngx_PontifaxMedisonFinanceMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PontifaxMedisonFinanceMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Pontifax Medison Finance.", "label": "Pontifax" } } }, "auth_ref": [] }, "sngx_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PreFundedWarrantMember", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to pre-funded warrants.", "label": "Pre-funded Warrant [Member]", "terseLabel": "Pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r589", "r590", "r593", "r594", "r595", "r596", "r750", "r754" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r70", "r499" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r70", "r499", "r517", "r754", "r755" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, 350,000 shares authorized; none issued or outstanding at March 31, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r70", "r430", "r586" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r138", "r236", "r237", "r560" ] }, "sngx_PrincipalMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PrincipalMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails" ], "lang": { "en-us": { "role": { "documentation": "Principal.", "label": "Principal [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Total gross proceeds", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r5" ] }, "sngx_ProceedsFromIssuanceOfCommonStockPursuantToMarketSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "ProceedsFromIssuanceOfCommonStockPursuantToMarketSalesAgreement", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock pursuant to FBR At-the-Market Sales Agreement,", "label": "Proceeds From Issuance Of Common Stock Pursuant To Market Sales Agreement", "terseLabel": "Proceeds from issuance of common stock pursuant to B. Riley At Market Issuance Sales Agreement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Total gross proceeds", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r5", "r471" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r229", "r422", "r454", "r455", "r456", "r457", "r458", "r459", "r559", "r582", "r587", "r680", "r718", "r719", "r724", "r749" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r229", "r422", "r454", "r455", "r456", "r457", "r458", "r459", "r559", "r582", "r587", "r680", "r718", "r719", "r724", "r749" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r129", "r140", "r142", "r153", "r161", "r168", "r176", "r177", "r198", "r218", "r224", "r227", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r378", "r381", "r382", "r394", "r397", "r426", "r438", "r476", "r520", "r537", "r538", "r568", "r584", "r585", "r598", "r691", "r720" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Office furniture and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r427", "r436", "r586" ] }, "sngx_PublicHealthSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PublicHealthSolutionsMember", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Public Health Solutions [Member]" } } }, "auth_ref": [] }, "sngx_PublicOfferingCostsIncludedInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PublicOfferingCostsIncludedInAccountsPayable", "crdr": "debit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of public offering costs included in accounts payable in non-cash investing and financing activities.", "label": "Public Offering Costs Included in Accounts Payable", "terseLabel": "Public offering costs included in accounts payable" } } }, "auth_ref": [] }, "sngx_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "PublicOfferingMember", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to public offering.", "label": "Public Offering" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r638" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r638" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r321", "r322", "r351", "r352", "r353", "r420", "r421", "r460", "r489", "r490", "r544", "r545", "r546", "r547", "r548", "r556", "r557", "r570", "r581", "r583", "r588", "r591", "r716", "r722", "r742", "r743", "r744", "r745", "r746" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r321", "r322", "r351", "r352", "r353", "r420", "r421", "r460", "r489", "r490", "r544", "r545", "r546", "r547", "r548", "r556", "r557", "r570", "r581", "r583", "r588", "r591", "r716", "r722", "r742", "r743", "r744", "r745", "r746" ] }, "us-gaap_ReceivablesLongTermContractsOrPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesLongTermContractsOrPrograms", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Research and development incentives receivable", "terseLabel": "Research and development incentives receivable, current", "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date." } } }, "auth_ref": [ "r687" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Licensing, Contracts and Grants Receivable", "terseLabel": "Contracts and Grants Receivable", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r710", "r711", "r712", "r713" ] }, "sngx_ReclassificationOfConvertibleDebtFromNonCurrentToCurrentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "ReclassificationOfConvertibleDebtFromNonCurrentToCurrentLiability", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of reclassification of convertible debt from non-current to current liability.", "label": "Reclassification of Convertible Debt From Non-Current to current Liability" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r605", "r616", "r626", "r651" ] }, "sngx_RedemptionOfPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "RedemptionOfPreferredStock", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of redemption of preferred stock.", "label": "Redemption of Preferred Stock", "terseLabel": "Redemption liability for Series D preferred stock" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCarryingValueOfConvertibleDebtDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Convertible Debt", "negatedLabel": "Convertible debt repayments", "terseLabel": "Repayment of debt principal", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r29" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Amount repaid", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r693" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r162", "r163", "r278", "r306", "r416", "r562", "r563" ] }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementMember", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement [Member]", "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r66", "r364", "r747" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r363" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r606", "r617", "r627", "r652" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r607", "r618", "r628", "r653" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r614", "r625", "r635", "r660" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r249", "r250", "r252", "r253" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r73", "r100", "r434", "r464", "r466", "r475", "r500", "r586" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r127", "r165", "r166", "r167", "r169", "r175", "r177", "r234", "r235", "r355", "r356", "r357", "r374", "r375", "r385", "r387", "r388", "r390", "r392", "r461", "r463", "r477", "r754" ] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "terseLabel": "Revenue from collaborative arrangement", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r110", "r731" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r522", "r558", "r565" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Revenues", "verboseLabel": "Total revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r148", "r161", "r199", "r200", "r217", "r222", "r223", "r229", "r231", "r232", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r397", "r426", "r720" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r669" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r669" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScenarioPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScenarioPlanMember", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Scenario, Plan [Member]", "documentation": "The scenario under which facts represent plans as distinct from actual." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r178", "r323", "r677", "r705" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive adjustments to the weighted average number of common shares excluded from the calculation", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r377" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r45", "r46", "r423" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of annual principle and interest payments due", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r8" ] }, "sngx_ScheduleOfPotentiallyDilutiveAdjustmentsToTheWeightedAverageNumberOfCommonSharesExcludedFromTheCalculationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://soligenix.com/20240331", "localname": "ScheduleOfPotentiallyDilutiveAdjustmentsToTheWeightedAverageNumberOfCommonSharesExcludedFromTheCalculationAbstract", "lang": { "en-us": { "role": { "label": "Schedule of potentially dilutive adjustments to the weighted average number of common shares excluded from the calculation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r41", "r42", "r43", "r44" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of operating segments", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r41", "r42", "r43", "r44" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r48", "r49", "r50", "r51", "r52", "r53", "r54", "r97", "r99", "r100", "r134", "r135", "r136", "r192", "r304", "r305", "r306", "r308", "r311", "r316", "r318", "r471", "r472", "r473", "r474", "r581", "r676", "r696" ] }, "sngx_SecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "SecondTrancheMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Second tranche.", "label": "Second Tranche [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r600" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r602" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r195", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r232", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r251", "r254", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r571", "r680", "r749" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Operating Segments" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegments" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Operating Segments", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r210", "r221", "r225", "r226", "r227", "r228", "r229", "r230", "r232" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment reporting", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Operating Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r216", "r231", "r569" ] }, "us-gaap_SeriesDPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesDPreferredStockMember", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series D Preferred Stock", "documentation": "Series D preferred stock." } } }, "auth_ref": [ "r684", "r685", "r723" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation", "verboseLabel": "Share-Based Compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights", "terseLabel": "Option vesting rights", "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, outstanding options", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r330", "r331" ] }, "sngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://soligenix.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock warrants plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice", "terseLabel": "Weighted average exercise price, outstanding warrants" } } }, "auth_ref": [] }, "sngx_ShareBasedCompensationArrangementServicePeriod": { "xbrltype": "durationItemType", "nsuri": "http://soligenix.com/20240331", "localname": "ShareBasedCompensationArrangementServicePeriod", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for equity-based payment award.", "label": "Share - Based Compensation Arrangement Service Period", "terseLabel": "Requisite period (in years)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r326", "r327", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r350", "r351", "r352", "r353", "r354" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r324", "r329", "r348", "r349", "r350", "r351", "r354", "r358", "r359", "r360", "r361" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "verboseLabel": "Shares issued price per share", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "sngx_SharebasedCompensationExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://soligenix.com/20240331", "localname": "SharebasedCompensationExpirationPeriod", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity based award expires.", "label": "Share based Compensation Expiration Period", "terseLabel": "Expiration period" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Fair value per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r89", "r158" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r128", "r195", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r232", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r251", "r254", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r571", "r680", "r749" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r116", "r134", "r135", "r136", "r161", "r182", "r183", "r186", "r188", "r192", "r193", "r233", "r261", "r264", "r265", "r266", "r272", "r273", "r304", "r305", "r308", "r311", "r318", "r397", "r471", "r472", "r473", "r474", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r499", "r521", "r539", "r549", "r550", "r551", "r552", "r553", "r676", "r696", "r706" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r10", "r24", "r127", "r145", "r146", "r147", "r165", "r166", "r167", "r169", "r175", "r177", "r191", "r234", "r235", "r320", "r355", "r356", "r357", "r374", "r375", "r385", "r386", "r387", "r388", "r389", "r390", "r392", "r404", "r405", "r406", "r407", "r408", "r409", "r415", "r461", "r462", "r463", "r477", "r539" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r165", "r166", "r167", "r191", "r422", "r469", "r488", "r491", "r492", "r493", "r494", "r495", "r496", "r499", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r514", "r515", "r516", "r518", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r539", "r592" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit)" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r178", "r323", "r677", "r678", "r705" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r165", "r166", "r167", "r191", "r422", "r469", "r488", "r491", "r492", "r493", "r494", "r495", "r496", "r499", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r514", "r515", "r516", "r518", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r539", "r592" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r609", "r620", "r630", "r655" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Number of shares issued on exercise of warrants", "verboseLabel": "Issuance of common stock associated with conversion of debt (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r10", "r23", "r51", "r100", "r291" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares issued", "verboseLabel": "Issuance of common stock", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r10", "r70", "r71", "r100", "r471", "r539", "r550" ] }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Issuance of shares for assets (in shares)", "verboseLabel": "Issuance of common stock for unexercised purchase option (in shares)", "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "sngx_StockIssuedDuringPeriodSharesPursuantToMarketSalesAgreement": { "xbrltype": "sharesItemType", "nsuri": "http://soligenix.com/20240331", "localname": "StockIssuedDuringPeriodSharesPursuantToMarketSalesAgreement", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares pursuant to market sales agreement.", "label": "Stock Issued During Period Shares Pursuant To Market Sales Agreement", "netLabel": "Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock associated with conversion of debt", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r10", "r24", "r100" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock pursuant to B. Riley At Market Issuance Sales Agreement", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r10", "r70", "r71", "r100", "r477", "r539", "r550", "r598" ] }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Fair value of shares issued in connection with asset purchase", "verboseLabel": "Issuance of common stock for unexercised purchase option", "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "sngx_StockIssuedDuringPeriodValuePursuantToMarketSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "StockIssuedDuringPeriodValuePursuantToMarketSalesAgreement", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value pursuant to market sales agreement.", "label": "Stock Issued During Period Value Pursuant To Market Sales Agreement", "netLabel": "Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement", "verboseLabel": "Number of shares sold" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r71", "r74", "r75", "r90", "r501", "r517", "r540", "r541", "r586", "r599", "r698", "r714", "r735", "r754" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Shareholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r96", "r160", "r303", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r320", "r391", "r542", "r543", "r554" ] }, "sngx_SubLicenseMilestonesOnCoveredProducts": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "SubLicenseMilestonesOnCoveredProducts", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of sub license milestones on covered products.", "label": "Sub License Milestones on Covered Products", "terseLabel": "Sub license milestones payments on covered products" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r410", "r418" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r410", "r418" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r410", "r418" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r410", "r418" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r410", "r418" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r417", "r419" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r649" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r261", "r264", "r265", "r266", "r272", "r273", "r362", "r432" ] }, "sngx_TemporaryEquityStockIssuedDuringPeriodValueStockDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "TemporaryEquityStockIssuedDuringPeriodValueStockDividend", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Value of stock classified as temporary equity issued to shareholders as a dividend during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, Stock Dividend", "terseLabel": "Declaration of Series D preferred stock" } } }, "auth_ref": [] }, "sngx_ThirdTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240331", "localname": "ThirdTrancheMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Third Tranche [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "documentation": "Information by title of individual or nature of relationship to individual or group of individuals." } } }, "auth_ref": [ "r709", "r738" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "auth_ref": [] }, "sngx_TotalLongTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "TotalLongTerm", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/DisclosureDebtPaymentsDueDetails" ], "lang": { "en-us": { "role": { "label": "Total Long Term", "totalLabel": "Total" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r641" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r648" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r668" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r670" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r671" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r672" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r670" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r670" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r673" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r671" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r249", "r250", "r252", "r253" ] }, "sngx_UkResearchAndDevelopmentIncentives": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "UkResearchAndDevelopmentIncentives", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "UK research and development incentives.", "label": "Uk Research And Development Incentives", "negatedLabel": "Research and development incentives" } } }, "auth_ref": [] }, "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnbilledReceivablesCurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Unbilled Receivables, Current", "terseLabel": "Unbilled revenue", "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r667" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r365", "r369" ] }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "crdr": "credit", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "terseLabel": "Interest and penalties", "documentation": "Amount of interest expense accrued for an underpayment of income taxes." } } }, "auth_ref": [ "r727" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates and Assumptions", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r38", "r39", "r40", "r111", "r112", "r113", "r114" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants", "terseLabel": "Common stock purchase warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r589", "r590", "r593", "r594", "r595", "r596" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Expiration term of warrants", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r734" ] }, "sngx_WarrantsIssuedPricePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://soligenix.com/20240331", "localname": "WarrantsIssuedPricePerUnit", "presentation": [ "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Price per share or per unit of warrants sold.", "label": "Warrants Issued, Price per Unit", "terseLabel": "Price per unit" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareWarrantsAndOptionsExpirationsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average", "documentation": "Average of a range of values, calculated with consideration of proportional relevance." } } }, "auth_ref": [ "r556", "r557", "r741", "r743", "r746" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted weighted average common shares outstanding (in Shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r181", "r188" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted average common shares outstanding (in Shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r179", "r188" ] }, "sngx_WorkingCapitalCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "WorkingCapitalCarryingValue", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of working capital, carrying value.", "label": "Working Capital Carrying Value", "terseLabel": "Working capital" } } }, "auth_ref": [] }, "sngx_WorkingCapitalIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240331", "localname": "WorkingCapitalIncreaseDecrease", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in working capital.", "label": "Working capital increase, decrease" } } }, "auth_ref": [] }, "sngx_WorkingCapitalPercentageIncreaseDecrease": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240331", "localname": "WorkingCapitalPercentageIncreaseDecrease", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percent increase (decrease) in working capital.", "label": "Working capital percentage increase, decrease", "terseLabel": "Working capital increase (decrease) as a percent" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "(m)", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r676": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r678": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 56 0001558370-24-007782-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-007782-xbrl.zip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end XML 58 sngx-20240331x10q_htm.xml IDEA: XBRL DOCUMENT 0000812796 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000812796 sngx:AssetPurchaseAgreementMember 2020-03-01 2020-03-31 0000812796 sngx:PontifaxMedisonFinanceMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2024-01-03 2024-01-03 0000812796 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000812796 us-gaap:RetainedEarningsMember 2024-03-31 0000812796 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000812796 us-gaap:RetainedEarningsMember 2023-12-31 0000812796 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000812796 us-gaap:RetainedEarningsMember 2023-03-31 0000812796 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000812796 us-gaap:RetainedEarningsMember 2022-12-31 0000812796 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000812796 us-gaap:CommonStockMember 2024-03-31 0000812796 us-gaap:CommonStockMember 2023-12-31 0000812796 us-gaap:CommonStockMember 2023-03-31 0000812796 us-gaap:CommonStockMember 2022-12-31 0000812796 sngx:PontifaxMedisonFinanceMember us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2024-04-15 0000812796 sngx:PontifaxMedisonFinanceMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2024-01-03 0000812796 sngx:PontifaxMedisonFinanceMember us-gaap:ConvertibleDebtMember 2024-01-03 0000812796 us-gaap:SubsequentEventMember 2024-04-22 0000812796 us-gaap:GrantMember 2024-01-01 2024-03-31 0000812796 us-gaap:GrantMember 2023-01-01 2023-03-31 0000812796 sngx:PontifaxMedisonFinanceMember us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2024-04-15 2024-04-15 0000812796 us-gaap:ConvertibleDebtMember 2024-01-03 2024-01-03 0000812796 sngx:AssetPurchaseAgreementMember 2014-09-01 2014-09-30 0000812796 sngx:PublicOfferingMember 2024-01-01 2024-03-31 0000812796 sngx:AtMarketIssuanceSalesAgreementMember 2023-01-01 2023-03-31 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000812796 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000812796 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000812796 sngx:PontifaxMedisonFinanceMember us-gaap:ConvertibleDebtMember 2023-04-19 0000812796 sngx:PontifaxMedisonFinanceMember us-gaap:ConvertibleDebtMember 2023-04-18 2023-04-18 0000812796 us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0000812796 us-gaap:MeasurementInputSharePriceMember 2024-03-31 0000812796 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-31 0000812796 us-gaap:MeasurementInputPriceVolatilityMember 2024-03-31 0000812796 us-gaap:MeasurementInputDiscountRateMember 2024-03-31 0000812796 us-gaap:MeasurementInputSharePriceMember 2023-04-19 0000812796 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-04-19 0000812796 us-gaap:MeasurementInputPriceVolatilityMember 2023-04-19 0000812796 us-gaap:MeasurementInputDiscountRateMember 2023-04-19 0000812796 srt:MaximumMember us-gaap:ConvertibleDebtMember 2020-12-31 0000812796 us-gaap:ConvertibleDebtMember 2020-12-31 0000812796 sngx:PontifaxMedisonFinanceMember us-gaap:ConvertibleDebtMember 2024-01-03 2024-01-03 0000812796 sngx:PontifaxMedisonFinanceMember us-gaap:ConvertibleDebtMember 2023-04-19 2023-04-19 0000812796 srt:WeightedAverageMember 2024-03-31 0000812796 srt:WeightedAverageMember 2023-03-31 0000812796 us-gaap:OperatingSegmentsMember sngx:PublicHealthSolutionsMember 2024-01-01 2024-03-31 0000812796 us-gaap:OperatingSegmentsMember sngx:BioTherapeuticsMember 2024-01-01 2024-03-31 0000812796 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-03-31 0000812796 us-gaap:OperatingSegmentsMember sngx:PublicHealthSolutionsMember 2023-01-01 2023-03-31 0000812796 us-gaap:OperatingSegmentsMember sngx:BioTherapeuticsMember 2023-01-01 2023-03-31 0000812796 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000812796 sngx:ThirdTrancheMember us-gaap:ConvertibleDebtMember 2020-12-31 0000812796 sngx:SecondTrancheMember us-gaap:ConvertibleDebtMember 2020-12-31 0000812796 sngx:FirstTrancheMember us-gaap:ConvertibleDebtMember 2020-12-31 0000812796 us-gaap:ConvertibleDebtMember 2024-03-31 0000812796 us-gaap:ConvertibleDebtMember 2023-12-31 0000812796 us-gaap:ResearchAndDevelopmentArrangementMember 2024-03-31 0000812796 us-gaap:LeaseAgreementsMember 2024-03-31 0000812796 us-gaap:CommonStockMember us-gaap:SubsequentEventMember sngx:PublicOfferingMember 2024-04-22 0000812796 sngx:PreFundedWarrantMember us-gaap:SubsequentEventMember sngx:PublicOfferingMember 2024-04-22 0000812796 sngx:CommonWarrantsMember us-gaap:SubsequentEventMember sngx:PublicOfferingMember 2024-04-22 0000812796 us-gaap:SubsequentEventMember sngx:PublicOfferingMember 2024-04-22 0000812796 2023-03-31 0000812796 2022-12-31 0000812796 us-gaap:OperatingSegmentsMember sngx:PublicHealthSolutionsMember 2024-03-31 0000812796 us-gaap:OperatingSegmentsMember sngx:BioTherapeuticsMember 2024-03-31 0000812796 us-gaap:CorporateNonSegmentMember 2024-03-31 0000812796 us-gaap:OperatingSegmentsMember sngx:PublicHealthSolutionsMember 2023-12-31 0000812796 us-gaap:OperatingSegmentsMember sngx:BioTherapeuticsMember 2023-12-31 0000812796 us-gaap:CorporateNonSegmentMember 2023-12-31 0000812796 srt:MaximumMember us-gaap:ScenarioPlanMember sngx:AssetPurchaseAgreementMember 2024-01-01 2024-03-31 0000812796 us-gaap:WarrantMember 2024-01-01 2024-03-31 0000812796 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000812796 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-03-31 0000812796 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000812796 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-03-31 0000812796 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000812796 2023-12-31 0000812796 us-gaap:SubsequentEventMember sngx:PublicOfferingMember 2024-04-22 2024-04-22 0000812796 sngx:PrincipalMember 2024-03-31 0000812796 sngx:InterestMember 2024-03-31 0000812796 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000812796 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000812796 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000812796 us-gaap:OneTimeTerminationBenefitsMember 2024-01-01 2024-03-31 0000812796 srt:DirectorMember 2024-01-01 2024-03-31 0000812796 2024-03-31 0000812796 sngx:AssetPurchaseAgreementMember 2024-01-01 2024-03-31 0000812796 srt:MinimumMember 2024-01-01 2024-03-31 0000812796 srt:MaximumMember 2024-01-01 2024-03-31 0000812796 sngx:CommonWarrantsMember us-gaap:SubsequentEventMember sngx:PublicOfferingMember 2024-04-22 2024-04-22 0000812796 us-gaap:CommonStockMember us-gaap:SubsequentEventMember sngx:PublicOfferingMember 2024-04-22 2024-04-22 0000812796 sngx:PreFundedWarrantMember us-gaap:SubsequentEventMember sngx:PublicOfferingMember 2024-04-22 2024-04-22 0000812796 2023-01-01 2023-03-31 0000812796 sngx:FromPeriodTillNovember2024Member 2022-06-21 0000812796 2022-06-21 0000812796 sngx:HybryteMember 2024-01-01 2024-03-31 0000812796 sngx:NationalInstitutesOfHealthMember 2024-03-31 0000812796 us-gaap:ConvertibleDebtMember 2024-01-01 2024-03-31 0000812796 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000812796 sngx:PontifaxMedisonFinanceMember sngx:NumberOfFirstEquityInstrumentsCommonStockIssuableUponConversionMember us-gaap:ConvertibleDebtMember 2023-04-19 2023-04-19 0000812796 us-gaap:ConvertibleDebtMember 2020-12-01 2020-12-31 0000812796 sngx:AssetPurchaseAgreementMember 2020-03-31 0000812796 2024-05-03 0000812796 2024-01-01 2024-03-31 shares iso4217:USD shares pure iso4217:USD sngx:segment -0.18 -0.36 10521233 2914929 0000812796 --12-31 2024 Q1 false P1Y P3M P3Y P2Y P4Y 10378238 10524437 0 0 10-Q true 2024-03-31 false 001-14778 SOLIGENIX, INC. DE 41-1505029 29 EMMONS DRIVE SUITE B-10 PRINCETON, NJ 08540 609 538-8200 Common Stock, par value $.001 per share SNGX NASDAQ Yes Yes Non-accelerated Filer true false false 15799837 7091548 8446158 117029 171254 25253 23894 132681 451876 866014 7818387 9507320 22777 22777 10339 11927 200569 229834 6313 25468 8058385 9797326 1436728 1111226 2602665 2418002 50216 251115 125143 121765 2996136 2250000 7210888 6152108 1010934 79125 111862 7290013 7274904 350000 350000 0 0 0.001 0.001 75000000 75000000 10524437 10378238 10524 10378 228353208 228193977 24143 22243 -227619503 -225704176 768372 2522422 8058385 9797326 117029 257178 117029 257178 117029 226040 31138 1095040 946451 1022051 1235376 2117091 2181827 -2117091 -2150689 1209 -366 28842 -103568 -6331 -6448 40869 -165382 201764 -56617 -1915327 -2207306 -1161197 -1915327 -1046109 -0.18 -0.18 -0.36 -0.36 10521233 10521233 2914929 2914929 -1915327 -1046109 1900 -12153 -1913427 -1058262 10378238 10378 228193977 22243 -225704176 2522422 146199 146 99270 99416 59961 59961 1900 1900 -1915327 -1915327 10524437 10524 228353208 24143 -227619503 768372 43 2908578 2909 217064964 24747 -219563446 -2470826 21195 21 70709 70730 -2341 -2341 -43 73634 73634 -12153 -12153 -1046109 -1046109 2929773 2930 217206966 12594 -220609555 -3387065 -1915327 -1046109 1588 1785 29265 26936 59961 73634 -165382 10242 -54225 102878 -414138 -60894 -17379 -98456 -29359 -26256 391929 -970757 -200899 -292200 -1342482 -2166253 70730 2288 8992 1000000 -8992 -931558 -3136 4046 -1354610 -3093765 8446158 13359615 7091548 10265850 17965 2110 64047 213490 34100 33325 99416 53 43 123689 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Note 1. Nature of Business</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Basis of Presentation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Soligenix, Inc. (the “Company”) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments: Specialized BioTherapeutics and Public Health Solutions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With agreement from the European Medicines Agency (“EMA”) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ in the treatment of CTCL patients with early-stage disease, <span style="background:#ffffff;">the Company is targeting to begin patient enrollment by </span>the end of 2024 with top-line results anticipated in the second half of 2026. Upon successful completion of the second Phase 3 study, called “FLASH2” (Fluorescent Light Activated Synthetic Hypericin 2), regulatory approval will be sought to support potential commercialization worldwide.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, the Company’s first-in-class innate defense regulator technology, and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer and aphthous ulcers in Behçet’s Disease. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s Public Health Solutions business segment includes development programs for RiVax<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of the vaccine programs incorporates the use of the Company’s proprietary heat stabilization platform technology, known as ThermoVax<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company primarily generates revenues under government grants and contracts. The Company was awarded a subcontract that originally provided for approximately $1.1 million from a U.S. Food and Drug Administration (“FDA”) Orphan Products Development grant over <span style="-sec-ix-hidden:Hidden_jLhVWf6ch0GqbtmuzLXIOA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">four years</span></span> for an expanded study of HyBryte™ in the treatment of CTCL. The Company will continue to apply for additional government funding.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, development of new technological innovations, dependence on key personnel, protections of proprietary technology, compliance with the FDA regulations, and other regulatory authorities, litigation, and product liability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Results for the three months ended March 31, 2024 are not necessarily indicative of results that may be expected for the full year.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Liquidity</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with Accounting Standards Codification 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the condensed consolidated </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">financial statements are issued. As of March 31, 2024, the Company had an accumulated deficit of $227,619,503. During the three months ended March 31, 2024, the Company incurred a net loss of $1,915,327 and used $1,342,482 of cash in operating activities. The Company expects to continue to generate losses in the foreseeable future. The Company’s liquidity needs will be determined largely by the budgeted operational expenditures incurred in regards to the progression of its product candidates. Management believes that the Company has sufficient resources available to support its development activities and business operations and timely satisfy its obligations as they become due through the first quarter of 2025. The Company does not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support its operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern through 12 months after the date the financial statements are issued.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, the Company plans to secure additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations, securing additional proceeds from government contract and grant programs, securing additional proceeds available from the sale of shares of the common stock via an At Market Issuance Sales Agreement and potentially amending the loan agreement with Pontifax Medison Finance (“Pontifax”) to reduce the conversion price in order to allow for conversion of a portion of the debt which will reduce the Company’s debt repayments; however, none of these alternatives are committed at this time. There can be no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to it to fund continuing operations, if at all, identify and enter into any strategic transactions that will provide the capital that it will require or achieve the other strategies to alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern. If none of these alternatives are available, or if available, are not available on satisfactory terms, the Company will not have sufficient cash resources and liquidity to fund its business operations for at least the 12 months following the date the financial statements are issued. The failure to obtain sufficient capital on acceptable terms when needed may require the Company to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives and its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. In addition, market instability, including as a result of geopolitical instability, may reduce the Company’s ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern. In addition, the perception that the Company may not be able to continue as a going concern may cause others to choose not to deal with it due to concerns about its ability to meet its contractual obligations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2024, the Company had cash and cash equivalents of $7,091,548 as compared to $8,446,158 as of December 31, 2023, representing a decrease of $1,354,610 or 16%. As of March 31, 2024, the Company had working capital of $607,499 as compared to working capital of $3,355,212 as of December 31, 2023, representing a decrease in working capital of $2,747,713 or 82%. The decrease in cash and cash equivalents was primarily related to cash used in operating activities during the three months ended March 31, 2024. The decrease in working capital is primarily the result of the reclassification of approximately $1 million of the Company’s convertible debt balance from a non-current liability as of December 31, 2023 to a current liability as of March 31, 2024 (resulting from the amendment to the loan and security agreement with Pontifax – see Note 4), and cash used in operating activities during the three months ended March 31, 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management’s business strategy can be outlined as follows:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Following agreement from the EMA on the key design components for the second confirmatory Phase 3 placebo-controlled FLASH2 clinical trial of HyBryte™ in CTCL and positive primary endpoint results </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">from the first Phase 3 FLASH study, initiate the FLASH2 study, while at the same time, continuing discussions with the FDA on potential modifications to the development path to adequately address their feedback. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expanding development of synthetic hypericin under the research name SGX302 into psoriasis with the conduct of a Phase 2a clinical trial, following the positive Phase 3 FLASH study and positive proof-of-concept demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Following feedback from the United Kingdom (“UK”) Medicines and Healthcare products Regulatory Agency (“MHRA”) that a second Phase 3 clinical trial of SGX942 (dusquetide) in the treatment in oral mucositis would be required to support a marketing authorization; design a second study and attempt to identify a potential partner(s) to continue this development program.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expanding development of dusquetide under the research name SGX945 into Behçet’s Disease with the conduct of a Phase 2a clinical trial, where previous studies with dusquetide in oral mucositis have validated the biologic activity in aphthous ulcers induced by chemotherapy and radiation.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Continue development of the Company’s heat stabilization platform technology, ThermoVax</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, in combination with its programs for RiVax</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> (ricin toxin vaccine), and filovirus vaccines (targeting Ebola, Sudan, and Marburg viruses and multivalent combinations), with United States (“U.S.”) government or non-governmental organization funding support.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Continue to apply for and secure additional government funding for the Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts and/or procurements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursue business development opportunities for pipeline programs, as well as explore all strategic alternatives, including but not limited to merger/acquisition strategies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Acquire or in-license new clinical-stage compounds for development, as well as evaluate new indications with existing pipeline compounds for development.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s plans with respect to its liquidity management include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.55pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company has up to approximately </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$673,000</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> in active government grant funding still available as of March 31, 2024 to support its associated research programs through May 2026, provided the federal agencies do not elect to terminate the grants for convenience. The Company plans to submit additional contract and grant applications for further support of its programs with various funding agencies. However, there can be no assurance that the Company will obtain additional governmental grant funding. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company has continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expects to continue to do so for the foreseeable future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company will continue to pursue Net Operating Loss (“NOL”) sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program if the program is available.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company plans to pursue potential partnerships for pipeline programs as well as continue to explore merger and acquisition strategies. However, there can be no assurances that the Company can consummate such transactions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company completed a public offering on April 22, 2024 of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">3,275,000</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of its common stock, pre-funded warrants to purchase </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">8,600,000</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of its common stock and common warrants to purchase up to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">11,875,000</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of its common stock at a combined public offering price of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.40</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The pre-funded warrants have an exercise price of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.001</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">. The common warrants have an exercise price of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.40</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share, are exercisable immediately and expire </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the issuance date. The total gross proceeds to the Company from this offering were approximately </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$4.75</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> (</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$4.3</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> net) million before deducting commissions and other estimated offering expenses. The Company plans to use the proceeds for further support of its programs, as well as for working capital. See Note 8.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.75pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company is currently evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate such a transaction, or consummate a transaction at favorable pricing.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">Nasdaq Capital Market Listing Requirements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">​</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;text-align:justify;margin:0pt;">On June 23, 2023, the Company received a letter from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between May 9, 2023 through June 22, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company would be provided with a compliance period of 180 calendar days, or until December 20, 2023, in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The Company was unable to regain compliance prior to the expiration of the 180-day period.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:5.2pt;text-align:justify;margin:0pt;"><span style="font-size:5.2pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;text-align:justify;margin:0pt;">On December 21, 2023, the Company received another written notice (the “Notice”) from the Staff stating that the Company had not complied with the minimum bid price requirement and was not eligible for a second 180-day period because the Company did not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for Nasdaq. As a result, the Notice indicated that the Company’s common stock would be suspended from trading on Nasdaq unless the Company requested a hearing before the Nasdaq Hearings Panel by December 28, 2023. On March 26, 2024, the Company had an oral hearing with a Nasdaq Hearings Panel to appeal the Staff’s delisting determination, which stayed the trading suspension of the Common Stock pending a final written decision by the Nasdaq Hearings Panel and expiration of any additional extension period granted by the panel following the hearing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:15.4pt;text-align:justify;margin:0pt;"><span style="font-size:15.4pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.45;text-align:justify;margin:0pt;">In order to regain compliance with Nasdaq’s minimum bid price requirement, the Company’s common stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> 2 1100000 -227619503 -1915327 -1342482 7091548 8446158 -1354610 0.16 607499 3355212 -2747713 0.82 1000000 673000000000 3275000 8600000 11875000 0.40 0.001 0.40 P5Y 4750000 4300000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 2. Summary of Significant Accounting Policies</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Principles of Consolidation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Segments</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: Specialized BioTherapeutics and Public Health Solutions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash and Cash Equivalents</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contracts and Grants Receivable</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Contracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for credit losses has been established. If amounts become uncollectible, they are charged to operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impairment of Long-Lived Assets</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Office furniture and equipment and right of use assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company did not record any impairment of long-lived assets for the three months ended March 31, 2024 and 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fair Value of Financial Instruments</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">FASB ASC 820 — <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on March 31, 2024. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The three levels of the fair value hierarchy are as follows:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 — Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">observable data or are supported by observable levels at which transactions are executed in the marketplace.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The carrying amounts reported in the condensed consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable, accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The carrying amount reported in the condensed consolidated balance sheet as of March 31, 2024 for the convertible debt is its fair value - see Note 4. The principal amount of the convertible debt was $2,900,585 at March 31, 2024 and the fair value was $2,996,136. The fair value of the debt was estimated using the Monte Carlo valuation method, which utilizes certain unobservable inputs. As a result, the fair value estimate represents a Level 3 measurement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A roll forward of the carrying value of the convertible debt to March 31, 2024 is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:22.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:16.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:18.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 3, 2024</b></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:18.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:22.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible debt at fair value</p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> 3,260,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (99,416)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (165,382)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> 2,996,136</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deferred Issuance Costs</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders’ equity as a reduction of additional paid-in capital generated as a result of the issuance.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s revenues include revenues generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also records revenue from contracts with customers in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), <i style="font-style:italic;">Revenue From Contracts with Customers</i>. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain amounts received from or billed to customers in accordance with contract terms are deferred and recognized as future performance obligations are satisfied. All amounts earned under contracts with customers other than sales-based royalties are classified as licensing revenue. Sales-based royalties under the Company’s license agreements would be recognized as royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research and Development Costs</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense when incurred in accordance with FASB ASC 730, <i style="font-style:italic;">Research and Development</i>. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Share-Based Compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of <span style="-sec-ix-hidden:Hidden_6RWM-Cl3xkqkbkT2HCUdxQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one year</span></span> (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then 25% each subsequent year for a period of <span style="-sec-ix-hidden:Hidden_es9KRvJYFESHn90ETWYzGQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three years</span></span>. These options have a ten-year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within <span style="-sec-ix-hidden:Hidden_z4aBmWlp-0C7SQxMawcD5w;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three months</span></span>, unless otherwise extended by the Board.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed under the Company’s 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestricted stock to the Company’s employees and non-employees (including consultants). The shares issued under the 2015 Plan are registered on Form S-8 (SEC File No. 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificates reflecting such shares reflect a Securities Act of 1933, as amended restrictive legend. Stock compensation expense for equity-classified awards to non-employees is measured on the date of grant and is recognized when the services are performed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no options issued during the three months ended March 31, 2024 and 2023. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Currency Transactions and Translation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with FASB ASC 830 <i style="font-style:italic;">Foreign Currency Matters</i>, the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency, the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statements of the UK subsidiary are translated into U.S. dollars and consolidated into the Company’s financials, with related translation adjustments reported as a cumulative translation adjustment (“CTA”), which is a component of accumulated other comprehensive income. During the three months ended March 31, 2024 and 2023, the Company recognized a foreign currency transaction gain of $1,209 and a foreign currency transaction loss of ($366), respectively, in the accompanying condensed consolidated statements of operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Income Taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company’s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward periods. Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company did not recognize an income tax benefit during the three months ended March 31, 2024. The Company recognized $1,161,197 of income tax benefit, net of transaction costs from the sale of its 2021 NOL carryforwards during the three months ended March 31, 2023. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interest and penalties recorded for the three months ended March 31, 2024 and 2023. Additionally, the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at March 31, 2024 or December 31, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loss Per Share</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic earnings per share (“EPS”) excludes dilution and is computed by dividing loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Included within the Company’s weighted average common shares outstanding for the three months ended March 31, 2024, are common shares issuable upon the exercise of the pre-funded warrants associated with the May 2023 public offering, as these pre-funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes potentially dilutive adjustments to the number of common shares which were excluded from the diluted calculation because their effect would be anti-dilutive due to the losses in each period:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,538,073</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 906,226</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 192,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,008,100</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 146,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 9,452,399</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 338,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The weighted average exercise prices of the Company’s warrants and stock options outstanding at March 31, 2024 were $1.50 and $5.52 per share, respectively. The weighted average exercise prices of the Company’s stock options outstanding at March 31, 2023 was $27.56 per share. The weighted average conversion price of the Company’s convertible debt at March 31, 2024 and 2023 was $1.44 and $61.50 per share, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates and Assumptions</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Principles of Consolidation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Segments</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: Specialized BioTherapeutics and Public Health Solutions.</p> 2 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash and Cash Equivalents</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contracts and Grants Receivable</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Contracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for credit losses has been established. If amounts become uncollectible, they are charged to operations.</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impairment of Long-Lived Assets</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Office furniture and equipment and right of use assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company did not record any impairment of long-lived assets for the three months ended March 31, 2024 and 2023.</p> 0 0 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fair Value of Financial Instruments</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">FASB ASC 820 — <i style="font-style:italic;">Fair Value Measurements and Disclosures,</i> defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on March 31, 2024. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The three levels of the fair value hierarchy are as follows:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 — Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">observable data or are supported by observable levels at which transactions are executed in the marketplace.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The carrying amounts reported in the condensed consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable, accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The carrying amount reported in the condensed consolidated balance sheet as of March 31, 2024 for the convertible debt is its fair value - see Note 4. The principal amount of the convertible debt was $2,900,585 at March 31, 2024 and the fair value was $2,996,136. The fair value of the debt was estimated using the Monte Carlo valuation method, which utilizes certain unobservable inputs. As a result, the fair value estimate represents a Level 3 measurement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A roll forward of the carrying value of the convertible debt to March 31, 2024 is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:22.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:16.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:18.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 3, 2024</b></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:18.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:22.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible debt at fair value</p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> 3,260,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (99,416)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (165,382)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> 2,996,136</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p> 2900585 2996136 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A roll forward of the carrying value of the convertible debt to March 31, 2024 is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:22.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:16.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:18.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 3, 2024</b></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:18.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:22.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible debt at fair value</p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> 3,260,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (99,416)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (165,382)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> 2,996,136</p></td></tr></table> 3260934 99416 -165382 2996136 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deferred Issuance Costs</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders’ equity as a reduction of additional paid-in capital generated as a result of the issuance.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s revenues include revenues generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also records revenue from contracts with customers in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), <i style="font-style:italic;">Revenue From Contracts with Customers</i>. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain amounts received from or billed to customers in accordance with contract terms are deferred and recognized as future performance obligations are satisfied. All amounts earned under contracts with customers other than sales-based royalties are classified as licensing revenue. Sales-based royalties under the Company’s license agreements would be recognized as royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research and Development Costs</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense when incurred in accordance with FASB ASC 730, <i style="font-style:italic;">Research and Development</i>. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Share-Based Compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of <span style="-sec-ix-hidden:Hidden_6RWM-Cl3xkqkbkT2HCUdxQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one year</span></span> (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then 25% each subsequent year for a period of <span style="-sec-ix-hidden:Hidden_es9KRvJYFESHn90ETWYzGQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three years</span></span>. These options have a ten-year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within <span style="-sec-ix-hidden:Hidden_z4aBmWlp-0C7SQxMawcD5w;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three months</span></span>, unless otherwise extended by the Board.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed under the Company’s 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestricted stock to the Company’s employees and non-employees (including consultants). The shares issued under the 2015 Plan are registered on Form S-8 (SEC File No. 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificates reflecting such shares reflect a Securities Act of 1933, as amended restrictive legend. Stock compensation expense for equity-classified awards to non-employees is measured on the date of grant and is recognized when the services are performed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no options issued during the three months ended March 31, 2024 and 2023. </p> 25% 25% P10Y <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Currency Transactions and Translation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with FASB ASC 830 <i style="font-style:italic;">Foreign Currency Matters</i>, the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency, the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statements of the UK subsidiary are translated into U.S. dollars and consolidated into the Company’s financials, with related translation adjustments reported as a cumulative translation adjustment (“CTA”), which is a component of accumulated other comprehensive income. During the three months ended March 31, 2024 and 2023, the Company recognized a foreign currency transaction gain of $1,209 and a foreign currency transaction loss of ($366), respectively, in the accompanying condensed consolidated statements of operations. </p> 1209 -366 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Income Taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company’s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward periods. Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company did not recognize an income tax benefit during the three months ended March 31, 2024. The Company recognized $1,161,197 of income tax benefit, net of transaction costs from the sale of its 2021 NOL carryforwards during the three months ended March 31, 2023. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interest and penalties recorded for the three months ended March 31, 2024 and 2023. Additionally, the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at March 31, 2024 or December 31, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p> -1161197 0 0 0 0 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loss Per Share</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic earnings per share (“EPS”) excludes dilution and is computed by dividing loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Included within the Company’s weighted average common shares outstanding for the three months ended March 31, 2024, are common shares issuable upon the exercise of the pre-funded warrants associated with the May 2023 public offering, as these pre-funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes potentially dilutive adjustments to the number of common shares which were excluded from the diluted calculation because their effect would be anti-dilutive due to the losses in each period:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,538,073</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 906,226</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 192,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,008,100</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 146,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 9,452,399</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 338,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The weighted average exercise prices of the Company’s warrants and stock options outstanding at March 31, 2024 were $1.50 and $5.52 per share, respectively. The weighted average exercise prices of the Company’s stock options outstanding at March 31, 2023 was $27.56 per share. The weighted average conversion price of the Company’s convertible debt at March 31, 2024 and 2023 was $1.44 and $61.50 per share, respectively. </p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,538,073</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 906,226</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 192,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,008,100</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 146,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 9,452,399</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 338,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr></table> 6538073 906226 192273 2008100 146342 9452399 338615 1.50 5.52 27.56 1.44 61.50 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates and Assumptions</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 3. Accrued Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following is a summary of the Company’s accrued expenses:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,070,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 1,993,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 531,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 424,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><b style="font-weight:bold;"> 2,602,665</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,418,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,070,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 1,993,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 531,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 424,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><b style="font-weight:bold;"> 2,602,665</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,418,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 2070955 1993784 531710 424218 2602665 2418002 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 4. Debt</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2020, the Company entered into a $20 million convertible debt financing agreement with Pontifax. Under the terms of the agreement with Pontifax, the Company had access to up to $20 million in convertible debt financing in three tranches, which will mature on June 15, 2025 and had an interest-only period for the first <span style="-sec-ix-hidden:Hidden_RlIUFfVokk2NHXE3QCouFA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">two years</span></span> with a fixed interest rate of 8.47% on borrowed amounts and an interest rate of 1% on amounts </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">available but not borrowed as an unused line of credit fee. After the interest-only period, the outstanding principal was to be repaid in quarterly payments of $1 million each commencing in the first quarter of 2023. The agreement is secured by a lien covering substantially all of the Company’s assets, other than intellectual property. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">Upon the closing of this transaction, the Company borrowed the first tranche of $10 million, had the option to draw the second tranche of $5 million at any time during the initial 12 months of the loan and the third tranche of $5 million upon filing of the new drug application for HyBryte™, subject to certain conditions. The Company elected to let the options to borrow both the second and third tranches expire as of December 15, 2021 and March 15, 2022, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">On April 19, 2023, the Company entered into an amendment to the convertible debt financing agreement dated December 15, 2020 with Pontifax. The amendment called for the immediate payment of $5 million of the outstanding principal balance and any accrued interest, waived any prepayment charge in connection with the repayment of this amount and resulted in an outstanding principal balance of $3 million. The amendment also provided for a new interest only period from the date of the amendment through June 30, 2024, reduced quarterly principal repayments from $1 million to $750,000 and eliminated the minimum cash covenant. Further, the amendment reduced the conversion price with respect to the remaining principal amount under the agreement to (i) 90% of the closing price of the Company’s common stock on the day before the delivery of the conversion notice with respect to the first 588,599 shares of the Company’s common stock issuable upon conversion and to (ii) $1.70 with respect to all shares of the Company’s common stock issuable upon conversion in excess of the first 588,599 shares so issued. The remaining terms of the agreement remain in effect without modification. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">On January, 3, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Company’s common stock. Upon conversion, the Company issued 146,199 shares of the Company’s common stock at $0.68 per share, reducing the remaining principal balance by $99,416. Pontifax may elect to convert the remaining outstanding loan drawn under the first tranche into additional shares of the Company’s common stock at any time prior to repayment. The Company also has the ability to force the conversion of the loan into shares of its common stock, subject to certain conditions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The amendment to the convertible debt financing agreement with Pontifax resulted in the extinguishment of the original convertible debt for accounting purposes. The Company concluded that the amended debt instrument has an embedded derivative that requires bifurcation pursuant to ASC 815-15-25-1 and qualifies for the fair value option in accordance with ASC 815-15-25-4 through ASC 815-15-25-6. The Company elected to account for the amended convertible debt using the fair value option, which requires the Company to record changes in fair value as a component of other income or expense. The fair value of the convertible debt as of March 31, 2024 was $2,996,136, which resulted in the recognition of $165,382 of other income from the change in the fair value of the convertible debt on the Company’s accompanying condensed consolidated statements of operations during the three months ended March 31, 2024. The fair value of the convertible debt was estimated using the Monte Carlo valuation method.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The key assumptions used in the Monte Carlo valuations were as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12/31/2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3/31/2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 0.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 0.60</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">141.90%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">148.80%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">13.62%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">16.16%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">4.65%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">5.03%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">Interest expense incurred during the three months ended March 31, 2024 and 2023 was $61,239 and $187,964, respectively. Interest expense paid during the three months ended March 31, 2024 and 2023 was $64,047 and $213,490, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">Annual principal and interest payments due as of March 31, 2024 in accordance with the amended terms of the Pontifax loan agreement, including the January 3, 2024 conversion and assuming no further conversions are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 198,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,448,305</p></td></tr><tr><td style="vertical-align:bottom;width:44.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 650,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 13,889</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 664,474</p></td></tr><tr><td style="vertical-align:bottom;width:44.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,900,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 212,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,112,779</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 20000000 20000000 three 0.0847 0.01 1000000 10000000 5000000 5000000 5000000 3000000 1000000 750000 0.90 588599 1.70 588599 146199 0.68 99416 2996136 -165382 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12/31/2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3/31/2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 0.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 0.60</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">141.90%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">148.80%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">13.62%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">16.16%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">4.65%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;">5.03%</p></td></tr></table> 0.76 0.60 1.4190 1.4880 0.1362 0.1616 0.0465 0.0503 61239 187964 64047 213490 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 198,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,448,305</p></td></tr><tr><td style="vertical-align:bottom;width:44.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 650,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 13,889</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 664,474</p></td></tr><tr><td style="vertical-align:bottom;width:44.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,900,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 212,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,112,779</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 2250000 198305 2448305 650585 13889 664474 2900585 212194 3112779 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 5. Shareholders’ Equity</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Stock</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following items represent transactions in the Company’s common stock for the three months ended March 31, 2024:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company issued Pontifax </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">146,199</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of fully vested common stock pursuant to conversion of a portion of the convertible debt principal balance at a conversion price of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.68</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share on January 3, 2024, the date of issuance. The conversion price was based on </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">90%</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the closing price of the Company’s common stock on the day before the delivery of the conversion notice.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The issuance of the Company’s common stock in connection with the convertible debt financing agreement as described above was exempt under Section 3(a)(9) of the Securities Act of 1933, as amended.</p> 146199 0.68 0.90 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6. Commitments and Contingencies</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Contractual Obligations</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has commitments of approximately $230,000 as of March 31, 2024 over the next five years for several licensing agreements with partners and universities. Additionally, the Company has collaboration and license agreements, which upon clinical or commercialization success, may require the payment of milestones of up to approximately $13.2 million, royalties on net sales of covered products ranging from 2% to 3% sub-license Investigational New Drug (“IND”) milestones on covered products of up to approximately $200,000, sub-license income royalties on covered products up to 15% and sub-license global net sales royalties on covered products ranging from 1.5% to 2.5%, if and when achieved. However, there can be no assurance that clinical or commercialization success will occur.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company currently leases office space which serves as the Company’s corporate headquarters, and both of the Company’s business segments (Specialized BioTherapeutics and Public Health Solutions), operate from this space. Pursuant to an amendment on June 21, 2022, the lease has been extended to October 2025. The current rent of $11,367 per month will be maintained until November 2024 when it will be increased to $11,625 per month where it will remain until expiration.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">In September 2014, the Company entered into an asset purchase agreement with Hy Biopharma Inc. (“Hy Biopharma”) pursuant to which the Company acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharma’s synthetic hypericin product. As consideration for the assets acquired, the Company paid $275,000 in cash and issued 12,328 shares of common stock with a fair value based on the Company’s stock price on the date of grant of $3.75 million. These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in the Company’s research and development activities and do not have alternative future use pursuant to GAAP. In March 2020, the Company issued 130,413 shares of common stock to Hy Biopharma as payment for achieving </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">a milestone: the Company determining the Phase 3 clinical trial of HyBryte™ to be successful in the treatment of CTCL. The number of shares of common stock issued to Hy Biopharma was calculated using an effective price of $38.40 per share, based upon a formula set forth in the purchase agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Provided the sole remaining future success-oriented milestone of FDA approval is attained, the Company will be required to make an additional payment of $5 million, if and when achieved. Such payment will be payable in restricted securities of the Company provided such number of shares does not exceed 19.9% ownership of the Company’s outstanding stock. As of March 31, 2024, no other milestone or royalty payments have been paid or accrued.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">As a result of the above agreements, the Company has the following contractual obligations:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">April 1 through December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 102,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 148,817</p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 116,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 162,250</p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 219,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 449,067</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;text-decoration-line:none;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Contingencies</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. A liability is only recorded if management determines that it is both probable and reasonably estimable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"> <span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p> 230000 13200000 0.02 0.03 200000 0.15 0.015 0.025 11367 11625 275000 12328 3750000 130413 38.40 5000000 0.199 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">April 1 through December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 102,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 148,817</p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 116,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 162,250</p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td></tr><tr><td style="vertical-align:bottom;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 219,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 449,067</p></td></tr></table> 46000 102817 148817 46000 116250 162250 46000 46000 46000 46000 46000 46000 230000 219067 449067 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7. Operating Segments</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 117,029</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 155,365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 101,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 117,029</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 257,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income (loss) from Operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (860,604)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (910,377)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (45,997)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,210,490)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,240,739)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (2,117,091)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,150,689)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization and Depreciation Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 953</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 159</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 476</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,588</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other (Expense) Income, Net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,540</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 194,224</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (62,699)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 201,764</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (56,617)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share-Based Compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 20,672</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 27,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 588</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 38,701</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 45,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 59,961</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 73,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">As of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identifiable Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 301,709</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 272,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 120,475</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,636,201</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 9,521,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,058,385</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 9,797,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 2 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 117,029</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 155,365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 101,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 117,029</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 257,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income (loss) from Operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (860,604)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (910,377)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (45,997)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,210,490)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,240,739)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (2,117,091)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,150,689)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization and Depreciation Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 953</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 159</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 476</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,588</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other (Expense) Income, Net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,540</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 194,224</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (62,699)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 201,764</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (56,617)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share-Based Compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 20,672</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 27,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 588</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 38,701</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 45,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 59,961</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 73,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">As of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identifiable Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 301,709</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 272,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 120,475</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,636,201</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 9,521,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,058,385</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 9,797,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 117029 155365 101813 117029 257178 -860604 -910377 -45997 427 -1210490 -1240739 -2117091 -2150689 953 1071 159 178 476 536 1588 1785 7540 6082 194224 -62699 201764 -56617 20672 27427 588 994 38701 45213 59961 73634 301709 272099 120475 3976 7636201 9521251 8058385 9797326 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 8. Subsequent Events</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pontifax Conversion of Convertible Debt</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 15, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Company’s common stock. Upon conversion, the Company issued 442,400 shares of the Company’s common stock at $0.35 per share, reducing the remaining principal balance by $154,840. Pontifax may elect to convert the remaining outstanding loan drawn under the first tranche into additional shares of the Company’s common stock at any time prior to repayment. The Company also has the ability to force the conversion of the loan into shares of its common stock, subject to certain conditions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">$</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.75</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> million Public Offering</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">On April 22, 2024, the Company completed a public offering of (i) 3,275,000 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 8,600,000 shares of the Company’s common stock and (iii) common warrants to purchase 11,875,000 shares of the Company’s common stock. The shares of common stock, or pre-funded warrants in lieu thereof, and the common warrants, were sold in units, with each unit consisting of one share of common stock or one pre-funded warrant in lieu thereof and one common warrant. Each unit comprised of common stock and common warrants was sold at a per unit price of $0.40. Each unit comprised of pre-funded warrants and common warrants was sold at a per unit price of $0.399, which represents the same per unit price less the $0.001 per share exercise price of the pre-funded warrants. The common warrants are exercisable at a price of $0.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to the Company from this offering were approximately $4.75 ($4.3 net) million before deducting commissions and other estimated offering expenses payable by the Company.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p> 442400 0.35 154840 4750000 3275000 8600000 11875000 1 1 1 0.40 0.399 0.001 0.40 P5Y 4750000 4300000 false false false false

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